0001213900-22-016222.txt : 20220330 0001213900-22-016222.hdr.sgml : 20220330 20220330165608 ACCESSION NUMBER: 0001213900-22-016222 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220330 DATE AS OF CHANGE: 20220330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Joway Health Industries Group Inc CENTRAL INDEX KEY: 0001263364 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS FABRICATED TEXTILE PRODUCTS [2390] IRS NUMBER: 980221494 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-108715 FILM NUMBER: 22787299 BUSINESS ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 BUSINESS PHONE: 862258896888 MAIL ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 FORMER COMPANY: FORMER CONFORMED NAME: G2 VENTURES INC DATE OF NAME CHANGE: 20030911 10-K 1 f10k2021_jowayhealth.htm ANNUAL REPORT
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

 ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission File Number: 333-108715

 

Joway Health Industries Group Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   98-0221494

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

   

600 South 3rd Street

Las Vegas, Nevada

  89101
(Address of Principal Executive Offices)   (Zip Code)

 

702-384-1990

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

None   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, par value $0.001

(Title of class)

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No

 

Indicate by check mark if the Registrant is not required to file Reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐   No

 

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small Reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” or an “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller Reporting company
    Emerging Growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a Report on and attestation to its management’s assessment of the effectiveness of its internal control over financial Reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit Report.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes    No ☐

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the Registrant’s most recently completed second fiscal quarter was approximately $92,610. Solely for purposes of this Annual Report, shares of common stock held by executive officers and directors of the Registrant as of such date have been excluded because such persons may be deemed to be affiliates. This determination of executive officers and directors as affiliates is not necessarily a conclusive determination for any other purposes.

 

Note.—If a determination as to whether a particular person or entity is an affiliate cannot be made without involving unreasonable effort and expense, the aggregate market value of the common stock held by non-affiliates may be calculated on the basis of assumptions reasonable under the circumstances, provided that the assumptions are set forth in this Form.

 

20,054,000 shares of common stock were issued and outstanding as of March 29, 2022.

 

 

 

 

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

Annual Report on Form 10-K

For the year ended December 31, 2021

 

TABLE OF CONTENTS

 

    Page
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   ii
     
PART I    
ITEM 1. BUSINESS   1
     
ITEM 1A. RISK FACTORS   3
     
ITEM 1B. UNRESOLVED STAFF COMMENTS   8
     
ITEM 2. PROPERTIES   8
     
ITEM 3. LEGAL PROCEEDINGS   8
     
ITEM 4. MINE SAFETY DISCLOSURES   8
     
PART II    
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES   9
     
ITEM 6. [RESERVED]   10
     
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   11
     
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   16
     
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA   16
     
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE   16
     
ITEM 9A. CONTROLS AND PROCEDURES   16
     
ITEM 9B. OTHER INFORMATION   18
     
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS   18
     
PART III    
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE   19
     
ITEM 11. EXECUTIVE COMPENSATION   20
     
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS   21
     
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE   22
     
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES   23
     
PART IV    
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES   24
     
ITEM 16. FORM 10–K SUMMARY   24
     
SIGNATURES   25

 

i

 

 

Special Note Regarding Forward-Looking Statements

 

In addition to historical information, this Report contains predictions, estimates and other forward-looking statements that relate to future events or our future financial performance. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. These risks and other factors include those listed under “Risk Factors” and elsewhere in this Report. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology.

 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in this Report in greater detail under the heading “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.

 

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

ii

 

 

PART I

 

Item 1. BUSINESS.

 

Overview

 

We are incorporated in the state of Nevada. Prior to the consummation of the Merger as of December 31, 2020, as more specifically described below, Joway Health Industries Group Inc. (the “Company” or “Joway Health”), through its operating entities in China, was engaged in the manufacture, distribution and sales of tourmaline-related healthcare products.

 

As a result of the consummation of the Merger on December 31, 2020, we became a shell company and as of the date of this Annual Report, we have no full time employees. Starting from January 1, 2021, we no longer have any assets or any business operations. The Report of our independent registered public accountants on our financial statements for the year ended December 31, 2021 states that these conditions, among others, raise substantial doubt about our ability to continue as a going concern.

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company.

 

As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.

 

Change in Control

 

On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe and JHP Holdings, Inc., a Nevada corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from Crystal Globe. The shares represent 83% of the issued and outstanding shares of the Company on a fully diluted basis. The purchase price for the shares paid by the Buyer was $100,000. Pursuant to the Purchase Agreement, each of Crystal Globe, the Buyer and Company made customary representations and warranties to each other. The parties agreed to certain customary post-closing covenants, including those relating to confidentiality, publicity and litigation support. The Company and Crystal Globe also agreed to certain indemnification provisions as they pertain to the Buyer for breaches or inaccuracies in their respective representations and warranties or covenants.

 

In connection with the acquisition of the 83% by the Buyer, Jinghe Zhang, the sole officer and director of the Company, resigned and the Buyer appointed Ramon Lata as the sole officer and director of the Company. The executive officers of the Company are currently located at 600 South 3rd Street, Las Vegas, Nevada 89101.

 

1

 

 

Shell Company Status

 

As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

 

Our objectives discussed below are extremely general and are not intended to restrict discretion of our Board of Directors to search for and enter into potential business opportunities or to reject any such opportunities.

 

We will not restrict our potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. Further, we may acquire or combine with a venture that is in its preliminary or early stages of development, one that is already in operation, or one that is in a more mature stage of its corporate existence. Accordingly, business opportunities may be available in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities difficult and complex.

 

We believe that there are numerous companies seeking the perceived benefits of a publicly registered corporation. These benefits are commonly thought to include the following:

 

  the ability to use registered securities to acquire assets or businesses;
     
  increased visibility in the marketplace;
     
  greater ease of borrowing from financial institutions;
     
  improved stock trading efficiency
     
  greater shareholder liquidity;
     
  greater ease in subsequently raising capital;
     
  ability to compensate key employees through stock options and other equity awards;
     
  enhanced corporate image; and
     
  a presence in the United States capital markets.

 

It is anticipated that any securities issued in any such reorganization would be issued in reliance upon exemption from registration under applicable federal and state securities laws. In some circumstances, however, as a negotiated element of a transaction, we may agree to register all or a part of such securities immediately after the transaction is consummated or at specified times thereafter. The issuance of substantial additional securities and their potential sale into any trading market which may develop in our securities may have a depressive effect on that market.

 

With respect to any merger or acquisition, negotiations with target company management are expected to focus on the percentage of our company that the target company shareholders would acquire in exchange for all of their shareholdings in the target company. Depending upon, among other things, the target company’s assets and liabilities, our existing shareholders will in all likelihood hold a substantially lesser percentage ownership interest in our company following any merger or acquisition. The percentage ownership of our existing shareholders may be subject to significant reduction in the event we acquire a target company with substantial assets. Any merger or acquisition effected by us can be expected to have a significant dilutive effect on the percentage of shares held by our shareholders at such time.

 

2

 

 

We will participate in a business opportunity only after the negotiation and execution of appropriate agreements. Although the terms of such agreements cannot be predicted, generally such agreements will require certain representations and warranties of the parties thereto, will specify certain events of default, will detail the terms of closing and the conditions which must be satisfied by the parties prior to and after such closing, will outline the manner of bearing costs, including costs associated with our attorneys and accountants, and will include miscellaneous other terms.

 

It is anticipated that the investigation of specific business opportunities and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require substantial management time and attention and substantial cost for accountants, attorneys and others. If a decision is made not to participate in a specific business opportunity, the costs theretofore incurred in the related investigation would not be recoverable. Furthermore, even if an agreement is reached for the participation in a specific business opportunity, the failure to consummate that transaction may result in our loss of the related costs incurred.

 

Competition

 

We expect to encounter substantial competition in our efforts to identify and consummate a transaction with a business opportunity. The primary competition will be from other companies organized and funded for similar purposes, small venture capital partnerships and corporations, small business investment companies and wealthy individuals, all of which may have substantially greater financial and other resources than we do. In view of our limited financial resources and limited management availability, we may be at a competitive disadvantage compared to our competitors.

 

Employees

 

We presently have no employees apart from Ramon Lata, our sole officer and director. Mr. Lata is engaged in outside business activities and anticipates that he will devote to our business limited time until the acquisition of a successful business opportunity has been identified. We expect no significant changes in the number of our employees other than such changes, if any, incident to a business combination.

 

We intend to hire additional management and other support personnel when we have reached a point in our proposed growth that would allow for such employment. In the interim, we will rely upon consultants to assist us in identifying and investigating acquisition opportunities.

 

Reports to Security Holders

 

We file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports, statement or other information that we file with the SEC at the SEC’s public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at (202) 551-8090 for further information on the public reference room. These SEC filings are also available to the public from commercial document retrieval services and at the Internet site maintained by the SEC at http://www.sec.gov.

 

Item 1A. RISK FACTORS

 

AS A SMALLER REPORTING COMPANY, WE ARE NOT REQUIRED TO PROVIDE A STATEMENT OF RISK FACTORS. NONETHELESS, WE ARE VOLUNTARILY PROVIDING RISK FACTORS HEREIN. THIS ANNUAL REPORT CONTAINS CERTAIN STATEMENTS RELATING TO FUTURE EVENTS OR THE FUTURE FINANCIAL PERFORMANCE OF OUR COMPANY. YOU ARE CAUTIONED THAT SUCH STATEMENTS ARE ONLY PREDICTIONS AND INVOLVE RISKS AND UNCERTAINTIES, AND THAT ACTUAL EVENTS OR RESULTS MAY DIFFER MATERIALLY. IN EVALUATING SUCH STATEMENTS, YOU SHOULD SPECIFICALLY CONSIDER THE VARIOUS FACTORS IDENTIFIED IN THIS ANNUAL REPORT, INCLUDING THE MATTERS SET FORTH BELOW, WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE INDICATED BY SUCH FORWARD-LOOKING STATEMENTS.

 

AN INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER THE FOLLOWING RISK FACTORS BEFORE DECIDING TO INVEST IN OUR COMPANY. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, OUR BUSINESS, FINANCIAL CONDITION, RESULTS OF OPERATIONS AND PROSPECTS FOR GROWTH WOULD LIKELY SUFFER. AS A RESULT, YOU MAY LOSE ALL OR PART OF YOUR INVESTMENT IN OUR COMPANY.

 

3

 

 

We are a shell company and may never be able to effectuate our business plan.

 

As a result of the Merger, the Company ceased operations and is now seeking a business combination with a private entity whose business would present an opportunity for its shareholders. We intend to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders. As a shell company with limited resources we may not be able to successfully effectuate our business plan. There can be no assurance that we will ever achieve any revenues or profitability. The revenue and income potential of our proposed business and operations is unproven as the lack of operating history makes it difficult to evaluate the future prospects of our business. We require financing to acquire businesses and implement our business plan. We cannot assure you that we will be successful in obtaining financing or acquiring businesses, or in operating those acquired businesses in a profitable manner.

 

We expect losses in the future because we have no revenue.

 

As we have no current revenue, we are expecting losses over the next twelve (12) months because we do not yet have any revenues to offset the expenses associated with our business plan. We cannot guarantee that we will ever be successful in generating revenues in the future. We recognize that if we are unable to generate revenues, we will not be able to earn profits or continue operations. There is no history upon which to base any assumption as to the likelihood that we will prove successful, and we can provide investors with no assurance that we will generate any operating revenues or ever achieve profitable operations.

 

If our business plans are not successful, we may not be able to continue operations as a going concern and our stockholders may lose their entire investment in us.

 

Since inception, we have had no revenue. On December 31, 2021, we had an accumulated deficit of approximately $7.4 million. These factors raise substantial doubt about our ability to continue as a going concern. We will, in all likelihood, sustain operating expenses without corresponding revenues, at least until the consummation of a business combination. This may result in our incurring a net operating loss that will increase continuously until we can consummate a business combination with a profitable business opportunity. We cannot assure you that we can identify a suitable business opportunity and consummate a business combination. If we cannot continue as a going concern, our stockholders may lose their entire investment in us.

 

We do not have any agreement for a business combination or other transaction.

 

We have no arrangement, agreement or understanding with respect to engaging in a merger with, joint venture with or acquisition of, a private or public entity. We cannot assure you that we will successfully identify and evaluate suitable business opportunities or that we will conclude a business combination. Management has not identified any particular industry or specific business within an industry for evaluation. We cannot guarantee that we will be able to negotiate a business combination on favorable terms, and there is consequently a risk that future funds allocated to the purchase of our shares will not be invested in a company with active business operations.

 

Future success is highly dependent on the ability of management to locate and attract a suitable acquisition.

 

The success of our proposed plan of operation will depend to a great extent on the operations, financial condition and management of the identified target company. While business combinations with entities having established operating histories are preferred, there can be no assurance that we will be successful in locating candidates meeting such criteria. The decision to enter into a business combination will likely be made without detailed feasibility studies, independent analysis, market surveys or similar information which, if we had more funds available to it, would be desirable. In the event we complete a business combination, the success of our operations will be dependent upon management of the target company and numerous other factors beyond our control. We cannot assure you that we will identify a target company and consummate a business combination.

 

There is competition for those private companies suitable for a merger or combination transaction of the type contemplated by management.

 

We are in a highly competitive market for a small number of business opportunities which could reduce the likelihood of consummating a successful business combination. We are and will continue to be an insignificant participant in the business of seeking mergers with, joint ventures with and acquisitions of small private and public entities. A large number of established and well-financed entities, including small public companies and venture capital firms, are active in mergers and acquisitions of companies that may be desirable target candidates for us. Nearly all these entities have significantly greater financial resources, technical expertise and managerial capabilities than we do. Consequently, we will be at a competitive disadvantage in identifying possible business opportunities and successfully completing a business combination. These competitive factors may reduce the likelihood of our identifying and consummating a successful business combination.

 

4

 

 

We have not conducted market research to identify business opportunities, which may affect our ability to identify a business to merge with or acquire.

 

We have neither conducted nor have others made available to us results of market research concerning prospective business opportunities. Therefore, we have no assurances that market demand exists for a merger or acquisition as contemplated by us. Our management has not identified any specific business combination or other transactions for formal evaluation by us, such that it may be expected that any such target business or transaction will present such a level of risk that conventional private or public offerings of securities or conventional bank financing will not be available. There is no assurance that we will be able to acquire a business opportunity on terms favorable to us. Decisions as to which business opportunity to participate in will be unilaterally made by our management, which may act without the consent, vote or approval of our stockholders.

 

Management intends to devote only a limited amount of time to seeking a target company, which may adversely impact our ability to identify a suitable acquisition candidate.

 

While seeking a business combination, our sole officer and director anticipates devoting limited time to our affairs in total. Our sole officer has not entered into a written employment agreement with us and is not expected to do so in the foreseeable future. This limited commitment may adversely impact our ability to identify and consummate a successful business combination.

 

We are dependent on the services of our sole officer to obtain capital required to implement our business plan and for identifying, investigating, negotiating and integrating potential acquisition opportunities. The loss of services of our sole officer could have a substantial adverse effect on us. The expansion of our business will be largely contingent on our ability to attract and retain highly qualified corporate and operations level management team. We cannot assure you that we will find suitable management personnel or will have financial resources to attract or retain such people if found.

 

The time and cost of preparing a private company to become a public reporting company may preclude us from entering into a merger or acquisition with the most attractive private companies.

 

Target companies that fail to comply with SEC reporting requirements may delay or preclude acquisition. Sections 13 and 15(d) of the Exchange Act require reporting companies to provide certain information about significant acquisitions, including audited consolidated financial statements for the company acquired.

 

The time and additional costs that may be incurred by some target entities to prepare these statements may significantly delay or essentially preclude consummation of an acquisition. Otherwise suitable acquisition prospects that do not have or are unable to obtain the required audited statements may be inappropriate for acquisition so long as the reporting requirements of the Exchange Act are applicable.

 

Any potential acquisition or merger with a foreign company may subject us to additional risks.

 

If we enter into a business combination with a foreign concern, we will be subject to risks inherent in business operations outside of the United States. These risks include, for example, currency fluctuations, regulatory problems, punitive tariffs, unstable local tax policies, trade embargoes, risks related to shipment of raw materials and finished goods across national borders and cultural and language differences. Foreign economies may differ favorably or unfavorably from the United States economy in growth of gross national product, rate of inflation, market development, rate of savings, and capital investment, resource self-sufficiency and balance of payments positions, and in other respects.

 

We will need to raise additional capital to execute our business plan. If our operations do not produce the necessary cash flow, or if we cannot obtain needed funds, we may be forced to reduce or cease our activities with consequent loss to investors.

 

We have a need for cash in order to pay obligations currently due in a timely manner, and to finance our business operations. Our continued operations will depend upon the sustainability of cash flow from our ability to raise additional funds, as required, through equity or debt financing. There is no assurance that we will be able to obtain additional funding when it is needed, or that such funding, if available, will be obtainable on terms acceptable to us. If we cannot obtain needed funds, we may be forced to reduce or cease our activities with consequent loss to investors. In addition, should we incur significant presently unforeseen expenses or delays, we may not be able to accomplish our goals.

 

5

 

 

If we fail to develop and maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud, as a result, current and potential shareholders could lose confidence in our financial reports, which could harm our business and the trading price of our Common Stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate and report on our internal controls over financial reporting. We plan to comply with Section 404 by strengthening, assessing and testing our system of internal controls to provide the basis for our report. The process of strengthening our internal controls and complying with Section 404 is expensive and time consuming, and requires significant management attention, especially given that we have not yet undertaken any efforts to comply with the requirements of Section 404. We cannot be certain that the measures we will undertake will ensure that we will maintain adequate controls over our financial processes and reporting in the future. Furthermore, if we are able to rapidly grow our business, the internal controls that we will need will become more complex, and significantly more resources will be required to ensure our internal controls remain effective. Failure to implement required controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. If we discover a material weakness in our internal controls, the disclosure of that fact, even if the weakness is quickly remedied, could diminish investors’ confidence in our financial statements and harm our stock price. In addition, non-compliance with Section 404 could subject us to a variety of administrative sanctions, including the suspension of trading, ineligibility for listing on the OTC Markets, one of the national securities exchanges, and the inability of registered broker-dealers to make a market in our Common Stock, which would further reduce our stock price.

 

Our principal stockholder owns a substantial interest in our voting stock and investors will not have any voice in our management, which could result in decisions adverse to our general shareholders.

 

Ramon Lata beneficially owns 83% of our outstanding Common Stock. As a result, he has and will have the ability to control substantially all matters submitted to our stockholders for approval including: (a) election of our Board; (b) removal of any of our directors; (c) amendments of our Articles of Incorporation or bylaws; (d) adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us, or (e) other significant corporate transactions.

 

Our failure to adopt certain corporate governance procedures may prevent us from obtaining a listing on a national securities exchange.

 

Ramon Lata is our sole officer and director. We have no directors that are “independent” as that term is defined in the rules of any national securities exchange. As a result, we do not have an audit, compensation or nominating and corporate governance committee. The functions of such committees would perform are performed by the Board as a whole. Consequently, there is a potential conflict of interest in Board decisions that may adversely affect our ability to become a listed security on a national securities exchange and as a result adversely affect the liquidity of our Common Stock.

 

Trading in our shares of Common Stock is limited, and will not improve unless we increase our sales, become profitable and secure more active market makers.

 

Our Common Stock is currently quoted on Pink tier of OTC Markets Group Inc., an over-the-counter quotation system, under the symbol “GTVI.” However, there is currently no trading market for our Common Stock and there is no assurance that a regular trading market will ever develop. The trading price of our securities could be subject to wide fluctuations, in response to quarterly variations in our operating results, announcements by us or others, developments affecting us, and other events or factors. In addition, the stock market has experienced extreme price and volume fluctuations in recent years. These fluctuations have had a substantial effect on the market prices for many companies, often unrelated to the operating performance of such companies, and may adversely affect the market prices of the securities Such risks could have an adverse effect on the stock’s future liquidity.

 

We may, in the future, issue additional common shares and preferred shares, convertible into common shares, which would reduce investors’ percent of ownership and may dilute our share value.

 

Our Articles of Incorporation authorizes the issuance of 201,000,000 shares of capital stock, consisting of 200,000,000 shares of Common Stock and 1,000,000 shares of preferred stock. The future issuance of Common Stock or shares of preferred stock convertible into Common Stock, may result in substantial dilution in the percentage of our Common Stock held by our then existing shareholders. We may value any Common Stock issued in the future on an arbitrary basis. The issuance of Common Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors and might have an adverse effect on any trading market for our Common Stock.

 

6

 

 

We do not have a class of our securities registered under Section 12 of the Exchange Act. Until we do, or we become subject to Section 15(d) of the Exchange Act, we will be a “voluntary filer.”

 

We are not currently required under Section 13 or Section 15(d) of the Exchange Act to file periodic reports with the SEC. We have in the past voluntarily elected to file some or all of these reports to ensure that sufficient information about us is publicly available to our stockholders and potential investors. Until we become subject to the reporting requirements under the Exchange Act, we are a “voluntary filer” and we are currently considered a non-reporting issuer under the Exchange Act. We will not be required to file reports under Section 13(a) or 15(d) of the Exchange Act until the earlier to occur of: (i) our registration of a class of securities under Section 12 of the Exchange Act, which would be required if we list a class of securities on a national securities exchange or if we meet the size requirements set forth in Section 12(g) of the Exchange Act, or which we may voluntarily elect to undertake at an earlier date; or (ii) the effectiveness of a registration statement under the Securities Act relating to our Common Stock. Until we become subject to the reporting requirements under either Section 13(a) or 15(d) of the Exchange Act, we are not subject to the SEC’s proxy rules, and large holders of our capital stock will not be subject to beneficial ownership reporting requirements under Sections 13 or 16 of the Exchange Act and their related rules. As a result, our stockholders and potential investors may not have available to them as much or as robust information as they may have if and when we become subject to those requirements. In addition, if we do not register under Section 12 of the Exchange Act, and remain a “voluntary filer”, we could cease filing annual, quarterly or current reports under the Exchange Act.

 

Our common shares are subject to the “penny stock” rules of the SEC, and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

 

Rule 15g-9 under the Exchange Act establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common shares and cause a decline in the market value of our stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

Because we do not intend to pay any cash dividends on our Common Stock, our stockholders will not be able to receive a return on their shares unless they sell them.

 

We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. We cannot assure you that you will be able to sell shares when you desire to do so.

 

7

 

 

Item 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

Item 2. PROPERTIES.

 

We do not currently own or rent any property. 

 

Item 3. LEGAL PROCEEDINGS.

 

We have no knowledge of any material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

 

Item 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

8

 

 

PART II

 

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Market Information

 

There is a limited public market for our common shares. Our Common Stock has been trading on the Over-the-Counter (“OTC”) Markets under the symbol “GTVI” since September 11, 2009. It is currently on the OTC Pink Markets. quoted on the OTC Markets is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

 

The OTC Markets is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter, or the OTC, equity securities, and may not necessarily represent actual transactions.

 

OTC securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

 

Holders of Our Common Stock

 

As of December 31, 2021, we had 430 shareholders of record of our common stock. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.

 

Dividends

 

In January 2022, we distributed a special dividend of $119,070 to our minority shareholders who represented 2,646,000 shares of our common stock. The special dividend distribution was made due to the Merger Agreement we made with Dynamic Elite and Crystal Globe on November 20, 2020. Other than the special distribution on January 2022, we do not pay dividends on our common stock and do not anticipate paying such dividends in the foreseeable future. The declaration of any future cash dividends is at the discretion of our Board and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

 

Stock Option Grants

 

To date, we have not granted any stock options.

 

Registration Rights

 

We have not granted registration rights to any person.

 

Recent Sales of Unregistered Securities

 

None.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

In 2021 and 2020, we have not granted any securities authorized for issuance under equity compensation plans.

 

9

 

 

Rule 10b-18 Transactions

 

During the year ended December 31, 2021, neither the Company nor any affiliated purchaser of the Company, purchased any equity securities of the Company that are registered pursuant to Section 12 of the Exchange Act.

 

Penny Stock Regulations

 

Our shares of common stock are subject to the “penny stock” rules of the Securities Exchange Act of 1934 and various rules under this Act. In general terms, “penny stock” is defined as any equity security that has a market price less than $5.00 per share, subject to certain exceptions. The rules provide that any equity security is considered to be a penny stock unless that security is registered and traded on a national securities exchange meeting specified criteria set by the SEC, issued by a registered investment company, and excluded from the definition on the basis of price (at least $5.00 per share), or based on the issuer’s net tangible assets or revenues. In the last case, the issuer must meet one of the following requirements: (i) net tangible assets must exceed $3,000,000 if the issuer has been in continuous operation for at least three years; or (ii) net tangible assets must exceed $5,000,000 if the issuer has been in operation for less than three years; or (iii) the issuer’s average revenues for each of the past three years must exceed $6,000,000.

 

Trading in shares of penny stock is subject to additional sales practice requirements for broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Accredited investors, in general, include individuals with assets in excess of $1,000,000 or annual income exceeding $200,000 (or $300,000 together with their spouse), and certain institutional investors. For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of the security and must have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent disclosing recent price information for the penny stocks. These rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock, to the extent it is penny stock, and may affect the ability of shareholders to sell their shares.

 

Item 6. [RESERVED].

 

We are a smaller reporting company as defined by Rule 229.10(f)(1) and are not required to provide information under this item.

 

10

 

 

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

 

The following discussion should be read in conjunction with our financial statements and notes to those financial statements, included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk factors” and elsewhere in this prospectus.

 

FORWARD-LOOKING STATEMENTS:

 

Certain statements made in this Report may constitute “forward-looking statements on our current expectations and projections about future events.” These forward-looking statements involve known or unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases you can identify forward-looking statements by some words such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. These forward-looking statements are made as of the date of this Report, and we assume no obligation to update these forward-looking statements whether as a result of new information, future events, or otherwise, other than as required by law. In light of these assumptions, risks, and uncertainties, the forward-looking events discussed in this Report might not occur and actual results and events may vary significantly from those discussed in the forward-looking statements.

 

Overview

 

As a result of the Merger, we are now seeking a business combination with a private entity whose business would present an opportunity for our shareholders. No specific assets or businesses have been definitively identified and there is no certainty that any such assets or business will be identified or that any transactions will be consummated. We may seek investors to purchase our stock to provide us with working capital to fund our operations. Thereafter, we will seek to establish or acquire businesses or assets with additional funds raised either via the issuance of shares or debt. There can be no assurance that additional capital will be available to us at all or on acceptable terms. We may seek to raise the required capital by other means. We may have to issue debt or equity or enter into a strategic arrangement with a third party. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds will have a severe negative impact on our ability to remain a viable company.

 

We do not expect to generate any revenues over the next 12 months, unless we are able to enter into a business combination with an operating company. Our principal business objective for the next 12 months will be to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for our shareholders. During the next 12 months we anticipate incurring costs related to filing of Exchange Act reports, and possible costs relating to consummating an acquisition or combination. We believe we will be able to meet these costs through use of funds in our treasury and additional amounts, as necessary, to be loaned by or invested in us by our stockholders, management or other investors.

 

We intend to contract out certain technical and administrative functions on an as-needed basis in order to conduct our operating activities. Our management team will select and hire these contractors and manage and evaluate their work performance.

 

We have no revenues and limited cash on hand. We have sustained losses since inception. We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

 

As of January 1, 2021, we become a shell company and have limited operating activities since then. The Report of our independent registered public accountants on our financial statements for the year ended December 31, 2021 states that these conditions, among others, raise substantial doubt about our ability to continue as a going concern.

 

11

 

 

Results of Operations

 

Year Ended December 31, 2021 Compared to Year Ended December 31, 2020

 

Revenues. During the years ended December 31, 2021 and 2020, we did not realize any revenues from operations.

 

Operating expenses. For the year ended December 31, 2021, our total operating expenses was $121,788, decreased by $100,819, or 45%, from $222,607 for the year ended December 31, 2020. This decrease was mainly due to disposal of operations in 2020 and becoming a shell company since January 1, 2021.

 

Loss from operations. As a result of the foregoing, our loss from operations was $121,788 for the year ended December 31, 2021, compared to $222,607 for the year ended December 31, 2020. This was mainly due to the less operating activities since January 1, 2021. We become a shell company after we disposed all of our operating entities in 2020.

 

Income taxes. Our income tax expenses did not incur for the years ended December 31, 2021 and 2020.

 

Net loss. For the year ended December 31, 2021, our net loss was $121,788 compared to $222,859 for the year ended December 31, 2020. The increased loss was primarily due to the increased operating expenses.

 

Liquidity and Capital Resources

 

As of December 31, 2021, we had current assets of $0, we had liabilities of $107,052, and our working capital deficit was $107,052. We anticipate that our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.

 

To date, we have managed to keep our monthly cash flow requirement low for two reasons. First, our sole officer does not draw a salary at this time. Second, we have been able to keep our operating expenses to a minimum by operating in space provided at no expense by our sole officer and director.

 

We currently have no external sources of liquidity such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

 

Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplates our continuation as a going concern. We have not yet generated any revenue and have incurred losses to date of approximately $7.4 million. In addition, our current liabilities exceed our current assets by $107,052. These factors raise substantial doubt about our ability to continue operating as a going concern. Our ability to continue our operations as a going concern, realize the carrying value of our assets, and discharge our liabilities in the normal course of business is dependent upon our ability to raise capital sufficient to fund our commitments and ongoing losses, and ultimately generate profitable operations.

 

Cash Flows

 

Operating Activities

 

For the year ended December 31, 2021, net cash used in operating activities was $70,079, related to our net loss of $121,788, reduced by an increase in other payables of $51,709.

 

For the year ended December 31, 2020, net cash used in operating activities was $564,761, related to our net loss from continuing operations of $222,859 and a cash outflow from our discontinued operations of $382,246, increased by a prepaid legal expense of $15,000 and an increase in other payables of $25,344. 

 

12

 

 

Investing Activities

 

For the year ended December 31, 2021, we reported cash inflow of $119,070 from investing activities due to disposal of our operating subsidiaries. For the year ended December 31, 2020, we had $79,446 cash outflow from our investing activities from our discontinued operations.

 

Financing Activities

 

For the year ended December 31, 2021, we reported a cash outflow of $48,991 from our financing activities which was mainly due to distribution of $119,070 as a special dividend to our minority shareholders and a financial support of $70,079 received from our related party. For the year ended December 31, 2020, we had $607,077 cash inflow from our financing activities which include $182,515 financial support received from our related party and $424,562 cash inflow from our discontinued operations.

 

Recent Accounting Pronouncements

 

For a description of our recent accounting pronouncements, see “Note 2 - Summary of Significant Accounting Policies” of this Annual Report on Form 10-K.

 

Critical Accounting Policies

 

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

 

The financial statements have been prepared in conformity GAAP, which contemplates our continuation as a going concern. The Company has no revenue since January 1, 2020 and has incurred losses to date of approximately $7.4 million. In addition, the Company’s current liabilities exceed its current assets by $107,052. To date, the Company has primarily funded its operations through advances from former stockholders, the sale of Common Stock and the loan from Hometown. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements. These factors raise substantial doubt about the Company’s ability to continue operating as a going concern. The Company’s ability to continue our operations as a going concern, realize the carrying value of our assets, and discharge our liabilities in the normal course of business is dependent upon our ability to raise capital sufficient to fund its commitments and ongoing losses, and ultimately generate profitable operations.

 

Recently Issued Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

13

 

 

Contractual Obligations

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Off Balance Sheet Items

 

Under SEC regulations, we are required to disclose off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, such as changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. An off-balance sheet arrangement means a transaction, agreement or contractual arrangement to which any entity that is not consolidated with us is a party, under which we have:

 

  any obligation under certain guarantee contracts,
     
  any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets,
     
  any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to our stock and classified in shareholder equity in our statement of financial position, and
     
  any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

 

We do not have any off-balance sheet arrangements that we are required to disclose pursuant to these regulations. In the ordinary course of business, we enter into operating lease commitments, purchase commitments and other contractual obligations. These transactions are recognized in our financial statements in accordance with generally accepted accounting principles in the United States.

 

Critical Accounting Policies

 

Management’s discussion and analysis of its financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.

 

Actual results may differ from these estimates under different assumptions or conditions. We believe that the following reflect the more critical accounting policies that currently affect our financial condition and results of operations.

 

Basis of Consolidation

 

The accompanying financial statements include Joway Health and its wholly owned subsidiaries and controlled VIEs for the periods prior to the consummation of the Merger as of December 31, 2020. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Pursuant to Accounting Standards Codification Topic 810 “Consolidation” (“ASC 810”), the Company is required to include the financial statements of its variable interest entities (“VIEs”) in its financial statements. ASC 810 requires a VIE to be consolidated by a company if that company is subject to a majority of the risk of loss for the VIE or is entitled to receive a majority of the VIE’s residual returns. VIEs are those entities in which a company, through contractual arrangements, bears the risk of, and enjoys the rewards normally associated with ownership of the entity, and therefore the company is the primary beneficiary of the entity.

 

14

 

 

Based on the various Contractual Agreements prior to the consummation of the Merger as of December 31, 2020, we believe we are able to exercise control over the VIEs, and to obtain the full economic benefits. We believe that the terms of the exclusive option agreement are currently exercisable and legally enforceable under PRC laws and regulations. We also believe that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for us to exercise our rights under the exclusive option agreement. A simple majority vote of our board of directors is required to pass a resolution to exercise our rights under the exclusive option agreement, for which consent of the shareholder of VIEs is not required. Therefore, we believe this gives us the power to direct the activities that most significantly impact VIEs’ economic performance. We believe that our ability to exercise effective control, together with the consulting service agreements and the equity pledge agreements, give us the rights to receive substantially all of the economic benefits from VIEs in consideration for the services provided by its wholly owned subsidiaries in China. Accordingly, as the primary beneficiary of VIEs and in accordance with U.S. GAAP, Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading, as VIEs of Junhe Consulting, has been consolidated in the Company’s financial statements. Sales from Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading are included in our total sales, their incomes or losses from operations are consolidated with ours, and our net income or loss includes net income or loss from Joway Shengshi, Joway Technology, Joway Decoration, and Shengtang Trading.

 

Going Concern

 

We incurred net loss of approximately $122,000 for the year ended December 31, 2021. We had accumulated deficit of approximately $7.4 million as of December 31, 2021. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

The continuation of us as a going concern through the next twelve months is dependent upon the continued financial support from its stockholders or external financing. We believe our sole officer and director will provide the additional cash to meet with our obligations as they become due. While we believe in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be neither no assurances to that effect, nor no assurance that we will be successful in securing sufficient funds to sustain the operations.

 

These conditions raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. We believe that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for the Company to continue as a going concern.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement as of December 31, 2020, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.

 

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

 

15

 

 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

The audited financial statements of Joway Health Industries Group Inc. as of December 31, 2021 and 2020 are appended to this Annual Report beginning on page F-1.

 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

Item 9A. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Exchange Act that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our senior management, consisting of Ramon Lata, President, Treasurer and Secretary (Principal Executive Officer and Principal Financial Officer), as appropriate to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our senior management, consisting of Ramon Lata, President, Secretary and Treasurer (Principal Executive Officer and Principal Financial Officer) of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2021. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, Mr. Ramon Lata, President, Treasurer and Secretary (Principal Executive Officer and Principal Financial Officer) concluded that our disclosure controls and procedures were not effective.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

16

 

 

As of December 31, 2021, our management, consisting solely of Ramon Lata, President, Treasurer and Secretary (Principal Executive Officer and Principal Financial Officer), assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in 2013 and SEC guidance on conducting such assessments. Based on that evaluation, we believe that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

 

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee and a lack of independent directors on our Board, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives; and (3) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by Mr. Lata, President, Treasurer and Secretary (Principal Executive Officer and Principal Financial Officer) in connection with the review of our financial statements as of December 31, 2021.

 

Management believes that the material weaknesses set forth in items (2) and (3) above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of independent directors on our Board results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

 

Assuming we are able to secure additional working capital, we will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us.

 

We also plan to appoint one or more outside directors to our Board who shall be appointed to an audit committee resulting in a fully functioning audit committee which will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management.

 

Management believes that the appointment of one or more independent directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of independent directors on our Board.

 

We anticipate that these initiatives will be implemented in conjunction with the acquisition of a business.

 

Changes in Internal Control over Financial Reporting

 

On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe and JHP Holdings, Inc., a Nevada corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from Crystal Globe. The shares represent 83% of the issued and outstanding shares of the Company on a fully diluted basis. The purchase price for the shares paid by the Buyer was $100,000. Pursuant to the Purchase Agreement, each of Crystal Globe, the Buyer and Company made customary representations and warranties to each other. The parties agreed to certain customary post-closing covenants, including those relating to confidentiality, publicity and litigation support. The Company and Crystal Globe also agreed to certain indemnification provisions as they pertain to the Buyer for breaches or inaccuracies in their respective representations and warranties or covenants.

 

In connection with the acquisition of the 83% by the Buyer, Jinghe Zhang, the sole officer and director of the Company, resigned and the Buyer appointed Ramon Lata as the new sole officer and director of the Company. The executive officers of the Company are currently located at 600 South 3rd Street, Las Vegas, Nevada 89101.

 

17

 

 

Item 9B. OTHER INFORMATION.

 

None.

 

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

18

 

 

PART III

 

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

Our Board of Directors

 

The Board of Directors is presently composed of one member, Ramon Lata, who was appointed effective as of February 3, 2022. Mr. Lata was also appointed as the President, Treasurer and Secretary of the Company.

 

Since December 2021, Ramon Lata has been a vice president at Wilhelmina International, a model and talent agency. Mr. Lata was a vice president at Factor Chosen LLC from April 2015 until September 2017, when it was acquired by MP Management. From September 2017 until November 2019, Mr. Lata was a vice president at Select Model LA., until it was acquired by MP Management.

 

Our directors hold their position until the next annual meeting of shareholders and until their successors are elected and qualified by our shareholders, or until earlier death, retirement, resignation or removal.

 

Involvement in Certain Legal Proceedings

 

To our knowledge, during the last ten years, none of our directors and executive officers (including those of our subsidiaries) has:

 

  Had a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.
     
  Been convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses.
     
  Been subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.
     
  Been found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.
     
  Been the subject to, or a party to, any sanction or order, not subsequently reverse, suspended or vacated, of any self-regulatory organization, any registered entity, or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Audit Committee

 

We do not presently have an audit committee. Our Board of Directors currently acts as our audit committee.

 

Compensation Committee

 

We do not presently have a compensation committee. Our Board of Directors currently acts as our compensation committee.

 

Nominating Committee

 

We do not presently have a nominating committee. Our Board of Directors currently acts as our nominating committee.

 

19

 

 

Code of Ethics

 

On May 11, 2012, our Board of Directors approved a renewed Code of Ethics which is applicable to our officers and senior executives, which include our Chief Financial Officer, Treasurer and Chief Accounting Officer. This Code embodies our commitment to conduct business in accordance with the highest ethical standards and applicable laws, rules and regulations. We will provide any person a copy of our Code of Ethics, without charge, upon written request to the Company’s Secretary. Requests should be addressed in writing to Joway Health Group Industries Group Inc., attn: Ramon Lata, 600 South 3rd Street, Las Vegas, Nevada 89101.

 

Our Executive Officers

 

Ramon Lata, who was appointed effective as of February 3, 2022, is our sole officer.

 

Item 11. EXECUTIVE COMPENSATION.

 

Executive Officer Compensation

 

The following is a summary of the compensation we paid to our Chief Executive Officer for the fiscal years ended December 31, 2021 and 2020. This includes all compensation, including any compensation paid to our Chief Executive Officers by any of our subsidiaries. No executive officer received compensation in excess of $100,000 in 2021 or 2020.

 

Summary Compensation Table

 

Name and principal position  Year  Salary
($)
   Bonus
($)
   Stock
awards
($)
   Option
awards
($)
   Non-equity
incentive
plan
compensation
($)
   Nonqualified
deferred
compensation
earnings
($)
   All other
compensation
($)
   Total
($)
 
Jinghe Zhang President, Chief Executive Officer  2020  $21,500 (1)                          —                     —                —   $21,500 
   2021  $                           $ 

 

Jinghe Zhang was the principal executive officer of the Company until February 3, 2022, when Crystal Globe Limited sold 83% of the issued and outstanding shares to JHP Holdings, Inc.

 

 

(1) The amount of $21,500 in the table above represents the compensation received by Mr. Zhang for the entire year of 2021.

 

Mr. Ramon Lata, our current principal executive officer and principal financial and accounting officer, is serving in such capacity without compensation.

 

Option Plan

 

There were no stock options and no common shares set aside for any stock option plan as of December 31, 2021.

 

Aggregated Option Exercises and Fiscal Year-End Option Value Table

 

There were no stock options exercised during the fiscal year ended December 31, 2021, by the executive officer named in the Executive Compensation Table.

 

Long-Term Incentive Plan (“LTIP”) Awards Table

 

There were no awards made to a named executive officer in the last completed fiscal year under any LTIP.

 

20

 

 

Director Compensation

 

The following is a summary of the compensation we paid to our directors for the fiscal year ended December 31, 2021.

 

Director Compensation

 

Name   Fees earned or paid in cash
($)
    Stock awards
($)
    Option awards
($)
    Non-equity incentive plan
compensation
($)
    Nonqualified deferred
compensation earnings
($)
    All other compensation
($)
    Total
($)
 
Jinghe Zhang   $                                     $    
Haibo Fan   $                                     $    
Jun Pang   $                                     $    

 

As of April 29, 2021, Jun Pang and Haibo Fan resigned as independent directors of the Company.

 

Mr. Ramon Lata, our current sole director, is serving in such capacity without compensation.

 

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The following table sets forth information regarding beneficial ownership of our common stock as of March 29, 2022 (i) by each person who is known by us to beneficially own more than 5% of our common stock; (ii) by each of our officers and directors; and (iii) by all of our officers and directors as a group. Unless otherwise indicated, the address of each listed stockholder is c/o Joway Health Industries Group, Inc., 600 South 3rd Street, Las Vegas, Nevada 89101.

 

In determining beneficial ownership of our common stock as of a given date, the number of shares shown includes shares of common stock which may be acquired on exercise of warrants or options or conversion of convertible securities within 60 days of that date. In determining the percent of common stock owned by a person or entity on March 29, 2022, (a) the numerator is the number of shares of the class beneficially owned by such person or entity, including shares which may be acquired within 60 days on exercise of warrants or options and conversion of convertible securities, and (b) the denominator is the sum of (i) the total shares of common stock outstanding on March 29, 2022, and (ii) the total number of shares that the beneficial owner may acquire upon conversion of the preferred and on exercise of the warrants and options, subject to limitations on conversion and exercise. Unless otherwise stated, each beneficial owner has sole power to vote and dispose of its shares.

 

The number of shares issued and outstanding as of March 29, 2022 was 20,054,000.

 

Name and Address  Number of Shares
Common Stock
Beneficially Owned
   Percentage
Ownership of
Shares of
Common Stock
 
Owner of More than 5% of Class        
JHP Holdings, Inc. (1)    16,644,820    83%
Director and Executive Officers          
Ramon Lata (2)   16,644,820    83%
           
All directors and executive officers (1 persons)   16,644,820    83%

 

 

(1)

JHP Holdings, Inc. holds a total of 16,644,820 shares of the Company’s common stock. As the shareholder and executive director of JHP Holdings, Mr. Lata is the beneficial owner of the shares of the Company held by JHP Holdings.

(2) Reflects the 16,644,820 shares held by JHP Holdings, Inc. Mr. Lata is the sole shareholder and executive officer and director of JHP Holdings and as such has voting and dispositive control over the shares held by JHP Holdings.

 

21

 

 

Item 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

The following are transactions for the last two completed fiscal years and any currently proposed transaction, in which the registrant was or is to be a participant and the amount involved exceeds the less of $120,000 or one percent of the average of the registrant’s total assets at December 31, 2021 and 2020, and in which any of the following persons had or will have a direct or indirect material interest.

 

  Any director or executive officer;
     
  Any immediate family member of a director or executive officer, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of such director, executive officer and any person (other than a tenant or employee) sharing the household of such director or executive officer; and
     
  any person who was in any of the following categories when a transaction in which such person had a direct or indirect material interest occurred or existed:
     
  any person who is known to the registrant to be the beneficial owner of more than five percent of any class of the registrant’s voting securities; or
     
  Any immediate family member of any such security holder, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of such security holder, and any person (other than a tenant or employee) sharing the household of such security holder.

 

Transaction with Crystal Globe

 

On November 20, 2020, we entered into a Merger Agreement (the “Merger Agreement”) with Crystal Globe Limited, a British Virgin Islands company which is a majority shareholder of Joway and the other parties signatory thereto. See “Business-Recent Events- Entry into a Material Definitive Agreement”. Upon completion of the transactions contemplated by the Merger Agreement, Crystal Globe acquired all our business in consideration for $119,070 in cash (the “Merger Consideration”). The Company has distributed the Merger Consideration to its shareholders (other than Crystal Globe) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company.

 

Transactions with Jinghe Zhang

 

During the years ended December 31, 2021 and 2020, we received financial supports of $66,235 and $182,515 from our former CEO and chairman, Mr. Jinghe Zhang. The loans due to him are for our daily operating activities without interest charge and due on demand.

 

On April 28, 2021, the Company entered into an agreement with Mr. Jinghe Zhang to release the Company from $295,928 of indebtedness owed to him. As of December 31, 2021 and 2020, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $3,999 and $233,693, respectively.

 

Transactions with Joway Shengshi

 

Joway Shengshi was one of the Company’s subsidiaries but has been sold via the Merger Agreement on December 31, 2020. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the years ended December 31, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our daily operating activities.

 

On April 28, 2021, Joway Shengshi released the Company from $463,698 of indebtedness owed to it. As of December 31, 2021 and 2020, the total unpaid principal balance due to Joway Shengshi was $0.

 

22

 

 

Other Related Party Transactions

 

Except as disclosed above, no executive officer, director or any member of these individuals’ immediate families, any corporation or organization with whom any of these individuals is an affiliate or any trust or estate in which any of these individuals serve as a trustee or in a similar capacity or has a substantial beneficial interest in is or has been indebted to us at any time since the beginning of our last fiscal year.

 

Procedures for Approval of Related Party Transactions

 

Our Director Board is charged with reviewing and approving all potential related party transactions. All such related party transactions must then be reported under applicable SEC rules. We have not adopted other procedures for review, or standards for approval, of such transactions, but instead review them on a case-by-case basis.

 

Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

Audit Fees

 

For each fiscal year of 2021 and 2020, we incurred aggregate fees and expenses of $10,000 and $79,000, respectively, from HHC for works completed for our annual audits and quarterly reviews.

 

Audit-Related Expenses

 

Audit-related expenses for 2021 and 2020 were $0, respectively.

 

Tax Fees

 

We incurred aggregate fees and expenses of $0 for each fiscal year of 2021 and 2020, respectively.

 

All Other Fees

 

We incurred other fees of $0 for each fiscal year of 2021 and 2020.

 

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

 

Since we did not have a formal audit committee, our board of directors served as our audit committee. We have not adopted pre-approval policies and procedures with respect to our accountants in 2020. All of the services provided and fees charged by our independent registered accounting firms in 2021 were approved by the board of directors.

 

Our Board of Directors has reviewed and discussed with HHC, our audited financial statements contained in this Annual Report on Form 10-K for the 2021 and 2020 fiscal years. The Board of Directors also has discussed with HHC, the matters required to be discussed pursuant to SAS No. 61 (Codification of Statements on Auditing Standards, AU Section 380), which includes, among other items, matters related to the conduct of the audit of our financial statements.

 

Our Board of Directors has received and reviewed the written disclosures and the letter from HHC required by Independence Standards Board Standard No.1 (Independence Discussions with Audit Committees), and has discussed with HHC its independence from our company.

 

Our Board of Directors has considered whether the provision of services other than audit services is compatible with maintaining auditor independence. Based on the review and discussions referred to above, the Board of Directors determined that the audited financial statements be included in our Annual Report on Form 10-K for our 2021 and 2020 fiscal years for filing with the SEC.

 

23

 

 

Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

 

Exhibit Number

  Description
3.1   Articles of Incorporation(1)
     
3.2   Bylaws(1)
     
4.2   Description of Capital Stock
     
10.35   Merger Agreement, dated as of November 20, 2020, by and among Crystal Globe Limited, Joway Health Industries Group Inc., Dynamic Elite International Limited and Joway Merger Subsidiary Limited (2)
     

10.36

 

Stock Purchase Agreement, dated as of January 3, 2022, by and among Crystal Globe Limited, Joway Health Industries Group Inc. and JHP Holdings, Inc. (3)

     
14.1   Code of Ethics(4)
     
21.1   List of Subsidiaries*
     
31.1   Certification of the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
     
32.1   Certification of the Principal Executive Officer of Registrant pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
     
101.INS   Inline XBRL Instance Document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

  

 

(1) Incorporated by reference to the exhibits to our registration statement on Form SB-2 filed with the SEC on September 11, 2003.
(2) Incorporated by reference to the exhibits to our Current Report on Form 8-K filed with the SEC on November 25, 2020.
(3) Incorporated by reference to the exhibits to our Current Report on Form 8-K filed with the SEC on February 10, 2022.
(4) Incorporated by reference to the exhibits to our Annual Report on Form 10-K filed with the SEC on March 1, 2010.

 

ITEM 16. FORM 10–K SUMMARY

 

None.

 

24

 

 

Signatures

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 29, 2022

 

  JOWAY HEALTH INDUSTRIES GROUP INC.
     
  By: /s/ Ramon Lata
    Ramon Lata
   

President and Chief Executive Officer

(Principal Executive Officer and Principal Financial and Accounting Officer)

 

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf of the registrant and in the capacities and on the dates indicated.

 

/s/ Ramon Lata   President and Chief Executive Officer   March 29, 2022
Ramon Lata

(Principal Executive Officer and Principal Financial and Accounting Officer)

   

 

25

 

 

 
 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the Board of Directors of

Joway Health Industries Group Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Joway Health Industries Group Inc. (the Company) as of December 31, 2021 and 2020, and the related statements of operations and other comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two year period ended December 31, 2021, and related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring significant losses and has accumulated deficiency in stockholders’ equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to this matter are also discussed in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ HHC

We have served as the Company’s auditor since 2013.

 

Forest Hills, New York

March 29, 2022

PCAOB ID #5867

 

F-1

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

BALANCE SHEETS

 

   As of
December 31,
 
   2021   2020 
ASSETS          
           
CURRENT ASSETS:          
Receivable from related party  $
-
   $119,070 
Total current assets   
-
    119,070 
           
Total assets  $
-
   $119,070 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Special dividend payable  $
-
   $119,070 
Other payables   103,053    51,344 
Due to related parties   3,999    693,546 
Total current liabilities   107,052    863,960 
           
COMMITMENTS   
-
    
-
 
           
STOCKHOLDERS’ EQUITY:          
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding   
-
    
-
 
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at December 31, 2021 and 2020, respectively   20,054    20,054 
Additional paid-in-capital   7,228,862    6,469,236 
Accumulated deficit   (7,355,968)   (7,234,180)
Total stockholders’ equity   (107,052)   (744,890)
Total liabilities and stockholders’ equity  $
-
   $119,070 

 

The accompanying notes are an integral part of these financial statements

 

F-2

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

 

   For the
Year ended
December 31,
 
   2021   2020 
REVENUES  $
-
   $
-
 
           
COST OF REVENUES   
-
    
-
 
           
GROSS PROFIT   
-
    
-
 
           
General and administrative expenses   121,788    222,607 
OPERATING EXPENSES   121,788    222,607 
           
INCOME FROM OPERATIONS   (121,788)   (222,607)
           
Other expenses   
-
    (252)
OTHER LOSS, NET   
-
    (252)
           
LOSS BEFORE INCOME TAXES   (121,788)   (222,859)
           
INCOME TAXES   
-
    
-
 
           
NET LOSS FROM CONTINUING OPERATIONS   (121,788)   (222,859)
           
Discontinued operations:          
Loss from operations of discontinued component, net of taxes   
-
    (760,538)
Loss from disposal of discontinued component, net of taxes   -    (1,340,795)
           
NET LOSS   (121,788)   (2,324,192)
           
OTHER COMPREHENSIVE LOSS:          
Foreign currency translation adjustments   
-
    165,413 
           
COMPREHENSIVE LOSS  $(121,788)  $(2,158,779)
           
LOSS PER COMMON SHARE, BASIC AND DILUTED:          
Continuing operations - Basic & diluted  $(0.01)  $(0.01)
Discontinued operations - Basic & diluted  $
-
   $(0.10)
           
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED   20,054,000    20,054,000 

 

The accompanying notes are an integral part of these financial statements

 

F-3

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

STATEMENT OF STOCKHOLDERS’ EQUITY

 

                       Accumulated     
   Common Stock   Additional            other     
   Number of   Common   paid-in   Statutory   Accumulated   comprehensive   Total 
   shares   stock   capital   reserves   deficit   income   equity 
BALANCE, December 31, 2019   20,054,000   $20,054   $7,361,665   $354,052   $(5,264,040)  $486,338   $2,958,069 
                                    
Net Loss   -    
-
    
-
    
-
    (2,324,192)   
-
    (2,324,192)
Disposal of subsidiary   -    
-
    (892,429)   (354,052)   354,052    (651,751)   (1,544,180)
Foreign currency translation gain   -    
-
    
-
    
-
    
-
    165,413    165,413 
                                    
BALANCE, December 31, 2020   20,054,000    20,054    6,469,236    
-
    (7,234,180)   
-
    (744,890)
                                    
Net Loss   -    
-
    
-
    
-
    (121,788)   
-
    (121,788)
Forgiveness of related party debts   -    
-
    759,626    
-
    
-
    
-
    759,626 
                                    
BALANCE, December 31, 2021   20,054,000   $20,054   $7,228,862   $-   $(7,355,968)  $-   $(107,052)

 

The accompanying notes are an integral part of these financial statements

 

F-4

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

STATEMENT OF CASH FLOWS

 

   For the
Year ended
December 31,
 
   2021   2020 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss from continuing operations  $(121,788)  $(222,859)
Adjustments to reconcile net loss to net cash provided by operating activities          
Changes in operating assets and liabilities:          
Prepaid Expense   
-
    15,000 
Other payables   51,709    25,344 
Net cash used in operating activities from continuing component   (70,079)   (182,515)
Net cash used in operating activities from discontinued component   
-
    (382,246)
Net cash used in operating activities   (70,079)   (564,761)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Cash received from disposal of subsidiaries   119,070    
-
 
Net cash provided by investing activities from continuing component   119,070    
-
 
Net cash used in investing activities from discontinued component   
-
    (79,446)
Net cash provided by (used in) investing activities   119,070    (79,446)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Distribution of special dividend   (119,070)   
-
 
Due to related parties   70,079    182,515 
Net cash provided by (used in) financing activities from continuing component   (48,991)   182,515 
Net cash provided by financing activities from discontinued component   
-
    424,562 
Net cash provided by (used in) financing activities   (48,991)   607,077 
           
EFFECT OF EXCHANGE RATE CHANGES ON CASH   
-
    37,130 
           
NET INCREASE IN CASH   
-
    
-
 
CASH, beginning of year   
-
    
-
 
CASH, end of year  $
-
   $
-
 
           
SUPPLEMENTAL DISCLOSURES:          
Income taxes paid  $
-
   $
-
 
Interest paid  $
-
   $
-
 
           
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES          
Receivable used to offset the selling price of disposal of Dynamic Elite and Subsidiaries  $
-
   $783,360 
Uncollected consideration from Disposal of Dynamic Elite and Subsidiaries  $
-
   $119,070 
Undistributed consideration to shareholders  $
-
   $119,070 
Forgiveness of related party debts  $759,626   $
-
 

 

The accompanying notes are an integral part of these financial statements

 

F-5

 

 

JOWAY HEALTH INDUSTRIES GROUP INC.

NOTES TO FINANCIAL STATEMENTS

 

Note 1 – ORGANIZATION

 

The financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”). Joway Health is hereinafter referred to as the “Company,” “we” and “us”.

 

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilized the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.

 

Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engaged in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.

 

Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducted its business through Tianjin Joway Shengshi Group Co., Ltd.

 

Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi was owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import & Export Trading Co., Ltd. are subsidiaries of Joway Shengshi.

 

Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and the construction of Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.

 

Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness Room for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.

 

Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.

 

F-6

 

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company.

 

As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.

 

On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health became a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

 

Note 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

 

As reflected in the accompanying financial statements, for the years ended December 31, 2021 and 2020, we incurred net losses of $121,788 and $2.3 million, respectively. In addition, we reported cash outflow of $0.07 million and $0.6 million from our operating activities for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of approximately $7.4 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.

 

The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.

 

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

 

F-7

 

 

Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Prior to the consummation of the Merger as of December 31, 2020, the Company’s functional currency is the Chinese Renminbi (“RMB”); however, the accompanying financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

Use of Estimates

 

The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

 

For the periods prior to the consummation of the Merger as of December 31, 2020, the Company consolidated financial statements including Dynamic Elite, its former wholly owned subsidiaries, and controlled VIEs. The financial statements of Dynamic Elite and controlled VIEs were included as part of the Company’s discontinued component. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

 

The accompanying financial statements are presented in USD. The functional currency of the Company is RMB for the periods prior to the consummation of the Merger as of December 31, 2020. The financial statements are translated into USD from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   December 31, 
   2020 
Year ended RMB: USD Exchange rate   6.5249 
Average yearly RMB: USD Exchange rate   6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

For the years ended December 31, 2021 and 2020 foreign currency translation adjustments of $0 and $165,413, have been reported as other comprehensive loss in the financial statements. After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

F-8

 

 

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners. Other comprehensive income is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

 

Prior to the consummation of the Merger as of December 31, 2020, the Company’s operations were carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations were influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC were subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable.

 

As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 (formerly Statement of Financial Accounting Standard (“SFAS”) No. 157 Fair Value Measurements) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as the following:

 

  Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

  Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

  Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.

 

F-9

 

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the years ended December 31, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

 

Deconsolidation

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

F-10

 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

The following is a reconciliation of the deconsolidation:

 

   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)

 

Note 4 – RECEIVABLE FROM RELATED PARTY

 

Receivable from related party consist of the following:

 

   December 31, 
   2021   2020 
Crystal Globe  $
-
   $119,070 

 

The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.

 

Note 5 – SPECIAL DIVIDEND PAYABLE

 

As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. 

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. 

 

F-11

 

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. 

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

Note 6 – OTHER PAYABLES

 

As of December 31, 2021 and 2020, the Company reported $103,053 and $51,344 as its other payables, respectively. The other payables mainly consist of payables for professional services, including audit, legal, and financial statement filing services. 

 

Note 7 – RELATED PARTY TRANSACTIONS

 

Payables due to related parties consist of the following:

 

   December 31, 
   2021   2020 
Jinghe Zhang  $3,999   $233,693 
Joway Shengshi   
-
    459,853 
Total  $3,999   $693,546 

 

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

 

Transactions with Jinghe Zhang

 

During the years ended December 31, 2021 and 2020, we received financial supports of $66,235 and $182,515 from our former CEO and chairman, Mr. Jinghe Zhang. The loans due to him are for our daily operating activities without interest charge and due on demand.

 

On April 28, 2021, the Company entered into an agreement with Mr. Jinghe Zhang to release the Company from $295,928 of indebtedness owed to him. As of December 31, 2021 and 2020, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $3,999 and $233,693, respectively.

 

Transactions with Joway Shengshi

 

Joway Shengshi was one of the Company’s subsidiaries but has been sold via the Merger Agreement on December 31, 2020. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the years ended December 31, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our daily operating activities.

 

On April 28, 2021, Joway Shengshi released the Company from $463,698 of indebtedness owed to it. As of December 31, 2021 and 2020, the total unpaid principal balance due to Joway Shengshi was $0.

 

F-12

 

 

Disposal of all of Joway Health’s subsidiaries and VIEs

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $902,430 in cash (the “Merger Consideration”). The Company was obligated to distribute the Merger Consideration to its shareholders in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. The Merger Consideration due from Crystal Globe was partly offset by the distribution due to Crystal Globe at the amount of $783,360. The remaining portion of $119,070 of Merger Consideration was paid by Crystal Globe in cash and distributed to the Company’s minority shareholders as a special dividend in January 2022. The transaction was completed on December 31, 2020.

 

Note 8 – INCOME TAXES

 

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

 

The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

 

Note 9 – SUBSEQUENT EVENTS

 

Change in Control

 

On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe Limited, a company incorporated under the laws of British Virgin Islands (the “Seller”), and JHP Holdings, Inc., a Nevada corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from the Seller.

 

On February 2, 2022, Mr. Ramon Lata was appointed to the board of the directors upon the resignation of Jinghe Zhang, the sole officer and director of the Company. Mr. Lata was also appointed as the President, Treasurer and Secretary of the Company.

 

In connection with the resignation of Mr. Zhang, all obligations owed to Mr. Zhang from the Company were cancelled and there are no further debts or liabilities owed by the Company to any affiliate or former affiliate of the Company.

 

F-13

384-1990 702 GTVI NONE false FY 0001263364 0001263364 2021-01-01 2021-12-31 0001263364 2022-03-29 0001263364 2021-06-30 0001263364 2021-12-31 0001263364 2020-12-31 0001263364 2020-01-01 2020-12-31 0001263364 us-gaap:CommonStockMember 2019-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2019-12-31 0001263364 us-gaap:RetainedEarningsMember 2019-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001263364 2019-12-31 0001263364 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2020-01-01 2020-12-31 0001263364 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001263364 us-gaap:CommonStockMember 2020-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2020-12-31 0001263364 us-gaap:RetainedEarningsMember 2020-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001263364 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2021-01-01 2021-12-31 0001263364 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001263364 us-gaap:CommonStockMember 2021-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001263364 us-gaap:RetainedEarningsMember 2021-12-31 0001263364 gtvi:DynamicEliteMember 2010-09-21 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2007-05-17 0001263364 gtvi:JowayShengshiToJowayTechnologyMember 2010-07-25 0001263364 gtvi:JowayShengshiToJowayDecorationMember 2010-07-09 0001263364 gtvi:JowayShengshiToShengtangTradingMember 2010-07-28 0001263364 gtvi:CrystalGlobeMember 2020-11-01 2020-11-20 0001263364 2021-01-01 2021-01-31 0001263364 2020-11-01 2020-11-20 0001263364 2020-11-20 0001263364 gtvi:JowayHealthMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 2021-01-31 0001263364 gtvi:YearEndedRMBUSDExchangeRateMember 2021-12-31 0001263364 gtvi:AverageYearlyRMBUSDExchangeRateMember 2021-12-31 0001263364 gtvi:JowayHealthsMember 2021-01-01 2021-12-31 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-12-31 0001263364 gtvi:CrystalGlobeMember 2020-12-31 0001263364 gtvi:JowayHealthsMember 2021-12-31 0001263364 gtvi:JowayHealthsMember 2020-11-20 0001263364 gtvi:JingheZhangMember 2021-01-01 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-01-01 2020-12-31 0001263364 gtvi:JingheZhangMember 2021-04-28 0001263364 gtvi:JingheZhangMember 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-12-31 0001263364 gtvi:JowayShengshiMember 2021-01-01 2021-12-31 0001263364 gtvi:JowayShengshiMember 2020-01-01 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-04-28 0001263364 gtvi:JowayShengshiMember 2020-12-31 0001263364 gtvi:JingheZhangMember 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-12-31 0001263364 gtvi:JowayShengshiMember 2020-12-31 0001263364 us-gaap:SubsequentEventMember 2022-02-03 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-4.2 2 f10k2021ex4-2_jowayhealth.htm DESCRIPTION OF CAPITAL STOCK

EXHIBIT 4.2

 

DESCRIPTION OF CAPITAL STOCK

 

Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, and 1,000,000 shares of preferred stock, par value $0.001 per share. As of March 29, 2022, there were 20,054,000 shares of common stock, and no shares of preferred stock, issued and outstanding.

 

Common Stock

 

Holders of our common stock are entitled to one vote per share. Our Articles of Incorporation do not provide for cumulative voting. Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds. However, the current policy of our board of directors is to retain earnings, if any, for the operation and expansion of the Company. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all of our assets which are legally available for distribution, after payment of or provision for all liabilities and the liquidation preference of any outstanding preferred stock. The holders of our common stock have no preemptive, subscription, redemption or conversion rights.

 

Preferred Stock

 

Our Articles of Incorporation authorize the issuance of up to 1,000,000 shares of preferred stock with designations, rights and preferences as may be determined from time to time by our board of directors (commonly known as "blank check" preferred stock). The board of directors may, without stockholder approval, issue preferred stock with voting, dividend, liquidation and conversion rights that could dilute the voting strength of our common stockholder and may assist management in impeding an unfriendly takeover or attempted changes in control.

EX-21.1 3 f10k2021ex21-1_jowayhealth.htm LIST OF SUBSIDIARIES

EXHIBIT 21.1

 

LIST OF SUBSIDIARIES

 

None.

EX-31.1 4 f10k2021ex31-1_jowayhealth.htm CERTIFICATION

EXHIBIT 31.1/31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT AND RULE 13A-14(A)

OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

I, Ramon Lata, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Joway Health Industries Group Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have;

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the most recent quarter (the registrant’s fourth quarter) covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 29, 2022 By: /s/ Ramon Lata
    Ramon Lata
   

President, Treasurer and Secretary

(Principal Executive Officer, Principal

Accounting and Financial Officer)

 

EX-32.1 5 f10k2021ex32-1_jowayhealth.htm CERTIFICATION

EXHIBIT 32.1/32.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL

ACCOUNTING AND FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Joway Health Industries Group Inc. (the “Company”) for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ramon Lata, President, Treasurer and Secretary of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that;

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: March 29, 2022 By: /s/ Ramon Lata
    Ramon Lata
    President, Treasurer and Secretary
    (Principal Executive Officer and Principal Accounting and Financial Officer)

EX-101.SCH 6 gtvi-20211231.xsd XBRL SCHEMA FILE 001 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statement of Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Receivable from Related Party link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Special Dividend Payable link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Other Payables link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Receivable from Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Organization (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Receivable from Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Special Dividend Payable (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Other Payables (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 gtvi-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gtvi-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 gtvi-20211231_lab.xml XBRL LABEL FILE EX-101.PRE 10 gtvi-20211231_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !; G # 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HKQCP]^T!\+O%/QF\9_ +0]6>X^ FL6NA?%.?5]%UKPW9>&=2NM 7Q0$DN? M$-AIBW5M!H4D>HSZC:++IRV\B2I=2(VZO3GDN<4X5:D\KQ\(4,)E^/K2EA:R M5+!9K4A1RO%5/=;C0S&K4A3P52SCB9SA&BI2E%/S(9UE%2=*$,SP$IU\5C\# M1C'%4FZN,RNG.KF>%AJE*OE]*G.IC*=T\-"$Y57&,9->Y45\R)^UU\%/^$4\ M2^,)M7UV/3_#W@OPU\2;;3+?PSK&L^*/%WP[\'K?5_$'B MC1O'6J6-WIGAJ+3]/.KSW\/V>_TO3VDA\R'P#^V)\"/B7\&]+^.'A/Q->W/A M36/%MO\ #FRT?4='OM$\;#XHW>N0>&+7X77?A/6$LM2L/'L_B*ZM=(71+U8! M'-<1W4US%IF^^7IEPSQ#"E*O+),T5&&,H9=.J\'5]G#'8JE6KX?"RFN9*K6I M8;$SIW2IOZMBHNO&IA<32P_-'B;AV=2-&&>97*K/!U\PA26,H^TE@<+5HT<1 MBHQ?*W2HU<1AHSM>HOK.%DJ$J>*PU7$?4-%>,-\>_AY_PJGQI\8+>[U34?#? MP\A\8Q^,-)TG2KC5_%^C>(/ ,U[9>+/!3^&M--U>W7C/2]6L+C15T&Q-S-?Z MG]GBTV2[AN[2XG\2^''[>?P7^(G@WXJ>/Y?#?QP^'/A7X-Z/8:]XUO\ XK_! M#XA^!;J/2M0M-9OEN]%T74-&DUS7X;2TT'49]1ETK3;F*PCC0W,B;Q@H<-<0 M8FCB\1A\GQ]:C@<9A\OQ?8K^**1 M[2\A*7-E>VYFL[VVECN+2XFA=7/+B,FS;"86>-Q678S#82GC*F73Q%>A*E2C MCJ-3%4JV$YIRBW7HU<%C*56$83]G5PU>G.<9TY171A\ZRC%XJ&!PF98+$XRI M@J>90PU"O"K5> K4\+5HXOEIJ2C0K4L=@ZM&$K/Q%XO\ "MYJ["6PAM-<\#>)=3\)^)+2Z2_2 MWDMQ9ZQI-VL,TJI#>6;6NH6KRV=W;S2>@6^KZ5=RPP6NIZ?.<&%YD5HTE!C9@XVURXC!XO"5J^'Q6%Q&'Q&&J2HXB MC7H5:56A5@HRG3K0G34J4X1G"4HSY91C.,FE&2;ZL/C,)BZ-#$X7%8?$X?$T MX5L-7H5Z56EB*4W*,*E&<*C56$Y0G&,H#$6$/_+0K3Y-7TF+R/-U/3H_M5M)> MVWF7MLGVBSBB\^6[@W2CS;:.']])/'NB2+]XSA.:R]E4T_=U-;I?NZFKC?F2 M_=ZN-GS6ORV=[6=MO:T]7[2G9)-OVE/12MRM_O-%*ZY6[)W5F[J^A15(:EIQ MAMKD7]D;>]EC@L[@74!ANYIB5AAMI1)Y<\LK*PCCB9WD*D*"0:NU+C*/Q1DM M6M4UK%VDM4M8O22W3T:3T*4HO:2>B>C3TDKQ>C>DEK%[-:IM:A17FGAWXO?# M[Q7\2OB/\(M"U^&]^(/PGL?!>I>.] \BXBFT:R^(%AJ.I>%K@32Q)!>)?VFE MWDDALY)Q:,L4=WY,D\2OW<.K:5<7'V2#4]/GNO-N(?LT-[;2W'G6>W[7#Y*2 MM)YMKN7[1'MWP;E\T+D9WK83%8::AB,-B*$Y4,/BE"K1J0D\-BZ,<3A<0E*% M_88G#SA7H5=*=6E*-2$I1=S"AC,)B8.IA\5AZ\(XC$864Z5:E4BL5@Z\L-B\ M.W&;7M\-B(3H5Z6M2E5C*G.,9*ST**XKPI\1O _CC5?&NB^$O$VD>(-3^'?B M1?"'C.UTN]@NWT'Q(=&TG7GTF],+NJW4&G:WI[7* D6]TUQ83%+VSNX(;FO^ M-O"OA>\TNPU[7M)TJ[U>=XK."_U*PLI"D5G?7LMW(EWI3KQDZ:4J52G M4BW"I"4TL9A)4/K,<5AI8;GE36(CB*,J#J0KSPTX*LJKI.<,12JT)151RC6I MU*&>(/VBOAEH%S\/](74-2\0^+_BEI5YKG@+P)X2TN?Q)XOU[ M1--MX;C5-=.G:89K;1_#VEKF2ZH-1O+6UFJS_M)? M#6R^.?AS]GG5$\8:-X_\9Z'XEUOP5.QD:^T5X)X,_:1^ M&OCCXQ>,?@1IW_"7:1\2/!WA73_'DFD^*_!/B7PO:>)? NHZO-X?B\9>#M4U MC3[6R\1^'8_$%O+HLM_:2@-?(?L\<]L#<#WNN7&8#&Y=5IT<=A:^$JU<-A\9 M2A7AR2JX7%TW6PN)IVE.,Z->FI2I5(3E&7)4C[LZ=6G2Z\%C\%F-*I6P&*H8 MNE2Q.)P=6I0GSQI8O!U%1Q6&J7C"5.OAZCC"K3G",H\].7O0JTJE7POXW?M/ M_LX_LTVWAV\_:&^.WPE^"%IXON-1M/"MS\5?'_ACP'!XCNM(CM)M5MM$E\2Z MEIR:E/IT5_8RWL5HTKVR7=NTJJLT9;QW3O\ @I'_ ,$^]84-I/[:_P"RWJ:G MD-8?'+X=78(]08/$$F1P>17T3\2O@K\&_C/:Z79?_#/XKV>AS75SHEI\ M2O ?A;QU;:/<7T<4-[<:5!XHTK5(M/GO(8(8KJ6T2&2XCAB25G6- /Y)_P#@ MOQ_P3H_9:_9MT#X+?M.?L[_"SPU\%_$'B_XI-\+?B'X8^'NEV_AWP-XIM]6\ M*Z_XET?7V\+:>(=%T;Q!I=QX9NK26\T6QL5U>TU)CJ:3W%E;S5]UX<\-<,\8 M\39'PQFF+S[+L1G&(>$6-P,,HQ%"&(<<15IJ-#$PC6C3E1HV#_AWXHM_MW@NX\1>+(-9U6Y\0^( M-(+K;:_)IEGH\-KI^E:G%/I:/>375Q:W,JP^5_1/B;]&S@GPWX/S'BS$\6<5 MX^.#GA*%'!PR_AZD\1B<;B(X;#TW5NU3@YR M)W&>7<(X;A'A++GC*>+Q%?&U,QXBJK#X;!4)8BO45+W75GR)1ITTTYSG%724 MFOZ[?@I^US^RU^TEJ>OZ+^SY^T5\%?C;J_A2RLM2\3:9\+/B5X1\=7_A_3]2 MGGM=/O=9M/#>K:C/IUK>W-K2W'_!3/\ X)V6NJW^ MA7/[HZ?J>G7,ME?Z?>6;>(Q<6UY97<,UM=6\ MT:2P3Q/%(JNI4?0'PO\ V>?@%\$9K^X^#/P0^$7PEN=5LK33=5N_AK\./!_@ M>[U73["22:QLM4NO#.CZ9<:C:VDTTTUM!>23QPRRRRQJLDCLWSW\8O\ @F?^ MP%\>/#NO^'/B/^R)\ KZ/Q&VH3WVO:%\,O"?A#QG#J>I.\]SKNG>-/"FEZ/X MGT_73=2->#5;;5$NVNBTLSR^9*LG\D8=Y \5/ZU#.XX)RHJG]7JY5+%PAJL1 M*I[6BL/4ELZ,:7LU9.-27,XM?V)B%GRPL?JD\E>.4*KG]8I9HL).IO1C3]C6 M>(IP>U651U&FU*$>5-/HX_\ @H3^PG,@DB_;"_9ME1AE7C^,O@)T8'H0RZX0 M1[@TYO\ @H+^PLH+-^U_^S>J@9+-\8_ 8 ZDDZY@#W-?YWOQ=^$=I\ OCG\ M=_@58:A=ZQI?P<^,7Q$^&VD:IJ(B.H7^D>$O$^HZ3I5U?M$JQ/>R:?;VQNI8 MU1)9_,D1$5PH\OURUFO++[#:,L5SJ-Q;:=;R% PCFU"XBLXI"G&\)).K;)$(" M@$GT[UZ!\3OVYOV,?@KJ/AO2/B_^U7^SY\,-4\8^%M,\<>$].\>_%SP-X5O? M$O@W67FCTCQ3H=MK6MV']3>VN$L=6LTFLKIH91#,Y1L?.G[,O_!(O]@+ M]G'X8^&O!EC^R]\&/'OB2WT33XO&'Q"^*/PZ\*_$3QKXS\0_9(1K&M:OK'C# M3=:GMQ?7PGF@TC36M-'TR%UM-/LX($PWU_\ $#]EW]FCXL'36^*'[//P/^(L MFC:#!X6T:;QQ\*? OBJXT;PS:[S:^'](N-;T*^GTO1;4R2-:Z9826]G;,[-# M#&S$G^*L7_JM#&588-<0UL#"I7C2JUZF2TL16A&2CAZOLX4)4Z2G&,YU*!/_EW7\>7_ 6[_82_9_\ V*_VH/A-K?[-_@RR M^&7@OX]^!O%>M^(/ASH*O#X-T/Q?X,UK2K.\U3PEIKO(F@6.NZ?K]BU[H%B( MM(L[ZP>ZTVVM8[Z6VC_) J@!.Q>!G[H_PK^MO#OZ,G!G'_".5<54>+>*L##, MJ52;PLLOX?J.C.E5JT*D'.37-RU*-2*DM))*2TE9?QYXE?2EXU\.N,6U*<5BXYCQ#35:G6I4J]*?(DU'FIUH-QO>+O%ZIW_T9M1_X*1_\$^] M'7?JW[:_[+FF+_>O_CC\.K0?G/X@CKUOX:?M3?LU?&?P+XO^*'PC^/GP@^)G MPX^'S:FGCKQWX$^(?A7Q3X2\'OHNCQ^(=77Q+X@T75+S2]%;3-!FBUF_&H7- MN;73)$O9MENPD/\ -9_P0H_X)I?LH?&WX+>)?VK?C_\ "?PE\:_&VI_$OQ-X M+\%Z1\2-%M/$WA#P;H7@Z.PM9[O3O#&J"YT._P!8UC4KR[>YU35+"ZGM8+6V MMK 6P$\D_P#3YX*^!WP5^&WAG7O!7PZ^#_PN\ ^#?%37;>)_"7@OX?\ A/PM MX9\1M?Z>FDWS:]H.AZ38Z7K#7NE1QZ9=MJ-K<&YT^-+*8O;*L8_F?CW(N&.% M^)\ZX*ZE?^"@W["S ,O[7_P"S>RD9!7XQ^ R"#T((UP@@ MU\]?M6_\$B/V!/VC?A/XL\*W'[,7P=^'GBY?#VIOX(^(WPI^'WA?X<>-/!OB M2WLII-%U73]5\'Z;HSWUM;7RP->Z)JPO='U6T$EI>VCHZ/'_ )]GAH2'1[1+ MC:\\*>1,^T -)"3$[!3DJ"Z,0,G&<9XK]9\%?!O@[Q8 M+._KD:-6IBL_PE:C5P;H^UIU*=.52+O"O2E&<9>JZ[I7AC3/VWOV5; M_P 1Z[JNGZ'HNA6GQW^&UQJ^K:SJUW#8:7I6G:?'XB:ZO-0U"^N(+.RM+>*2 M>YN9HX84>1U4_P"?1\#O@SI_[17[0?P"^ 6K:C>Z-HOQB^+W@CP#KNIZ6$&I M66@:WK,$6NSZ>SJR1WRZ0EZ+29U9()V2=D=8RC?Z#/PA_P"";G[!/P*T;P]H MWPT_9$_9_P!&/A>73[S2->U#X8>$_$OC&/5-+FCN;+7+CQIXFTO5_%5YKT-Y M$EZNL7.KR:@MXJ7$CG'$^=XW,<#4S"3J4,AP=' M#T(XAX:%Y0A5E4G4JQE:$4K0@Y.2O%'K^"'BOQEXNY3F>=XC)>&,CP.7X^&7 M15'$9]C*^(KN@L14M&I.G"G"G3E%. M^)/BI\6O%NE>"? ?A.S^VZUK^KS&."(.ZPVUG:P1K)=:AJ>H7+Q6>FZ78PW% M_J%Y-%:VEO+-(J'\#P^'Q&,Q%#"82A6Q6*Q-:GA\-AL/2J5\1B*]:<:=*C1H MTH5*M6K5J3C"G3IPG.'KXO%UZ.%PN&HU,1B<3B*M.AA\ M/0HPE4JUJU:K.G2I4J=.,ISJ5)QA&,6VUI?TFOG;XT?M9(M%\,R#5;>-RE]XCNB[6T/Y*_L@_L*_M:?\%3?BIX@T+X-R?\(U\./# M^JB+XO?M)>/_ .T]2\-^']0G1+N71[&0S?VMX^\?WL$Z747A^PO%^S1W$%]X MCU?1K&Y@N9_Z7PWT=X\-\.QXJ\6.)(\)X6=.-6CD.6T\-C<[GSQ4HTL9BL34 M_L[!5Y)QB\-AZ>9XBG.7LYR]K&5./\Q8GZ1SXFXDEPEX1\-3XOQ=.I.GB.(, MQJ8G Y%3Y).,ZN$P^'I_VACJ$6I..)KU,MP]6,5.$?9251_V?^*O^"^O_!++ MPGJ46FW7[1D^J&0X:^T'X:?$S4].A_>"/,]RGA2/8!GS#B-OW0+X[5[=\*O^ M"OO_ 33^,VHVNC>"/VPOA"NL7DL$%OI?B_5;[X>74US/\ Q)X7T.\O&YEETGP;\-M3\+66D6@/_'O;7>HZW>1I\L^J71^:NT^*W_!M M=_P2E^(6BW%AX0^#_C3X&ZRT$JV/B7X5?%?QY]ML[EHBD4\VE^/=9\<:!J,< M<@61[:\TMTE&Y0\18.OY3C7X4.LZ&!AQQ2HQ;BLPGB,IQ,IKF:55X*K@\*FK M6ER0G3;6ETVK?K>!7BPJ"KXZIP/5KR2F\!3PV;8:,79-TEC*6-Q,K[Q4Y0FD M[2:<5)'[OZ9J>FZUI]IJVCZC8ZMI>H0)=6&I:9=V]_I][;2C=%<6EY:R2VUS M!(.4FAD>-QRK$5XYX[_:*^%/PX^,7P4^ WBO7;JS^)O[0;>.A\,=#MM(U._A MU9?ASX>_X2?Q5+J&I6=M+8:'!::3F2UFU6>UCU"X#6EFTUP#'7\27[2W[''_ M 4U_P""'%RWQ*^!/[2'Q'^('[)5SJ=M:3^//!\]Y9MX$GO9W@TZU^,7PGOY M=>\)6]G--)';6OC+3;6^\.W-Y);Q:BF@7MS9V4N__P $TOVFOC5^U9_P5S_9 M#^(WQQ^)6O?$SQ';:1\6M'TO4=8-A;6VE:0GP:^(%R+#2-(T>RTW1=*MY;B6 M2YN5T_3[<8^K@Z>%Q> MXBAF&%R[$5\%@\7A*BQ&#HTUB8TJF*K1KM5,/3E"A34J\:U+X3//&W,/->URWA6/6)]5BTVYT M[7-.ET74[G2[>TU6:::*%U>-3+YA\)?@Q\3?'WBS_@JCH6O>!_B#\+-&_:PN M(4^%GC+Q/9V6E)<:9=_ '2OA1=:BK:9JVJZCI-_IGB**YN(;*^M+:\DTR"*_ M@C8/Y4?ZXT5]S_KUC(1K>PR[!T*T\BX3R&C75?&57AZ7!V:83-\MQ<:5:]&K MB:V,P.'>+A7C+#2I*5.G2BIMGP[X&PE1TXXC,<77HQSOBK.ZU'V&$HK$5.+L MKQF49CA)5:+56CAZ."QV(CA9T9+$QJRC5J5'*$4?D1\/?A?\;?@CJVG?M 6G MPG\6^-_%'P9_X)__ @_9'T7X0:'>:/:7_Q$^+G@WQ7?ZSKNL:5<:AJ=MHP\ M":;(FCQ:5XROK^TFETO4_$,MCILTD7D35M$^"?Q$^*'P!^$6KV_P'\=_ 7Q3 M\(OVY?!_[4?C;P#XV\0>$M6\;?%R>P\77OC'XJ^+=G@S5-4\.O=^)+WQGKNI M>$O#D^KQ2"]\,:;I8-G$FF;_ -@**Z:GB+F,ZGUK^S-QE;ANM/,H8UT'CL/77^J'#E*>&PU2C@L10R^='$4I4\ M;B8OY#_9 ^#?B3X4:!\<=4\6&>*[^-_[3WQF^/NEZ#>R^;<^%_#GQ UNRD\, M:/>VPWP:;JPTC1[+6-9TZWFN4L-;U.^B:X>X27;;_:&TGQ5??LU?M%6&E^#_ M !-XJ\;_ !2\!_$SPGX?\+^'+6TOM6-WXB\'ZSX1\'6K^)-2M=$\/VVH6_AC2]6O+)-8UN_L-&L;JXMTM9-3OK2U:9'G3,O@; MXY>"?'WC'6_A_IEKXST;QCX?\.Z5XLU#1/&/@/Q=X/E?P[K.IZIHUCJ>G7GB M#2+'3=6B_M71M1L+R'3+VZNM-N+<)J,%J9[?S?.>+X@Q6.?&5;*:F)PSS#!X M^>(C2JTL!- R*CCITZ>C.O*G+&QJ2]%8/A["8! M<%4=6G5Q\?]8J6?REB71K4_92KXC^T,^K8&%2I&B^2K"A M"I'!.G'Y[_9W^ VE^+?V0_V4OA]\:_!?BK1=>^$?PN^$FBZSX+UK4[S1)--\ M=_#;1?"MK-+;G2F%G\/?"MMH%C>>-+3X=Z!?F2%M:UJ+5/%>BZQ)X6\ M,Z:TD%M::=K+ZFBI8V5A&J*9H?IJBO/Q/$F.QN/K8K%_V++%8G M^S*>-QV,Q^/G*$-9VAB,?4M.2E5JT:<:%>I.G.JGZ.%X9P&"R^AA<)R4>&R^E>$7&E2K3GB*-.%6--K\N_@G\)_ MB-\-OVDOVF_@]X_^&/\ PF_[-O[2VF:/\2Y/$'AOPA;Z1\'_ Q\3]3\.3>% M/BIX)N= UWQCXB\0FQ\>:%HOASQ-=:I%%/HO_"47&K:&_!.CR>(/%FLV. M@Z-%>Z3IKZAJ$ODP?VAKNJV>AZ-9(0&:2ZU/5]1L=.LH(U>6XN[J&&-2S@5Y MA\9OVA_AG\ Y?A_#\2+KQ+9/\4?&FF_#GP,="\%^*_%B:WX\UH2-H7A-9/#. MD:HECK&N);WDFE0ZBUI%>1V%^Z3 6LI'U>%XSXIS#&81Y;D^'Q&*Q.*X"SG%XK&<- MXJJJ%?!YEF5>.'G*%2G17Y>>-_V8/$MMXS_8S\:>$OAA\9/$NCP_M92?'#XN M:#XWL_AI.?A=I&K74[7Q!J MMAJ7BY894:2^O_./@C^S%^T)IWPS_P"":FM^//A/XGEUO]G7Q3^V+X2^*'A7 M61X;O_%.B^#_ (O^$OBKX>^%:PI)K=QINI^"X+74_".C7=O;ZE<1Z)97MJMQ M8?9-*O#;_J_=?M>?!&Q\9?&+P%>:GXQA\3? /P]IWBKXJV:?#+XB7L7AK0=< M6:3PY?Q76G^&;N#7O^$F@M;VZ\/VOAU]5O-3MK"^G@M]EI,5RO$'[;7[.7A7 MQ'XL\)Z_XRU73=>\#?%;X6_!7Q792^"/&[_V-\0?C79)J/POTVXGA\/R6\FG M>+K2:VDLM?MY9M#M6N[6+4K^RFF6.OHZ7&'']3!T,OAPG7Q4J5*MBH5Y8?-< M1BY9?G>!SRC3?-2J4XQHU\MXGC##8NG2IU*U/"956FZ]24Y8CYVMP=X?K&5, MPGQ90PJE4HX)T85\JP^%689-F&18FHG"K3J2J5Z&9<+REB,)4JU*="IBLVHQ MC0A&*P_Y1_!3]CC]H*[^#/[%'P\^+6A?%?PO\,/#W[+GQ9^!/Q2\"^![_P " M6GCOX;_%CQ+XUTO5M$\?)/KO_"1Z7:VNH>']'GT71/'_ (-!\5>"+J2WOK34 M]+T[7-5=/V7\,?$C5K7P/\0)KCX=_$B_U3X1:MJ'@VVT>6X\.>(O%WQ.'A_1 M-&NM/\1>'KW3M4M]'OI/%*ZC&I_M2YT.ZL]3BU&/6K'2'@DB3W6O,/BO\4O MOP'^'WB#XE^.CJFF^#/#A6^U^\\.>%M>\4WEHFH7J127[Z%X3TO5=:NQ)>7* M-=36FGW,IDF\R4$L6KX_/.,,RXWQM&CB\GP]?$U\SJU\#E^6/$T(SQF:9WC\ MQQ5.%."=:OBL=#,ZF5NO.O/$5*5+!5N7Z]AX5:WV62<'Y;P3A,1B,+G&(P^' MI9=3I9AC\SCAJ\H83+L^-[/QQX6\8?"?X_>%/ W@0^&_%FB?#_ M ,47K>//"_B?QW_PD?Q%U6PUG6OAM\0G_L^TL?#\,>HR^'M>\2#3(I+2W@L& M^6O"OPI\>?$;XW?MIZ)\'="FT;Q[H_\ P5&^"GCB/XDV=OIUA8>!O!OA/P1\ M)?$WQ)EO;XW-K=RC7_"[ZSI4_AZV@G7Q?<^(_LMXD]O-J$]M^S%M^T?\+]4' M@:?PS=^)O&FF?$GX=:C\5?!&N>"?!/BWQ7H.O^"M*M;.[O+^UU?1='N[*._5 M-4T>&+0KF6#7+B\UK2KY+R\2$>2?!GXJ_LJ+X2M_CQ\#_ OJ":-^TU\2 MI+&_\1^$OA=XUAU[Q[\0;6ZUG2;K5_%VC'08_$-G-ITNDZS9:CKOB33K"#2[ M72YHK^YMK*QB$7U> XLX@P>"QU:KPI6ACEEF6%KXFE&:P.!I\09;@\/*E3GBZ665Z&8T?8X*K3A\ICN%.'<7C,'AZ7%=&I@ M:F99CQ%CL/4Q-"IC(RQN0<.Y3C<=DF)I86K*+Q^-GP_F.,Q$:M6.%K9GAL1E M];VN-HSGY'^RG\/?B5^SIXH_:T75O@=K6LWGQB_;R\6>.]#\0>%[CP3!9S?! MSXIV_A9](\:7>J:CK>F7MWI?@:6VUZ?Q-X92"36]-NY+E='TS47U 23^\?M! M?"OQE\0/$ME?^'/#/P>UBWTOP%KVGP7GQ&^%A\<:LNOZQ?PV%G%IVK#Q;H/V M.RL;"ZO[S[#)93P1O+>74DD\D\$,'L/Q=^-_PI^ WAVT\5_%SQII?@G0-0UC M3- L;_4X[V87FM:S?6VF:7IUM!I]K>74MQ>ZA>VEI"%AV>=<1*[H&!H\??&_ MX4_"_P 2_#WP=X\\::9X<\4?%;Q-9^#OAYHEW'>S7WBCQ)?B=[73+!+.UN4C MDDCM;F4S7CVULD=O,[S*(VQ\=5SGB#,\XP_$=#(ZD\=CJ&(HPKT,-FV)P^81 MRC*A7G0KXG*<-B,OEFV;9UC\+&O46'5H86>+PZJXF6&PM+#.4U5 M=3\J/B5^R9^TGX>^+OQN\8_":*'1_B1\0?AG^RWX%_9Q^)_PXE?P=\.O@M8? M"[QQ=ZC\8O!7B3P=)XBN)[7P/X@TV?\ X2L:/J4?BC3_ !?+?:CH,,]MK,-@ MH]KUGP=\>OB_^UI\'/C#:_!SQ[\$=9_9[UKXL^$?'?B'7_B%X6U_X<_&OX-: M]H.I#PKH/@/2M+\0:E)'JGC#Q99^$?$>KZGJG@[POJ'@V#3Y].U35]?N;#2+ M<_:GC;]HKX/?#KXB>!/A9XU\6MH'C'XEZS;^&_!D-YH'B5M!U;Q/?6T]YI?A M9_&$&CR^$=-\3ZU:VMU<:)X=U37+/6-7BMY'T^RN!LW>27_[?'[,.G?'M/V9 MY_&?B63XP/XLT[P.-"L_A=\4+W1!XFU.SM;^WT]_&UKX/F\$HL=K=Q27EV_B M 65BZS0WEQ#-;S1I])1XAXUS3#T:M/@]9A7H<+YA3H9G2RK,I37#T\%_8&9X MR:IU7A,5E4<)0G0JT<3*O@L'FSKYO2>'S2O6>)^;J\.\$97B:U.IQC++Z-?B MG+ZE?*ZV:Y:H/B&&.?$&5X.G[6E];PN:O%XB->C6PT*..QF41P^3U?K&58>B ML+XQ\$/ _P :/'?[7P_:DUKX5_$#]G'2=3^"&H_"[XV?#OQ_XW\->.+;QWX\ MT+Q/IMW\/;[X?#PYXC\16-GX4\):7-XKFD\2P6G@Q?$$^MVZKX7>[GUJ_'Z7 MU\R:)^V!\!O$?Q_U7]F31/$OB#4/B_HG]I?VII,7P\^(2^&[5M'TN#5]3C/Q M F\,1^ II;*VN8H)XH/$DLBZD7TH*=1BEMD^FZ^*XKQ.;8K&9=4S7)Y9'&&2 M991RG!2HXN%\CIQQ,LMJPKX^=3'8ZC*GB:T,+B\54G4>$IX7#0E*CA*4I_;< M)X;*<+@\QIY5G$<\E//,SKYMC8U<)*V>59X:.9T9T,!"G@<%6C4PU*>*PN&I MPA];J8K$SC&MBJL8%?SF_P#!RY_R9[\"/^SJ/"W_ *K/XHU_1E7\YO\ P_ C_LZCPM_P"JS^*-?4^"G_)U^!/^Q[3_ /4/,CY+QQ_Y-'Q__P!D_5_] M3,L/X^%Z#Z#^5?U9_P#!LT!_PA/[91[GXB?"<9]AX2\2D#\"Q/XFOY3%Z#Z# M^5?U<_\ !LY#(G@3]L69E(CE^(_PL1&(X9HO"/B N >Y42H3Z;AZU_?/TJ4W MX.YK97MG'#C?E_PIM:_,_P ]_HDM?\1FRSSR7B&WG_PGQ>GR/Z@****_RU/] M7C_-E_;I_P"3\OVW/^SIOC/_ .IGJ5?+3?\ (0\/_P#8S^&?_3[I]?5'[=D; MQ_MY?MM;U*[_ -J/XS.N>ZMXSU(J?Q'-?*[?\A#P_P#]C/X9_P#3[I]?[,<+ MIKPOR)-6?^HV6Z/SX;PC7X-/YG^*/%+3\6\]:::?'N8ZK_LH\6OS37R/]3^B MBBO\9S_:X_D'_P"#F?\ Y+)^Q9_V(_QN_P#3U\.J_F^;H?H?Y5_2#_POAU7\WS=#]#_ "K_ %?^C9_R9WA;_KUC_P#U:9D?Y&?2 MA_Y/1Q1_W3/_ %68 _MV_P"#>T ?\$Z](..6^-?QC9CZG^W[89/X #Z 5^X= M?B%_P;XPR0_\$ZM#,BE1+\9OC'+'D$;H_P#A(XH]PSC(WQN,^JFOV]K_ #=\ M4TUXE\?)JS7%V?77_<_/_,_TU\*FGX9\ -:K_4_(+6V_Y%U+_(I:E_R#K_\ MZ\KK_P!$25_E=:#_ ,>3?]?5Y_Z535_JBZE_R#K_ /Z\KK_T1)7^5[HL;Q6C MI(I5A=7F0>H/VJ:OZD^AX^=G;ZMP^K]+NKFK2OWLG]Q_)_TWFO[.\/E= M7>+XA:76RI95=V\KJ_J?9_\ P3T_Y2#_ +$G_9Q7@?\ ]&7E?Z0%?YO_ /P3 MT_Y2#_L2?]G%>!__ $9>5_I 5\M],7_DX'#O_9*K_P!6^*/K?H7_ /)N,^_[ M*NI_ZK,.-=TC1Y)'6..-6>21V"(B("S.[,0JJJ@EF) !)( K^#?_@KC_P % M"=6_;/\ CCJ'@GP1K,G_ SA\']=O])\!65I(RV7COQ-8-/INL_$_4!D?;([ MR3[5I_@U)5"6'AW_ $Z..*]UN_K^GG_@LO\ M':C^S?^P9\4=2\.7LVG^-/B MM<:7\$_"-[:S/#=6%UX^6\A\0ZG;RQ#S89].\%6'B:XM+B,H8-1%DPEC,GFGB/FF'A7J8#%3R;AN-6" MG##XF-&$\US.$9)KZQ3AB*.786I;FHJKC:E-QJ5.>/R7TR/$K&X&CE7AKE6) MGAX9EA89SQ+.C.4)U\(ZTX95EK/#ULPQ5.]JWL\'3FI4X,OCG\2?AA\!/AVH;QQ\9_'?AOX=^'I'&Z"PN?$>H16=SK-V,J!8:%IS7>M: M@[,JQV.GW#NZ(I:O]*_]EC]F?X7?L@? ;X=?L]?!_1H=(\&?#W0K?3DN/)CC MU/Q+K(?&/B*>/YK[Q)XJUB2[UK6;R1FW7=VT,'E6<%M!%_&?_P0,^$] MO\2/^"D=CXSU"T6ZL/@1\%O'GCNU:1()(8/$OB:YT;X=Z-(R2JS"9--\2^(; MBUFA"R0S6P;>%R#_ '9U\9]+;BG$YCQWA>&85I+ Y'EV&Q%2A&;Y)X['JI44 MZD4[.5'"PC&"DFXNM*2LY)GVOT/^$\+EGA_B.*)T(_VAG^8XFA3KR@O:1P& M=.ER0DU=0JXF./#6O\ @WQAHFF^ M)/"GBK1]1\/^(_#^L6L5]I6M:)J]I+8ZGIFHV.1AP> M:_BE_9;_ &0I/V#_ /@X3^#W[/.GF]E^'=VGQ;^(OP6O;^4W%Q/\,_$WP<^( MLNGZ5-=%(_M5WX2U"#4/"]U.4#RC38;F3)N [?V\5\B_$C]BCX+_ !1_:U_9 M[_;3\0_\)7:?&K]FSPS\0O"'@6;1=8L[+PUJ^@?$?2+W1]7L?&6D3Z3=W6LK MI<>I:C>>'VL]3TEK"^OKF:?[;%((%^VX,XPQ7"TN(,,JM7^S>).',XR3,,/! M2G&<\5@,3#+\1[-22]IA\9.$?:;QH5ZR;<8\I\/QKP=A>*X\/8J5*E_:?#7$ MF3YYEV(ERPG"&$Q^%GF&']HXMJGB,'"I+DU4J]"C9*M?%'X' M7]CH_@'PMJWB?6(=/\)_%_P7XN\0ZJ\>G:?J%O81:3H&B:EJ$=QJ48MKBYMX M;*&*[NKB&TFP_B1\#/BQH?PJ^"EIX;OM<\?:79_M8/\ $'XYW<^DRM\1O''[ M-/C/XF?$#XA:EX6\0Z/:Z)H&IZJ;"[\4>$[OQK\/-+\.*-7BT74M-M?#]RV^ MRN/TXHK[3+>-L=E>491D^'P6#J8?*LXS3.)3KN=26,K9IA%@W2FO9IX:.$A> MMA:F'K2:Q<<-BJM&=7!865/XG-.!\#FV;YOG&(QN,IXC-,GRO)XQP_)3C@Z. M68Q8U58/VLEB98N<50Q4*]&">#GBL+3K0I8[%1J?A/\ \*:_:$N_B/\ L5'Q M]X.^(>M>#=,_;-_:\UN&+3],\3W;?#G]E;Q[H7C/2OA%X8^)=]8/,=!TEY=4 MT.+3?#^KW$;^&M$DTG3KNVTY_#=_]@]IO_@3\:KK]J/XNZCXJ\6?'+PW\._! ME]\)/&/[-DWPAL-/U:#4_ASX1^&=WX4\9?">?QCXA_M2?PY>:CXBEUB_\4>& M=4NM+G\<7E[X7\3V-WJFH:1$;#];Z*]6OXF9G6DI1RO*J%LJS#*TJ5-RC3CF M&=4LXJXO#0Q&%Q5'#XJ4*=7+<1..'J_7,'C,;.JZ.(KWAY=#PQRNE35.>:9I MB.7-,!FG-6J6G5> R>ME5/"8FIA\5A*V(PL:E6EF6&A+$4OJ>+P6!A25;#X> MT_Y_O'G[.7[06J_LX+\--<^&NO\ Q0T7X;_M9?L@?$33_&-[X>U+3?B#\3?A M!X9U'PX/&H\:_"FZU/5X;OQ_\./#L2:+X]U'P/"VB?%"\.K>)=-L;W67UZ6X M^R/^"BOA;Q5XPTS]BO3/ ?@[XGWZ>$?VS?@K\2O$E]\-O NJ^(]1^'GP\\': M7XKL]<\4W"6>A:_I>GS:$VN:6MGIEY8:A%_"&@W-M::CJ^O:GHFG7 M=M9&.6Y5H-.#RZK=P175U:V,MM:7,L77_##XO^&?BQ::O=^'],\9:.-%.CM= M0^,_!^N^$9KBUU_1[;7M(U'3#K5I;PZMIUYIMU'(;O3IKF.UN%FL;W[->V\U MNGI5>,.)ISR/BK$<-TEEV49AQ!C<-7I3Q&'R[%8OB3+89=C754:M>G&K&4_K ML8X? T8&51SSA+#\2U7F&;X#(,%B:-6GAL1F.%PO# MF9_VG@XTI2I4)SI.%*."D\1CZU10HRK+&8C,85*J_"C]I+X._&RYUG_@K/8> M%O!/[0_Q!U3XJ_!']FG0?@SXSN/A[KJ:GXY\9?#BYUZ'Q!9^%M;\*^$_#.D> M?X8N]:T\Z??VUK8K=V@NK^QO]1MK2ZNDS_B[\(_C-KWQ8_:)U_2O@O\ &'4M M*\6?MH?\$P/B)H%^GPT\9/%K/@WX/^!O"]G\4?$<(?2EFDL?!M]I5_;:X9%6 MY^T1I';Q7+W$/F?NYX2^.?P\\:_%GXJ_!+0M0U-_B+\&;'P3J?CS2+W0]6T^ MUL=-^(=EJ6H>$K[3M7NK6/2]:M]3M](U$LVEW=R]G):O%>)!(R*W6_$#XA>" M?A7X0UKQ[\1/$VE>$?"'AZW2YU;7=8N/(M+999H[:U@C55>XO+^_NYH+'3-, ML8;G4=4U"XMM/T^UN;VX@@D]3#^*/$.7U<#E\N$\/+'5<#D=+#49U,RCBL;1 MED_#^"RVM0PV%P<>:.987*<%C*%/#4?95)XNI+#TE!TU'S<1X7\/8^CC,QCQ M97A@8C$5XT\MEA<'6CFW$.+S.CB,3BL;+E>6XG-\=A*]3$UE5I1P=.. M(JN:J.7YW^!!\3_@/\;?C]\3];\%?$WXH?!W6-(^)_CVQU*Y\,7EE\8/ FLR M?%;2[2^^'%A8OXC@\(_%CP%KNGQ7_C?X7Z[;1V?C#P'\-?"]KX6UH^3>Z#IU MS]A?M):A/!\)GN-.T+Q5XEGG\9_"NZATSP?X3U[Q=K$EIIWQ)\)Z]J-VVC:% MI]_?"RLM'TR^O;R::W6%(X?L[%KF>WMYHO%?[1GP3T&V^&=C\0]5O/#$OQI\ M;Z)X"^''A[QEX0\2:=JGBKQ9JVJ&'P]8?V->:.UQIAU">T.H6,NOPZ8@M+=K MJ7RO*=5[SXM?%[X=? WP1?\ Q$^*?B>R\)^$M/OM&TJ34KM+B>2YU;Q%JUGH M>A:3I]C90W%]J.IZMJU_:65G965O//(\ID*+!%-+'\5CL;F>/S;A_'5N&L0L MQG4P^#PE+#QQD(9[#*(4LJIT<-3HT*D*N,IXF#H8W$992:G7C&G5P\,2L36K M?9X'!97@,HXBP%'B;#RRV-/$XS&5,0\%.>0SSB=7-JE;$SJUZ=2E@ZN%DJ^" MPV9U.:%"4ZE/$3PSPU&A\=?!']G+QW\!OVJ-9MO"(AN/V2O$'@3XG^//A]HC MQ_9K[X-?%?XA^-/AKJ'CSX=:9;NZ21_#[Q;)I-[X_P#"^G"UCC\-:W+XJT6% M+>Q_L^.3E_V3O!.M^"?VP?VV?#Y\!>/?#GP6F\=>%OB;\"+O7_ VO:1X'E\; M>/\ PHD/[2>I^#-)-=M[.!+FTL[G7?$ESX>TC5+?P MIX7LKJ_LK>\\2>(Y-,T:&:Y2+[8SK(J>@>/OC+\-_AI;>%)O%7B2&.[\>ZFF MB^ =#T>UOO$GB3QUJ\EC)J:V'A'P_H%MJ6K:ZZ:?$]_=7-C:26&G6 _M#4[N MRL0;D=M7.^*L;@\35Q>18K%1XPR#"Y#A!_'GC_Q=KOQ.^">M6.B>!?!OB+Q7.-*\#?&7P!XM M\2WFH3:-I]U9Z7%9:#IE[>P+J=S:R:D]K);:9'=W,;1+E?MVVWB7QAX[_8'O M/"'@#XH>*['P+^UK\._C%XVNO#OPU\;ZM:^%/A_:^#?B!HEUK&OR6FB.-/OK M+4-;TZ&\\.RK_P ))9Q7+3W&DQ0HSU]FZC^T!\+M(\46G@_5=>?3M:DN/"&G M:LEW9W$=GX3UWXA/!%X"\,^,;_:;3PYXC\9W%PEKX6 MNZ?Q1_:/^$GP?U:?0/&?B&X37[#P+K7Q4UK0M#T?5?$6L>'OA7X:O(K#Q)\2 M==T_1[6[N=.\&Z'>SQ6M[JDJ%Y)V>&QM[R2WN5A,CS?.\NAPSE^'X7Q&-K99 M4XLS+!+FS"%3,8<3Y53R7&57"CAY0AA\#1KX>I0G2J6J5L3A77J>RQ>#6+>> M95D>8SXFS#$<4X;!4+O#?AOP_=Z99^/] M(UV?[5H[6.FZM>ZA%^BU[ITUYXIT*VCLC;Z)HL>H^([F5(4BM+W7[YYK&PAP MBA9IH$NM9U6\+99+V33+M@\[I+%\F_$+_@HO^RU\-O%GA?P=J_B3QQKVH^,_ M#?@GQ;X;U+P'\)OB9X^\+ZEH'Q$42>#[X>+/"7A;5O#MN-8MW@O(XKO48)8+ M*ZM+NY2&"XB=MJ__ &]/V=]/^/:_LV2:A\0[CXGMXOT[P-Y=A\(/B=?>#D\1 MZE9VM]':R_$*V\+2>"8X+6WNT_M&^?75M-/EBN;>[FBGMY8U,?EG&&/R[),+ M1X,S+!8'*,DS?%82<,+C:U2K@ZV)IU,YS6I7Q.-;^''CFTUR+7M4D\=^&+/Q3XD\8^&;76I/%]QI.L>'?$ M'PY\11VLFDW>L:'K>CVXG:'3_P!)Z^:_@W^UW^SY\?O'/C_X;_"OQ_%XA\:? M#7RYO$NAW.A^(] N)=*ENCIZ>)/#S^(=)TN'Q7X5;5$ETM?$WAR34]$>^C$4 M=ZZ3VDEQ]*5\_P 68K.L3F<(Y]@,;E^.H8+"0A0S.-9YA]2JT:>(P4L1B<5@ M\%B\;3=":^I8C%4ZU:."=+#?6Z]/"TO8?0<)87)<-EE1Y#C\%F.!KXW%3G7R MR=!9%O_ %6?Q1K^C*OYS?\ @Y<_Y,]^!'_9U'A;_P!5G\4:^J\% M/^3K\"?]CVG_ .H>9'R'CC_R:/C_ /[)^K_ZF98?Q\+T'T'\J_0+]A[]I?\ MX*I?!/PU\4=*_P""<_P'U3XQZ!J?B?0;_P")EQI?PSL/'KZ/X@71I[;0[::Z MN]8TE[ 7.E1331VJ^+54L Q/[.>C* "<9)/C$X ZGCI7]KE%?YQKQ I)IO@?@5I-73R&EKY:5+Z M[::G^F;X!JM-?ZZ\<*Z:NL]K75UNO'Y?" MGQLUSXC>*]2^+/AN?2X]#GT+Q_=:K/+XFTN;1X9KB+3);/4WGB>RCN)T@*[! M-)]X\$W_ "$/#_\ V,_AG_T^Z?7U+^W3_P GY?MN?]G3?&?_ -3/4J^6F_Y" M'A__ +&?PS_Z?=/K_5O(L2\9XNZ>?XB$ MJU>?VZU6495:LK+FJ5)RLKV/]3^BBBO\7S_;<_D'_P"#F?\ Y+)^Q9_V(_QN M_P#3U\.J_F^)P"?09K^D'_@YG_Y+)^Q9_P!B/\;O_3U\.J_F^;H?H?Y5_J_] M&O\ Y,[PM_UZQ_\ ZM,R/\C/I0_\GHXH_P"Z;_ZK, ?J3^R+^U[_ ,%L/A1\ M"-&\'_L)?LS:U\5O@+I_B?Q?)IGBC2_@[IGC*&3Q'>:S->>*+-M+?\ Q'+1_P#YLJ_9W_@W MM_Y1U:-_V6KXQ_\ J06]?N%7\-^)7'=/#^(/&F'?!O!>(EAN)G_*0?\ 8D_[.*\#_P#HR\K_ $@*_P W M_P#X)Z?\I!_V)/\ LXKP/_Z,O*_T@*_,?IB_\G X=_[)5?\ JWQ1^I?0O_Y- MQGW_ &5=3_U68<_EU_X.:/%$MIX,_8S\%YD%OKWQ#^+'BB4!U$#3>$O"GAC2 MK<2(3N>0)XUN3$0"J@2[CN9*_E1K^M?_ (.;? NHWG[.7[-?Q;M+?S=.^&WQ MXNO#FO7"C+V6G?$WPA?V=I.Y"$I;R:WX8TFSD=G2(3W5LC;I7A4_R21.)8HY M%.0ZA@?J*_HGZ*.,PM?PGP>&HN/ML'G&=T\5%23DJM7&JO&4EO'FHSHV36JC M=.S/YL^EW@L70\6\5BJZE[#&Y+DL\))Q:C[*C@Y4)0B]I7M*%2+\ MXO34_L[Z+.+HXKP7X<5*2E+"XW/,)72^Q6IYBJCB]/Y*].2>J:EN[.Q1117\ M_']#!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !117SYXI_:D^"?@WXDZM\(-=\1^(1\2M#\%C MXC:EX2TCX:_$_P 2ZC#X"-XFFMXPA?PWX-U:SOO#L>J2#29M4L+JYM8-6632 MYI$OXI;=.S!Y?CLQJ5*67X/%8VI1HSQ-:GA:,Z\Z6'IRI0J8BHH?PZ-.=>A& MI5FXTX2K4E.<74AS<>-S' 9;3I5I"A7E3HP4JDXT:KA"2I5.3Z#HKF_!WB_PY\0/"7AGQUX/U./6O"GC'0= M)\3^&]7B@NK:/4]"URQ@U+2K]+:^@M;ZV6ZLKF&86]Y;6]U#O\NX@BF5XUZ2 MN:I3J4:E2C6ISI5J-2I2JTJD90J4JM*V;[*T/G^?+!%+B?"7XO_#CXZ>"+'XC?"GQ-!XN M\&:CJ.O:3::U;V&K:8KZGX8UN_\ #FOV,ECK=AIFIVUQI>N:7J&FW,=S90D3 MVLFS?'M=M_J.-^I_VA]3Q7U!5(47C?J]7ZHJM25:%.D\1R>Q52<\/7A"'/S2 MG1JQBG*G-1Y_K^!>,_L_ZYA?K_LY5OJ7UBE];]E"-*%-9\7^*O 6F:O'=>+?!-CXZFM8["Z74H](U%D6QNKF2W^RLMVENSQ"1?'/COP?\,_">M^._'_B M+2_"?A#PY:I>:WX@UFX%KI^GP2W$-G!YLA#,\UU>7-M96=M"DES>7MS;V=K# M-CAEAL0\3B?J_U?#QH595Z_UM0EA?8T8TY5:OUF-2G+#^SA-U ME.#I*:DKV\9A(T*^*EBL/'"X;ZQ]9Q,J]*.'P_U-SCB_;UI5(TJ/U65.HL0Z MM2"H.G-57!Q=NLHKC_ 7C[PE\3_">D^./ VK#6_#&MB]_L[4?L.I:9)))INH MW>DZC;W.FZQ9Z?JNGWEAJEA>Z?>V6H65K>6EW:SP3P1R1LH["LZU&KAZM6A7 MI5*%>A4G2K4:L)4ZM*K3DX5*=2G-*4)PDG&<))2C)--=]*-:CB*-+$8>K3KT M*].%:C6HSC4I5J52*G3J4JD&X3ISBU*$XMQE%II]OB7_ (*.^&O%7CC]A_\ M:4\!>!?"?B7QOXU\>_"[Q'X/\*>&/"FD7.LZMJFNZY:-;6$(@MUVVMKYO-UJ M%W)!969 5#>1?'WP;\:O&?PE_8LG\$:=XSLO OA/QGX-F_:&\#6_A&T MO_&]QX/'PWUKPI:/J/P\\5P2V?BK2O"?C>]TK6?$/A*[TK5Y[JVM;77]+TZ_ MN-$M@_Z;USOB'Q9H'A9+4ZU?^1/?M-'INGVMK>ZIK&J26\8EGBTG1-*MKW5] M4FB1D+Q:?97,BF2)2H:6,-];DG%6+RS"97EV$RO"XV>79WFF=4I5E7KSK58 M9+EF3551]C1C1I99GT<]HU?;RJ1J55B<4OJF*PE2U'$X.K4PRO.K[WY*_LP_ M#KXC?LR_M)_M7:S=_#_]HGXK^#3\*/V,?AWX \9>)--T;5O'/Q(7P>OB?POX MFOKKQ!<7?AOP]K-[X$L_&.D7WB.Z:XM;V70M+U">VBU74]/O(W^COVV?@_XL M^)GC?]D+Q.NE>)O%7PC^#_QTO?B!\6_"'@N6]'BJ26#P)XBT_P"&7C;2[+2[ MNUUC6%^'_P 0+K2]5N]+T1;O6%AO/[8L;.9]';;]9S?%[P%;>']?\27>I:K9 M6?A;0O\ A)O$&FWWA+Q?9>+=*T BOQ)AZ65XG%RSK#T<17P-*6&B^*L!FB4G5KU:N-R[^UHY3 ME%:ACZS5:G]7P5:M]%_VI;_X)?\ !/30?B_X.^)'Q.^+?PS_ M &T_AG\9OB=JOA;PG=^*9M ^#WA#Q-\3[;1]3\9:UH$3:-J/C/1_!NL>$8?$ M-CI37&L:CJ+7MW%87,BW%Q+WW_!43X8?M>?%CX8^(_#_ ,+/AG\+OB+X&'B_ MX$:GX8LK?Q%XY'Q@L+_0/BGX+\1:_?)X4A\(S>$3IB7.G_\ $\UA?%*ZEI_@ MBUU*>STZ741)9WOWFW[5OP)7Q'\9/"0\6ZL_B+]GW2;;7?C'I(_AOX-^+>D>-H;CP#\19;&#X?:O-HGB6QOO',^J0S7.EP>#_ UJ&C6O MBCQ+-JMG;SW^EQ:-HMZ^I:;!-J-DL]C&]POH4N*N)LOS/AS.H\#X2E/),TS/ M&X.A5RO,XY=6Q/%>.I<74J.%PU"KA%@%]4H>WRI8.I54LFEB,2Z57#5)UZ/G M5.$^&,?EG$F32XYQE6GG>5Y5@<;B*6:Y6\QHX;A' 5N#ZM;%8JO1QCQ\OK5= MT,U>,ITG'.84,,JE+$PC0J_+_P"WUXPUL7TOXN MI\"_#^EZK-H_@C2Y8+Z^T :OXAUOPM;"[\5WX.BV:K>K>Z;HUSJ^LK#!>K8+ M/\\?M,?!7]H7Q#\;-7^-_P ./#'CO1_$E]^PZGPW_9;_ .$3O;6W/P._:$O/ M%;>)=6T'QI:P7?\ 8NGZ/XALHO"6G:MXEUFSG\'R:1X/H;7QOI5G/\*]*T;6_B7;Z]'?>%[GP#IGB#3+[6M(NO%]MXEM M-)G\/BZTG3;W43%J<=M/;6D!GNXH$>(OGV7[0WPAU#5_"WA^'Q1,-*U3QG8>%M$'B+7M0\)6.IZ!:7/B33K'1FCO/M^C1WMG=>=;V M]G-<75Q!!)YN2<19WD&'P>'P'"<4LJQU6I7R^M2 M>!P4/[,R; TJL\&JL,;P[+%X?&SCEN.J8N7I9WP[D6?U\9B,?Q;3C#,*^5/+ MHX5Y+AJ^ J9-6S3 4J=#'TJL<;C9K-,YQU2E'&.C4P?$2PM?"1EF6!I8./YA M_$S]DCX[^*]>_:,\*WTUW<:Y^TE\\+67P,3X5CXP ZG M+#+%X;ET2[\":QJ'@31=0>2]UN+5M*M=--Y/#J9L>B_X*)?LY_$SXT?%+3-= M\&^$_%>D-H_[,WQ4\.^ /BK\)RUQXPU_XP:UKVDR:1\"OC+I4DITO4_V<_&O MAV/5$URV\16G_".MJ>J:C+J.M^'WM[5]2^[O '[8'[.?Q..AMX/^(T=S;>)_ M%NK^ /#FHZUX7\:^$-'U[QYH,^I6NL>"='UKQAX--3\)1W:-K=EX4 MUS5-5T72=>N+,?/'IU_JNAZM8V\YX:XL9E( V%^O_7;C+)LVRS&8O(5A<7D6 M S&,<-7RW&X2,:5;"\-Y/C,56I>RG&G0H8;(,DP%7#U88C 477Q$,11I8K'X M:K@^-\#\&YSE.:8+"Y_+%87//I5Z?!GPQXKT#P[X>\06_ASP M;=_$O3_ ]M#9>"])UOPMX;TDWWA[P[!!''&F@_\ "2VUEI^C6BHL'_"-Z9): M_P"HB2%^[U*QN+KQ+HZ?8Y8]"T*TU/Q!<-#"#!J&N7WGV-I;+#$I-S+!!<:S MJ%TC*2UY%?BE\3- \.>'/ \OPC\#^,KO4O#_AWP[;V>OWNO2^)/&WB#Q/ MJ7C+4+*_T33TT_1]/T_3'N7?0E?4/T@K)EUW1H-Z[HUKRJ2]O-4J:^K4ZL\5[% MR=2LUQ9!EDLIP>(PM3,5FM>KF688W%8SZCEV7U)8K'5:6(JPK8?+&Z'MJ]M4D(-Q&#]SX(4Y5/%G@2$4V_[.RN,8Q6[E*3M&*3;=TD]3^0->@^@_E7]6 MO_!LT"/!'[9)['XB_"C'X>$O$E?R=#5-/ ^UP\#'WU_QK^K_P#X-G=3TA_! M_P"U_IL&IV,FJR^-OA9JITU+F$WHTW_A'/$MDE]]D#>?]E-U');FYV&+SE\D ML'&#_>OTI7&MX.YS[*4:CI9KPY4FH2C)QA_:L8.346VHJ4XINUES*[5U?_/O MZ)JE1\9LH56$Z?M'_\ L9_#7_I]T^OI#]MS MQ%X?U?\ ;;_;#UW2=7L=0TO6_P!I;XQ7]A>VEU#-=619K>XB9HYHF M:-MDD;,C ?*Q R?FB#4M+;4-&DFO;>.&VUS1;N=WE1$2&UU2TN)G=R<*B1QL MSL>%4$G %?[-<,PY/#?(<)*4(XC_ %*RNDZ4I1C-59<.8-*FXN2DIJ4E%Q:4 ME+W7%231_B?Q1/F\4L^QD8SEAO\ 7G,ZRK1A*5-TH\18QN<9*+BX6BY*2;BX MV:;33?\ JC452TW4+/5].L-5TZY@O-/U.RM=0L;NVE2>VNK.]@CN;6YMYXBT MPU_Q- MX5LM.N9;?/F107<_A_5(K:5P$GDLKE$W-!(!_-U_:NG_ //U#_WVO^-?ZO?1 MP<:/@[PDJLHTW5P^/J04Y1BW!YKF:C)*33Y96;B[6:U3:U/\C?I.[4-+NO^">UE9V&H6EY=:9\:?BO%JEM;W,4TVGW%[J M=AJ-O#=PHQDMGGL;JVNX4F56E@F29,HX-?N-7^<'BM"5/Q-X_A)--<79Z]>T ML:YQ:[J4)QE%JZ<91:;33?\ IEX3U(U?##P_G%II\(9"KKO' QIR7DXSISC) M/52C)-)II4M2_P"0=?\ _7E=?^B)*_RNM!_X\F_Z^KS_ -*IJ_U,_%>KZ?X? M\+>)=>U>ZM['2=$T#6-7U.^NIH[:UL]/TW3KF\O;JYN)2L4%O;VT,LTTTA$< M4:,[D*I-?Y9&G7VG06^U;N JTUQ*A$BD%)9GD0@YY!5@0?0U_4/T,%R8KC^O M-J%)4>'J7/)J,74<\UJ\1T6G&K1XJO.$DXRBJN4T)TVXM*24E&5G:SY6DVTTO MDC]NW]EO1_VS_P!DOXV_LX:K/!87?Q"\'W$7A/6IT#)X=\?:'<6_B'P%X@)V M.ZPZ5XMTO2+F]\D":73UN[=&7SB:_P U+25\2^%M<\3_ S^(>CWGA?XC_#G MQ#J_@KQOX8U.-H-0T/Q-X0PS*/+N;=H;J!GAF1V_U9 M*_F,_P""WW_!&#Q-^TEJM[^V?^QKI5C'^TII&DQ1_%GX6)-#IMM^T!H.AV<5 MOIFJZ%QTF>ZL]8TS3I-1^/\ H]^+E/PY MSROEN;U)+A[.ZE)UIMODP6,BE2CB&F[1IUJ?+"K.R49TZ52G-2G2BVW*,YPBN:T9?@#_P $ M]OCU9_LR_MJ?L^_&/5[Q+#POI/C-/"WCB\D($-IX'\?6=SX/\1ZC.2C_ +C1 MK?5X]=?&WC2\&2-2TB_Z-T#?&OAZ^N-%\3^$O%>F7N@^(="U6U8PWF MEZSHVJ0VNH:;>V[ADEMKNWCD7&=NTAC_ &:_\$A/^"QWPS\3?#_PA^S%^U#X MYTOP?X[\':?IWAGX9_%'Q/J<5IX;\?>&[1%LM%T#Q/KEY(EIH?C+1+5+;3;> M^U2>'3O$UA%;2_:XM:CN(K_]H^DQP2N/X/+G'$XV6 M5>TEC,%F5'#474Q&(C@:E;$T,9"C2JU882O3Q,:=2E1K.'XA]%WCF7A_C\Y\ M,>.5/(8YCF"S#(,9F2EA<''-/9QPF.RVKB:_L\/AWCJ=+#XC!U*U6E2J8JC4 MP\JE.I6H^T_IBHJ"UNK:]MH+RRN(+NTNHDGMKJUFCN+:X@E4/%-!/$SQ312( M0R21LR.I#*2"#4DDD<,21V(5$1069F(55!)( ) MK^#FFFTTTTVFFFFFG9III---6::33T:3T/[^332::::3333335TTTVFFFFFF MTTTTVM1]<;+\0_!$/Q!LOA3)XFTH?$;4/!^I>/[7P<+@/KC^"](UG2_#U_XE M>T0,8-*AUO6M-TN.YN&B6YO)WBM1.;6[\C\8/^"B_P#P7@_95_8OTO4_ 7PK MUO2?VD_VFK^1M#\,_#'X=WQ\1:)HOB6\7R--3QMK^@F[B\\7TD$2^#_#LNH> M+M2N"+$6FEB7[?#YG_P1I_9 _;=A^,'QD_X*3?\ !0/Q7J>G_&_]I+P#:>!/ M"WP6U"UB@U'P!\./^$BTGQ59R^([%&:W\&7:RZ-IUAX<^'6E\>&M'-W+XDED M\17\]IIOUE/A6MALEQ>>9Y6>3T98>2R3!5X..8YUC9NE[+V.$J*-:AEM*G*K M5KXZM2I1J>[M?#GA32+[7M=N['2]3UJYLM(TR![K4+U=,T:TO]4NX[ M.UCEN9TL[.XE2WBEE\LK&Q%TJ52M5IT:,)U:U:I"E2I4XN4ZE6K.%.G3A%:R MG4J3A"$5K*D80E)V46UTU%>&?"K]I'X-_&B]M-+^'_ (LDO]8U+P)H'Q2TG1-9\/\ MB7PCK>L_#/Q5-);>&_B#H^D>+='T34=4\'ZUGB*,I15.4HJI2E**E&-:C)QDHS4: MU&3@HU:4JI116#XH\4>'/!/AW6O%WB_7-+\->%_#FG76KZ[K^M7L&G:5I.F6 M43375[?7MR\<%O!#&I9G=QDX50695.%.G4JU(4J4)U:M6<*=*E3A.I4J5*DH MPITZ=.$9SJ5)SG"$(0A.M^$KK4;F MQL=5N=%NQJWA_P 0>&;Z#4+6"UNVCDTOQ-I>D:F(9K*^L;ZTNOLGV6\L[N"> MVFD1\CMJJM1K8:K4H8BE4HUJ4N2K2JQ<*E.5HOEG%W<7:47:[TDG=IIDT*]' M$T:>(P]6G7H58\]*M2DITZD;R7-":LI*\)*]EK&2:3304445D:A17'^$?'OA M3QV_BI/"VIR:DW@KQ?J_@/Q,)--U;3?[.\5:%%9S:IIB'5;&Q%^EM%J%HZZE MIIO-*N1-_HE].8Y0G85I5HU,_B9X)\ W&AV'B?7([76O%$U];>%_#=C:WVM>* M?$\^FVIO=1C\/>&-%MK_ %W6!86Q26_EL;":WL5GMC>2P?:8/,UH4*^)J1HX M>C5KUI*3C2HTY5)M0C*I.7+!-J,*<)5*DWRPITXRJ5*E.$93CC7Q%#"TI5L3 M6I8>C%Q4JM:I"E33G.-.$>:;2:=2I.-.G3J5)1A+NZ*X?P)\2/ M!OQ+LM:O_!FK/JL'AOQ)J?@_7UETW5=*N=(\4:,EL^KZ%?6>L6-A=1:AIAN[ M>.]B\EE@G=H&?SHY43N**]"MAJLZ&(HU*%>DU&I1K0E3JTVXPFE.$TI1;A4I MS5UK"I"2;C.,I.A7H8FC#$8:M2Q%"JG*G6HSC4I5$I3@W"<&XR2G2J0=GI.G M4@TI0G&)11161J%%%% !7XD_M4^%?&7B;_@H;<>(M!O?B1X*\)Z+^R+\.O"N MK>.=+^%?C?Q%X,\2>)/#G[5/A[XLZO\ ":[\0Z5X$\2A)]?\!V4EZ]UX7G@O MH)'ALI=13-]I[_MM17TW"G$M3A;'XS'TL'3QL\7D^8Y0H5:BA"C#,7@?:8A1 MGA<72K5*4<#%4Z5:BZ7-5E4DU.E0E#Y;BWABGQ9E^"R^KC:N"IX/.6K'^RPSE#%82K1IU98^3J5:-95N6E&G%.%6O&?X&?MA:;X^\2?$_P"( M'B#X1^ /CMH/A'4?^"57Q6M?AMI/A7P=\6-!L]/^."_$'1M4^#6E6NA>'M/M M['1/BM:Z+;RW^AZ+=VUMXCT2)&M-0AM7A\D1^ ]:^/'@NQ_;",/@W]JWQ1H4 MGP:_8:\=^#_#_ANQ^(%AXK\5_%6?2K1/V@)O#NN>--"U-[R2XU.31W^-^AZ% M;W6OZEH/]M6FFZ:-:=Y+?]Q_%_CWPIX$/A9?%6IR:8?&GC#1O 7AK9INK:B- M0\5Z^EV^DZ9(=*L;X:>EVMC=9U+4S9Z5;F,+=7T#2Q"3L*^VAXEU:&2X#+:_ M">#KX*-'!T,/B<5C<7*IBX9/C\/5G/ZS++9U*E=SA]6Q6(A5E5A5Q5:K_'J) M+XNIX9T<1G6.S&AQ7BZ&.=;'5L1A\)@L'&.$GG67XBE"'U:.90ITJ$83>)P> M'G2C2E1P]*BOW%-M_P ]MII'[1>D>-?AM8ZSX?\ CG;^'O!?_!6M-<\*0VWA M3XG0:?H/[*.O_!2SUBXS:V;:U]D^$2>.-8MH7TK7=2O[#2-=\[3)TM+K3M0M M+/[(_P""8-]K_P ._P!G'X;?"SQC\-_BKX?\2^)?B;^U3KLDVL?#OQ/HNC^& M+"'XT>*/%>COXPO]:L-..@-XP\/^+-(U'P8;B!XO$,?VV.TE$]A(SS_):N2U^'L!A:=;$8;%2KX/&8FE+ZQA? M;3HU'3C@XQJ?[17J8BK& M(+&^OM _X2%_"4RL=T<^I[X+6^E@\X_:<\%?%'X@_!S_ (*2^!(/AY\9/&'A MEOB3^Q-XO_9Z\/S> _BIJXO=1N]$^%4?QLU3X>V]_I$U[?0PZAHWBBY\80V0 MEL].U)=8OYX+>]O1-/\ T,7GCSPA9>"=3^(S:]97G@C2-!U;Q/>>(M'\[7K% MM!T2UNKW4M1L!HD6H7&K0PVUE>7LLHKB1XT?9T'7-+\3:'HWB3 M1+DWFB^(-)T[7-(O#;W-H;O2]6LX;^PN3:WL-O>6QGM+B*4V]W;P7,)?RYX8 MI5=%]O+O%/'Y11RVJN%<(_[(QN00IXJIB,90?U_AS"<,15.=2.7PG1Q>*P_# M//BHQJ1KTZ6:YDDIQDG4\/,_"O+\ZJ9E0EQ7BU_:^"X@G4PU+#X*O?+^),3Q M.I5(0GF%2G6P>%K\3/)/&HLYM9 M^'_]GZ3IHU"Z@N;,[7PN\%^);WXL_P#!4+4_%>C_ !:BT&T\=G6_@]%J$/Q0 MLO#VKV&J_LZ2^%O&,GP^L2L-CXFTV]\87/B2.>Q\-0ZC ?$\%GJ^G6RZA'I% MZ_ZY45\XO$'$++)9:LGRZ$I8/+L(\;1E.EB[9?F.1XZ51U/J]2[QBR22Q47+ MWL;G&=9E[5UL=+#KZ+_B'F'_ +2EF+SG,:D7B\PQ7U&O&%;!IX[ Y[A(TU3^ ML4[+!RSN*PLN7WUD M@_5OXKZG\:/%%S\#=(TOPYXXN[3XI?$GX1:-\;O%/A;3-6A\6Z%\ =+^"T7Q M'U'PQJELL>EZ_P" +/XM_&*PUOX?^(]7@.F16-G+<:9K.H:1>75G):?JC7,> M(O"&B>)Q&^H)?VM]!;W-K:ZQHFK:IX?URS@O(S'<16NLZ+=V.H0Q2 AS$+@Q M"98YQ&)HHY$]G,_%*.<8O"8C$\-97A7A<1F.(A.E.MB.6>/PV948+D^J823I MX3$X^AF%.'-54\5E.5N=*2PZ4/(R[PMEE.%QU##\29GBOKL,'"I"K"EAKQPN M*RZO.*J?6\7&+Q&'P-? 2ERTG##9OFL8U8_69<_Y0_LR:-\3;7]F76_B'\:H M/BGH?Q8\8I^U5XM\:>$O%_A_Q!?^+[6;QSKFI:%X'^%.D:*MA?:_JFD>#O#/ MASPQ/81>%+!O#Z,NFW=L;F357G;Y#\"^ ?BAX=_9R_X(]V>N6WQUU.Z^%7QT M^%.L_$GX:W_P4UB&/X/Z3X/\#>-= \1:OKKZ+\-++Q9IUGH.J:[I>CK/XBUJ M_@U&+5GOK<:A%:27MI_0KX:\%:%X5!?3UU*]OY+6"RN-;\0:UJ_B77[JVM@! M##-3P6&H5)>PJ8OV^K\,8U\# MEV'KYSBZ=; Y1A\LE6=-8FKB:M'B'A[B.IF&,G''86A7Q.*Q7#].GB:/L:F" M?UW$XBG'V]/"^Q_$'6O#OC>__:1_X*S^(=.N_C/X*T#QI\*_@]IW@V71/@]J M&JZ-\7-0\&?!?Q'X#\2Z5H&H^(OAOX@EUJ?1/%FK6/A\P^#[VUN;U=6FU"TD MO+*T.HV3OV<_AM\3O"^@?\$K_C%K7A'QO=>"/@3^S3XG^"_Q7\"77@W7K+QC M\(_B'XE\">$M*'CNY\&:IIEMXHU&TL9?#&J^ ]?NM'TZ\O-*L-4CU&P2^T.^ MU>=/V\KSRS^+'P\O_B?J_P &;/Q-:7'Q.T#PI8^.-9\(QV^H?;M.\)ZI??V9 MINMW-P;0:F>XEMKQ8H7%E=F'-^(F8XS 5<#AL@HU*.'R["4L M;.G4KUYT\KP/ D/#W%U:M6CE].KAW6P=>AC5F%:O4> QU2GA:3G@,1/#5G'P MYR[ XZGC<3Q!6A6Q.9XRO@H5:5"C"IFN.X\J^(>$HTJ-?,*M'$*CC:6(P/U" MC0I/'X&G/%U>3,,-#%4/C']M?X:Z_P#M%_L\>+S\%/"U]?>)6\4_!#QEKFF: MEX?3PI??&_P-\+?']CXZU#X8>;XH@TS4&^T:F>.O!'C:XTC6AX4\42WOA0ZGJZWWB/X=^(='U'P-?'P]<0:DBG7M M)LKU=5NM*U*]T22#PRNK37AFO++,D D:O7J^4;S]M7]GVS\0Q>%O[<\<7NN7 M5KX^U'3+/2O@Y\8-677-(^%VIQ:-\0=<\/W.G>!KFUUW0O"^J7%K9WNLZ3-= MZ=<2W=J=.N+V.XA=_FL/B)PE'-J."H M8RECJL(QCB*'LLLIO#RG]7^K4WB,/RRRZ7U>'TN)PV59'FE;.,?G6!P-;.L- MEV"Q5+'4,)#"XNOE-?&U\'5P-*;E/#U_;9G-8B$7B?K%18?$*4,R7UBI\!_L M'_ /1?$?P1NM<^/.G_%FUL?@W^US\_$&WT)_!.F>.O'4DVBZY%XJT#3/[1URRBU:6R$.CC4;>"RBWOB7K'Q+\*_' M?]F?]MK0?ASK-]X=\2>)/%GP?^*FE^#?"OQ;U_XKZM\"?B/(ESX>O?'GPV?X M7:5J7AA?@9XF\-:)KVH12WNI/&M[XFCTA=174XY)?UL\)^*=#\<>%O#?C3PQ M>-J/AOQ;H6D^)?#^H/:7M@U_HFN6$&IZ5>FRU&WM+^T^U6-U!.+>]M;>ZB$@ M2>"*561>@KV\7X@XRKG^;YCF&41JQQT\VP&(R7$XW$PPN"R[-,)/!9QE=",, M+0G1KXC,,/A*QN995BZ6-R;-*\ZF*Q$*^'P^75\3EU# TJU#"/ 9KB_8U:-+% M5,/7_+K_ (*$^)/%OQ$^!<>F_#/P;\;[?Q)X'_:L_9QLC>>'O!OC_3=2UOPY M#XN\'>*?&GB;PK/X8@?5=9\"6W@+5==T_P 1ZPT4.EQ3V6NZ'>)]NMDAD^7] M.3]JB\\&^/M"T:W^*>F?#+P[_P %2_B-)XCL]:\"^/\ 6-5'['GB#2[B[\-W M?AGPQ>'1O$'C7X0VWQ$U5]3U?2_"U_+/;Z#;W!LH)-%L+BQE_>6BHRCQ!AD^ M3X?)Z/#>68JEAL=/'4:^/KU<74A4K5E6J\JJX&T:BE*M+#U>=_5ISHN-*I'# M0A5O.?#Z>=9Q6SBMQ)F6%JU\#]1JT(/AMX?^.?C M7P]>I?:K\1['X]W>L"S\3#23>(AI\_B#1;!7EDNMYNM'N;VTCO[.UU2"&1Y+"Z MN;":"^AMKI8IWLKBVNEC-O<022:E?-\3<0XWB/%8#$YA0AA\1@5VIQ=* MG5I4*^:8REB8X98?"T,+*NLXJ3G2PF'HX27+3JX>E2IS5-?1\+\.8'AK"YAA M&\<6 M-[;6,.CZ>EKXWUG1XO#(T6>&_NFNM.:>74C?I%<+&EG$7_!/]I'_ (-U_P!J M/]KSQA9>._VC_P#@KI\1?BCXATJSFT_0_P"U/V;/#^FZ)X']"ANYDCEO6T_3H;B^DBA>]GN&AB*?U545&4\49SD4J=3*:^'P->E3 MG2ABZ.7X!8WDJ2E*<98UX=XJ:ESN+;K)NFH4FW3A&"TS?A;)<]C5IYO0Q&/P M]:<*E3"5\PQ\L#STXP4)1P/M_JD''D4DHT6E4TJ9U5Y=,UBPO;)I%63R1(JN/ZSJ*]K$>)?&^,H M5<+B\]K8K#5X.G7P^)P^%KT*U-VO"K1K4JE*I!M)N,X25TFK-*4?$PWACP-@ ML12Q6#R&AA,50FJE#$X6OB"?!'BF_UT0Z'\/OV.?A=X-UW2O#>K7=R]KX;C\<^&_'^E>*)$T_39HM+? M5;:]T_4+Z.%YY)(GN)%K]PZ*^:HYQB\/B*F*I4LNC6J2I2N\IRR=.G*BFH2H M4:F&G1P\K^]-TJ:]I-1G44I1BU]/6R;"8C#4\+5JYE*C352-EFV9PJ5(U?CC MB*U/$PK8B-KQBJU22A!RA"T9-/\ C./_ :3:P26/_!1[Q(S,Q9F;]G&Q9G9 MB2SNS?&HLSLQ+,S$LS$EB22:0_\ !I+JQ!!_X*.>(B",$']F^P((]"#\:<$5 M_9E17U?_ !%/C_\ Z*3&_P#@-'_Y$^1?A1X?-W?#.!;;NVW5NW>][[WOK>][ MZG\^/P%_X)/_ /!2[]F?P'IWPR^$7_!:SQI:>!]#LUT_PYH'CC]CWX;_ !-M M_#5C&,0:=H-WXY^)6LZGIVEVHPEII<5\=/LHAY-G;V\/R#[S_:._9J_;^^)^ MH^"9?@/_ ,%((OV<-'T7X=:/X:\;Z7#^R5\+/BC=>.?'EJ]R=;^(T&K^)_$F MGW/A0ZS');)#X5TR*XTO23;-);7$K7#A?T;HKYJMQ!F&)Q$L77AEE;$3=652 MK4R7*92JSK.,JE2LOJBC5JN4>95)Q'LNP^&CA*%3-*.' M@J4:=*GG6;05*%&,HTZ=%K%\U*DHRY72A)4Y1C3BXVI4U#^1_P",O_!LE\VC,DA;R[_B$FU?_I([XC_\1OL/_GTU_9C17T-' MQ-XYP]*G0P^?XC#T*,(TJ-"A1PU&C2IP7+"G2I4J=.G3IPBDHPA"$8K1177Y MVOX7\"8JM5Q&)X>PV(Q%>:VL"Z]IMI^S3XVZ,R0W,:,RG]S?@!\%_VN?AY\(/B;X/\ MCG^V?!^T%\6?%$NNO\.?C"G[//@+X60_#".^\+V^E:'$_P /O#.M:AH7C,:# MXECG\4NVL7MJVJK/_8ESY=G&LI^R:*\#-.),VSJL\1FE7#8S$RG1J3Q57+\! M];J.@XNG&KB8X>->K3M",)TZM2I"I27LJG-3]Q?097PUE&2T8X;*Z6*P6%A3 MK4J>$I9CCUA*4:ZFJCI85UW0HU+SE.%6E3ISI57[6FXU$I'\]/[0/_!)7_@I M/^U#X#U'X8_&/_@M3XVU'P'KEJMEXC\->"_V/_AQ\-+'Q/99!EL/$,O@;XEZ M-J&JZ7<,H-UI5S>MIUXH$=Y;7$8"5^<@_P"#275@,#_@HYXC '0#]F^P 'X? M\+IK^S&BO4R_C_BO**,L/E69QRRA.?M)T*6*5/C6K MQRQNJO'(C*\;JKHP8 C]>_@=_P $^/\ @I_\%_\ A!=#E_X+,^*OB)X \):S MX>:WC4_MI149EQSQ/G,*<,WQ]+-(47)T5F& P&,]BYJTW2>(P]25) MR27-[.4.;EBY*3C%K3*^!.%\DG4GD^7U,JE5Y/;/+L?C\'[90;<%66'KTHU5 M%M\JJ1G:[LU=W****^1/KS\Z?VVO^"5'[$/[?\!OOV@/A#92?$&"Q%AI/QD\ M"7;>"/BWH]O& +>)/%VE1$ZY9V@&+72O%MCXBT:W!?RM.7>V?YR?B]_P:A?$ MC2;ZXN/V9/VX+2719-YM?#7QX^'ERU]:+O)C@F\8> =2\G4%V;5\\^"K)U*Y M:.8DD?VF45]3D?&W%?#=HY-GF/P=..U"-:52@O*-*I*48+RIR@NT4?*Y[P1P MGQ+>6=Y%E^.J/>M.A"%=OO*K3C&4GYS4GWDS^&KPC_P0Q_X+Q_!]?[#^#_[: M_P +/"?AU601IX2_:*_:!\%V2JH$0:+0M.^';VT'EQ* J1NHP @( !'O6G?\ M&_?_ 50^.1M]*_:\_X*L:R_@J;:-4T#PEX@^,WQ8O9HE;#VZ1^.O$/@G00T MD6Y8Y[BROHH2P9[2X :(_P!C=%>UBO%+C'%R=6KC, L3)WEC(9/E:QLI-?&\ M7+!5,1[2_O<_MG/FUYMCQ<)X6<&X**IT<%CGATDHX.><9I+!1BGI".$CC*>' M5-*T>14>3E]UQLW?\BOV"?\ @B7^PS_P3_O[#QOX#\$ZC\4OC?:1;1\8XS$8W$S^*MB:LZL[7;Y4Y-J$;MM1A&$4];-ZGW&!R_ Y9AX83+\ M)A\%AH?#1PU*%*%[)7:BDY2LDG*(/%_P :DTGX41R>!O!GB?QA/X<\)^-->TG0OB-X MLUA?#6C:Q)INE>'_ #J'B&_DFFB6YNI8X[?3(KJ[(C7[MHKU$K5)TJ-:O@JT,3AHU9TZ=6?LX8FCAJTHJ$O:?5XTY6A4J,\ MK/=Y+FN3+%U<"LUP&*RZIBZ-.%6M1H8VC/#8F5*%2I2A[2>%K8FC";G%T M_K$JD;SITT?/'PH_9M^'/PP\5R_$C2YO$7B7QS=?#?PG\)[#Q1XMGL?MV@?" MSPA/<:AX>\!^'=&T?1_#NA^&]"M[Z[?4;^VL=#M;_5=22"ZUNYO;FTMVA^:O MV2/@UXOUGXF_&_\ :+^*+_%[PQJFI?M%_&6#X2_#SQ1XO\;6GA^P^%EI;:3X M T;6[_P/K=Z]D\?B>;0-<\8^%XC;_P!F:9IWB2&_T2"W%\2OZ.45Z$.*LV6' MSNE5K2Q.)SO"9?EU;'XB:J8G#9;@,3BL3+ 82+P[H4:&+>)]C7]E3P\HT(U( M47!XO%U*OFSX3RAXG(ZM*A'#87(L7F.94,OP\'3PV)S/,,+A<+',,7)8A5ZU M?"+#>VH*K4Q,95Y4IUE..#PE.E^0?QQ\#_M8?&C]H+XE>%=.M/'G@W0]$^,? M[*\'P1\<:7J%YHO@[P3\'?"CP?$WX\?%&SUBR*:;KGCKQGK5E=?!^7PQ??:] M:_LF>RL)--M_"MYK6IW/KW_!030-,^+FM_L>?LU7^EV^N6?Q=_:<\.>*?&&C MW*F:UNOA;\#="UCXF>.H]2MUC?S-*U"YLO#'AV]$I2UE?Q!:V5P76]2*3]'J M\K\+_!+X6^#/&WBKXC>'/"%E8^-O&>I:EJVO^(9KS5=3O)K[6H=&@UF334U6 M_OK;P_#K$?A[0CJUGX>@TNSU*72;">]MYY[:.1?=PG&\:>)R7&3P%# 3X5RW M%TLBH9515/VV;XK*WED(H+#UE3SE0H+$<^8QQ#@Z=7&2QE'PL7P M-.IA<[P4,?6Q]/BO-,)5SZOFU:51T,GPN:K-)Y=@<'2I5&_&=]X1\3_ !=L=%^-/B'X M?>$-0\?^)/"OP\@\,>(+G38X?"&BZAIFMWFDZYXQB\-Z;KVI6=Y#9:9HZ7<6 MN2KI&H7:OPOQN^"NO^#/V$='_9L^%.O?'V#67\&Q>'M"^(5L^I>-OB'H>H>& M]*U+Q]:W7Q*DT:YN-4U3P_XR\1:'9?#KQ1H_AN::7^S/&+:7I4<.C67@.+:V7X7A["T,NP48Y#F\\[JS3=\YQ\<0Z^!K9G&KA,3&I++H2GA*$5* MIAJN#E*C6P5YU*TO5Q_"-',<5Q%BJ^8XQRS_ ">&1TX-:9/@)4%1QU'+)4\7 MAG3CF,XPQ5>3A3Q%/%P5:EC?=IT8?!5MX8\=R?L26WAS7?#OQ4^%?Q-^-/A. MWMO&]A\,M9O/%7C+X$^+_B]'&OBK5/"EZ+FYO+?PQ\(;C5;J\TO0]+NKN^TK MPYH-OX>M^RCI7Q0\#?L8W7BCXE_#+Q):?&2[\$>(M6\1_#'3=4 MUJ2]UW5?!7AA_!_ARW\':3<7SZIX)G^)FC^$])\6GPI%>Q7^B>+O&>L-,]IJ M,LT5O]_45-;BNK7P&-R^66X-4LPXEI\1XB4:N*53]U*48952J.]:&7_5_889 MRGB*^(4<)A<3"4,;'$8C&U1X3I4,?@L?#,L8ZN7\,U>&\-"5'"RIWK1BYYM5 MIZ4JF/\ K'ML2HPH4,,Y8O$X><:F#E0H8/\ -CX::9^TE\(_^"9,2^#]$\:^ M+?VJ],^!?B#Q'IVD^.[BZU/Q?=_%SQ/:7_B.XM)HO%-[=7]Z_AK6M9GL-#T3 M7IEN[NUT+3]'N(P95+]#^QG\*OBGX3^('QH\?>*]9\=)\//%/A?X'>$? FB^ M/K_5'\1^+O$G@7P3.OQ0^-_B/0-8S?>&]?\ B)XKUMM-DM[J'3=2U*S\*P:E MJ.E6=M-I$:?H-16N*XRQ.)PG$N&66971J<49MB\RQV+A0YL10I8O%8?%K+\+ MS4HTZ6&PM7"TU@YPA1J8>G4Q2A3Y\3*K3RPO!F&PV+X9Q+S3-:U/A;*<)EF! MPDZ]J%>KA<+B,&\QQ;5652KB<72Q-26-C.5:&)JT\*YU?9X:-"K^%>G_ [_ M &E_$WQD\&^*[W1?VA=$\*_$/_@I'XY^*-_:Q:EXUM+7P+\ O@!X0UGPYX \ M.Z]IVIZC%;Z;X/\ CCXV#>*K>POC!X6GTF^66TC226UC?]C-0^*&A:;\6/#/ MP=N--\2MXC\6>!_%?C[2]7@T6:?PE'I7@W6/#&B:O8:AKTY\6Z5/8 M6%Q J7EJ+J2.X$L*PR^D5173-.349M76QM5U6>TAT^;41!']MDL;>66>&S:Y MV^;]ECGFEF6 .(A+(\FW>=U&?\5PXDG@OKN4X;"TLMRW'X+!4&4ZRP<,NH4YTI7XW M&ULRHPKOZOAHY@L7AL-3AB7"C+&3S*O4A57+]5FX*-.O3H4(0O5\ :+X3\1> M OV[/CK\:/B9H7B;7O#'CCX3_!?X??L^>)O#WA?Q%XQM/"6E:3<>*+[XK^!; MZ'P[::Q<>%;_ ,0^,I?#WBJ;5=0L-,T;6]/CL(9M5,_A]HA]_P!%>)E6;5,K MCFE*-&%:EF^55LHQ2W$LNJ36-KI-RV^3RD\*_8S^ M%7Q3\)_$#XT>/O%>L^.D^'GBGPO\#O"/@31?'U_JC^(_%WB3P+X)G7XH?&_Q M'H&L9OO#>O\ Q$\5ZVVFR6]U#INI:E9^%8-2U'2K.VFTB-/T&HKNP_$E;"Y% MFN24L#@7_:]=3Q.95H3KY@L-'^SW3P=.K6]HE"A++J4L/6YHU:/M\;R1A*&%RVC*%#+WB9_7U4QE2E1Y+SKQS&LL11Y)4J M[H8+GFJ>&]C7_#&V^&G[2'C+XS^&/$4NE_'CPUX7\??\%#/'OQCN8[FY\>6] MEX$^ /[,G@;5=*\*>'=1L]2U&:#2]/\ VAO'D;ZMX:T.\:'PWJ6GZTD^EZ?' M#(R0_17[-%O\8_AW_P $[/'WB+Q]X*^,FN?&?7-%^/WQ.G^&FL)XGO?B&OB7 MQYK7BWQ1X;^'/ABVCOT\80C2X]3T?PY8&">PO(KR&[O=*>.T^R7)_42BOHG5K4G?\ #0/B'Q)X M0_8:_9Z_9IL=8LM1\>WLOCWXP_'7XCQ>+?C5\5?#\R7CW.JGX+Z+=M::MJVG M--KB>7<6>I7#"2YB3],?VO/!WQ'\2?"3]FOX5?#[2_BW>)KWQW^!.B_$+Q7X M7U74K#Q;X/\ A9X6F.M>.==\7:EHFLVR-'X@TK0QX1U@7T^I:6]UXHDN;F"6 M6W@D3]!:*O,/$K'YCC-_"?CSXJ_M"_%_XC7OACQ59ZS!/H'AI=<;PGX$\.^'=,U5_M MRZ59^!?"'AZ\MFL]/M+'5+K59K^T^USW=S+7Q)^S'\./VEI_BQ^QWXD\?Z-^ MT'X?T2_\0_M>_M'_ !*L]>U7QB^D>&9_B3K-AX%^"OP-\;Q:]J+I&/!7@:X? MQ/#I>OE[FVFLI8=$BEG,JR?N?17+#CVO2Q'$^(I9+E<'Q-'V4J=ZTX95AJ>2 MXO),-ALO]I0J-0PU'%>WISJ\M6=7#T%5G)0]J=<^ *%7#\+8>KG>:S7#$O;* MHE1ISS;%3SO"9YB<3F/L\133GB:V%="<*3G2A1Q&(=.$7-4CX:\>:'\0_$G[ M?7P-O+;1/B/8_"CX:_ [XC>(]:\1Z5?:Y;_#KQ9\0?&6NZ=X5\->&/$=J-0B M\,W=_P""_#MMXI\2Q)_"#5O@AXR^%[WNG>$XO'.F^-=5\4_%#7O&'C&QN8+;PUXBM$T M3P=X4TW3M4/]HW?@^^\3)X907&O7TM?HQ17G8?BRIAWA)0RS!\^ X9EP[@JT M:E:%?"U98ZMCY9W1JJA4Y'I8CA*EB5C(U M,SQCIX_BB/$>-H2IT9X?%48X&AE\\,^! MK+2O@3X-\0MI-U:ZG'I1\3^)-1\9VVFHTB^(-=\)Z-!##--IK1FC\7?AM\3? M"W_!*6X^"W@#POX^\8?%*\^ ?@CX4?8KRTU'4_'+CX>\*>-/&FI6L$^I M:P;_ $7^V/$'C6]5'GU*W^P.0B31_)^I%%=>#XVJ8+ <+9?2R7+/9\,9[A.( M'4Y\5&>?-*-"C%P48\JX\;P/3QV/XKS"KG>9JI MQ1D.+X>4%#"RADV$QE&E1JSRQRD[S483<(UZ?+&5>M+F(/AE\+='UJ'6?'?B2_?PMJ M=O\ 9X-0\.Z+J/AJ_.H7-SI U7Q=#=ZP L4ES!Z7^UY??%XZM^SGH'@GPUXV MU+X4:S\3M2OOV@9? %HVH^)I/"/A;P)XA\1>$/ $UM8NU[;>'OB7\0;+P_X2 M\3:M;30:?;Z?,VG:WJ=AH6L7]T/MNBN2AQ;7ISRN>(R_"8^>78WB3,:M3&5< M15K9ACN)(R57&8JM*$ZBQ67-QK8"JI5U#%4XXNI1=>\GUU^$:%2&:T\/F.+P M%/,L%PSEU*E@Z6'I4,OP'#4HNE@\+0C.G3>%S)*5',:3C0<\+4EA*=?V%HGY MP>%O!_QY^!'_ 35\1^&_%=KXR^)OQ_TCX._$R^LO"_A75-:\3^*+7Q;XOG\ M2:MX-^'GAS6=&==*-8U_4_ _Q*^(/?BU\1K. M36;U[2[U^#Q!J.G^$I;RTCGU@FSU/^UV1'AFE_5BBNJ7'.,G@>)\'4RS*W5X MJQV98_&XJG1]C/"U,R^H1E2P%"%&=+#8?#TL'5I4:4:D+K&5JLY>WA&M5Y8\ M"8.GCN%L93S3-52X4P&69?@L)4K>WABZ66_7Y1JYA7G6A5Q.(Q%7&4:U:K*G M*SP5&E"'U>\2'4/#EP\DT.M:!SO(Q"=5U*M*BL/3DI5\1.C&-)3J$+WQ!\58+N6&3_ (2?Q3JVHZS9PSR2S.W? M_MRZ)^T)XA^,'Q(\0_"GPK\9M0T3X4_L+_%2W\,6?@BX\7V.C_$GX[?&75KS MP3X-TW18M+NX--U/Q'\*M M]8\8W=SI43>(K"/7=.CBD.;=8OUYHK[__ (B+ M56=9;G$.''H\T:T: M;I4:N,IXUZTW5K82C3J4_82G&'PK\0(?CI\'?^">U[I'P7TKQK\0/C]X%_9_ MT#PCX/35@FK>/=9\86&A:5X6E\57,.H7,S:IK]IF[\7I87TTEW?W-HEE=0M= MRR6U<)^Q!\*?%'A'XP_M7^-?%_@[Q[X?-]K_ ,,?A3\.=6\>I//?^)/A=\+/ M -A<0^+!J]W=22ZIJ?CWXA>,_'_BOQ+):PFTBUZ>[CDN'N 5K]):*\:/%V(C MDW$&4K+L"JO$>/KXW'YI!UJ>-Y,1CL)F$\%&-.,,-+"1K862A2<*481Q%;EI MI^SY/9EP=AIYUP[F\LQQTJ7#6 H8' 97-4:F!Y\/@,7ET,;*524\3'&2HXI. MI54ZLIRPU!2J->TU[PIJ&N:+8Z??V0\2#PAX9%Q8W"RZA'X?GGA MM[C2$L;Z?]#J*\G*\WEE>'SJE3P\:E7.,IJ90L2Z]6G+!8?$XO 8C&3I4X0E M"M4Q5#+Z>!FJLH1AAJU?D;G.Q[&:Y/'-<3DE:IB)4J.39O3SEX94*52..Q&& MP>88;!4ZU2+?CK^U;\$_AS% M#\5O!7P,\'? WXM^(_B%XS\ >*O&/@/0M8USQ+=Z!X%\!> =,U7P]=VFCQ^) M=&LI/%/B;8L0U?3M*:VN+.XME$)K8_; T;XH:G\2OV/='^'GA3XF:OX3\'_$ M+QG\3_B)K7@K5=:M=.?2OA?\.=4U/P5\._&1L]0BM=2L/B/X^G\-V_DZQ9:I MYZ:%>0VRI<7;^=^@5%>OAN,<7AZN0MX+"5L-P_E./RW"X.K*I[&MB,SH9S0Q MF;8BI&BZ]3'5/[9J3BI5*U"E]3P4*:A&ESKQ\5P;A,32S^*QV+H8GB'-LOS+ M%8VE&G[:CALKQ&35\%E&&IRK^PIX"FLFA3FX4Z%>JL;CIU'.59P?YV?LD6?Q M0\#_ +"&E:K\2?"GQ>N?C)XNL/&OCWQ[X;LH+FP^)UOXU^+?BS5O$VK6/A:P M\23F;0[CP@_BA=-T>VU**QM-,C\/":*T33XX9);7_!/+X=?$OX=?"3Q-%\6K M'Q9<>+-!\4:]\.-#\3^(;O78;[XO?#GX$?&OQ*L M=;N)_&,=\UO?^)-0TJQ\0WMO;F^B0?H311F'%]?'X?B;#_V;@<.N)\]I9WB) MT95>;!1H5<1.EEN!3I04,%&A6IX-QG)\V'PN%DJ$,316)D9=P=0R_$<,8C^T ML=B'POD57),/"M&C;'2KT:$*N98Z2JS<\9*M2J8M.G%6Q&*Q477J8>M+#Q_/ M7_@FK\*]7^'WP!U7Q5XY^'FK?#SXN?&CXH?$WXM?%+3?$&E2Z5KBZMXL\<^( M+_P[HUW%=E=0>U\)^#YM"\.6/VB"WMDCLI?[,22P>&>7]"J**\?/\YK\0YUF M>=XFG&C6S+%U,2Z%.I6JTL+3<:5*AA*$\1*59X?!X;#X;"8=5'S1H8>E%VL[ M^SP_DU#AW),KR3#5)UZ668.GA5B*E*C1K8JI&56KB,97IX>,:*Q&,Q.(Q.+Q ,+IQ495\15DM&K?_9 end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 29, 2022
Jun. 30, 2021
Document Information Line Items      
Entity Registrant Name Joway Health Industries Group Inc    
Trading Symbol GTVI    
Document Type 10-K    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   20,054,000  
Entity Public Float     $ 92,610
Amendment Flag false    
Entity Central Index Key 0001263364    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company true    
ICFR Auditor Attestation Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 333-108715    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 98-0221494    
Entity Address, Address Line One 600    
Entity Address, Address Line Two South 3rd Street    
Entity Address, City or Town Las Vegas    
Entity Address, State or Province NV    
Entity Address, Postal Zip Code 89101    
Local Phone Number 384-1990    
City Area Code 702    
Security Exchange Name NONE    
Title of 12(g) Security Common Stock, par value $0.001    
Entity Interactive Data Current Yes    
Auditor Name HHC    
Auditor Location Forest Hills, New York    
Auditor Firm ID 5867    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS:    
Receivable from related party $ 119,070
Total current assets 119,070
Total assets 119,070
CURRENT LIABILITIES:    
Special dividend payable 119,070
Other payables 103,053 51,344
Due to related parties 3,999 693,546
Total current liabilities 107,052 863,960
COMMITMENTS
STOCKHOLDERS’ EQUITY:    
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at December 31, 2021 and 2020, respectively 20,054 20,054
Additional paid-in-capital 7,228,862 6,469,236
Accumulated deficit (7,355,968) (7,234,180)
Total stockholders’ equity (107,052) (744,890)
Total liabilities and stockholders’ equity $ 119,070
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 20,054,000 20,054,000
Common stock, shares outstanding 20,054,000 20,054,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
REVENUES
COST OF REVENUES
GROSS PROFIT
General and administrative expenses 121,788 222,607
OPERATING EXPENSES 121,788 222,607
INCOME FROM OPERATIONS (121,788) (222,607)
Other expenses (252)
OTHER LOSS, NET (252)
LOSS BEFORE INCOME TAXES (121,788) (222,859)
INCOME TAXES
NET LOSS FROM CONTINUING OPERATIONS (121,788) (222,859)
Discontinued operations:    
Loss from operations of discontinued component, net of taxes (760,538)
Loss from disposal of discontinued component, net of taxes   (1,340,795)
NET LOSS (121,788) (2,324,192)
OTHER COMPREHENSIVE LOSS:    
Foreign currency translation adjustments 165,413
COMPREHENSIVE LOSS $ (121,788) $ (2,158,779)
LOSS PER COMMON SHARE, BASIC AND DILUTED:    
Continuing operations - Basic & diluted (in Dollars per share) $ (0.01) $ (0.01)
Discontinued operations - Basic & diluted (in Dollars per share) $ (0.1)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares) 20,054,000 20,054,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Stockholders’ Equity - USD ($)
Common Stock
Additional paid-in capital
Statutory reserves
Accumulated deficit
Accumulated other comprehensive income
Total
Balance at Dec. 31, 2019 $ 20,054 $ 7,361,665 $ 354,052 $ (5,264,040) $ 486,338 $ 2,958,069
Balance (in Shares) at Dec. 31, 2019 20,054,000          
Net Loss (2,324,192) (2,324,192)
Disposal of subsidiary (892,429) (354,052) 354,052 (651,751) (1,544,180)
Foreign currency translation gain 165,413 165,413
Balance at Dec. 31, 2020 $ 20,054 6,469,236 (7,234,180) (744,890)
Balance (in Shares) at Dec. 31, 2020 20,054,000          
Net Loss (121,788) (121,788)
Forgiveness of related party debts 759,626 759,626
Balance at Dec. 31, 2021 $ 20,054 $ 7,228,862   $ (7,355,968)   $ (107,052)
Balance (in Shares) at Dec. 31, 2021 20,054,000          
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss from continuing operations $ (121,788) $ (222,859)
Changes in operating assets and liabilities:    
Prepaid Expense 15,000
Other payables 51,709 25,344
Net cash used in operating activities from continuing component (70,079) (182,515)
Net cash used in operating activities from discontinued component (382,246)
Net cash used in operating activities (70,079) (564,761)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash received from disposal of subsidiaries 119,070
Net cash provided by investing activities from continuing component 119,070
Net cash used in investing activities from discontinued component (79,446)
Net cash provided by (used in) investing activities 119,070 (79,446)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Distribution of special dividend (119,070)
Due to related parties 70,079 182,515
Net cash provided by (used in) financing activities from continuing component (48,991) 182,515
Net cash provided by financing activities from discontinued component 424,562
Net cash provided by (used in) financing activities (48,991) 607,077
EFFECT OF EXCHANGE RATE CHANGES ON CASH 37,130
NET INCREASE IN CASH
CASH, beginning of year
CASH, end of year
SUPPLEMENTAL DISCLOSURES:    
Income taxes paid
Interest paid
NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES    
Receivable used to offset the selling price of disposal of Dynamic Elite and Subsidiaries 783,360
Uncollected consideration from Disposal of Dynamic Elite and Subsidiaries 119,070
Undistributed consideration to shareholders 119,070
Forgiveness of related party debts $ 759,626
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Organization
12 Months Ended
Dec. 31, 2021
Organization [Abstract]  
ORGANIZATION

Note 1 – ORGANIZATION

 

The financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”). Joway Health is hereinafter referred to as the “Company,” “we” and “us”.

 

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilized the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.

 

Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engaged in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.

 

Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducted its business through Tianjin Joway Shengshi Group Co., Ltd.

 

Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi was owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import & Export Trading Co., Ltd. are subsidiaries of Joway Shengshi.

 

Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and the construction of Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.

 

Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness Room for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.

 

Tianjin Oriental Shengtang Import & Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company.

 

As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.

 

On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health became a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern
12 Months Ended
Dec. 31, 2021
Going Concern [Abstract]  
GOING CONCERN

Note 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

 

As reflected in the accompanying financial statements, for the years ended December 31, 2021 and 2020, we incurred net losses of $121,788 and $2.3 million, respectively. In addition, we reported cash outflow of $0.07 million and $0.6 million from our operating activities for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of approximately $7.4 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.

 

The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.

 

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Prior to the consummation of the Merger as of December 31, 2020, the Company’s functional currency is the Chinese Renminbi (“RMB”); however, the accompanying financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

Use of Estimates

 

The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

 

For the periods prior to the consummation of the Merger as of December 31, 2020, the Company consolidated financial statements including Dynamic Elite, its former wholly owned subsidiaries, and controlled VIEs. The financial statements of Dynamic Elite and controlled VIEs were included as part of the Company’s discontinued component. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

 

The accompanying financial statements are presented in USD. The functional currency of the Company is RMB for the periods prior to the consummation of the Merger as of December 31, 2020. The financial statements are translated into USD from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   December 31, 
   2020 
Year ended RMB: USD Exchange rate   6.5249 
Average yearly RMB: USD Exchange rate   6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

For the years ended December 31, 2021 and 2020 foreign currency translation adjustments of $0 and $165,413, have been reported as other comprehensive loss in the financial statements. After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners. Other comprehensive income is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

 

Prior to the consummation of the Merger as of December 31, 2020, the Company’s operations were carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations were influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC were subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable.

 

As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 (formerly Statement of Financial Accounting Standard (“SFAS”) No. 157 Fair Value Measurements) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as the following:

 

  Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

  Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

  Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the years ended December 31, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

 

Deconsolidation

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

The following is a reconciliation of the deconsolidation:

 

   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Receivable from Related Party
12 Months Ended
Dec. 31, 2021
Receivable From Related Party Disclosure [Abstract]  
RECEIVABLE FROM RELATED PARTY

Note 4 – RECEIVABLE FROM RELATED PARTY

 

Receivable from related party consist of the following:

 

   December 31, 
   2021   2020 
Crystal Globe  $
-
   $119,070 

 

The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Special Dividend Payable
12 Months Ended
Dec. 31, 2021
Disclosure of Restrictions on Dividends, Loans and Advances Disclosure [Abstract]  
SPECIAL DIVIDEND PAYABLE

Note 5 – SPECIAL DIVIDEND PAYABLE

 

As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. 

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. 

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. 

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. 

 

As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Other Payables
12 Months Ended
Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]  
OTHER PAYABLES

Note 6 – OTHER PAYABLES

 

As of December 31, 2021 and 2020, the Company reported $103,053 and $51,344 as its other payables, respectively. The other payables mainly consist of payables for professional services, including audit, legal, and financial statement filing services. 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

Note 7 – RELATED PARTY TRANSACTIONS

 

Payables due to related parties consist of the following:

 

   December 31, 
   2021   2020 
Jinghe Zhang  $3,999   $233,693 
Joway Shengshi   
-
    459,853 
Total  $3,999   $693,546 

 

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

 

Transactions with Jinghe Zhang

 

During the years ended December 31, 2021 and 2020, we received financial supports of $66,235 and $182,515 from our former CEO and chairman, Mr. Jinghe Zhang. The loans due to him are for our daily operating activities without interest charge and due on demand.

 

On April 28, 2021, the Company entered into an agreement with Mr. Jinghe Zhang to release the Company from $295,928 of indebtedness owed to him. As of December 31, 2021 and 2020, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $3,999 and $233,693, respectively.

 

Transactions with Joway Shengshi

 

Joway Shengshi was one of the Company’s subsidiaries but has been sold via the Merger Agreement on December 31, 2020. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the years ended December 31, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our daily operating activities.

 

On April 28, 2021, Joway Shengshi released the Company from $463,698 of indebtedness owed to it. As of December 31, 2021 and 2020, the total unpaid principal balance due to Joway Shengshi was $0.

 

Disposal of all of Joway Health’s subsidiaries and VIEs

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $902,430 in cash (the “Merger Consideration”). The Company was obligated to distribute the Merger Consideration to its shareholders in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. The Merger Consideration due from Crystal Globe was partly offset by the distribution due to Crystal Globe at the amount of $783,360. The remaining portion of $119,070 of Merger Consideration was paid by Crystal Globe in cash and distributed to the Company’s minority shareholders as a special dividend in January 2022. The transaction was completed on December 31, 2020.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

Note 8 – INCOME TAXES

 

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

 

The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

Note 9 – SUBSEQUENT EVENTS

 

Change in Control

 

On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe Limited, a company incorporated under the laws of British Virgin Islands (the “Seller”), and JHP Holdings, Inc., a Nevada corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from the Seller.

 

On February 2, 2022, Mr. Ramon Lata was appointed to the board of the directors upon the resignation of Jinghe Zhang, the sole officer and director of the Company. Mr. Lata was also appointed as the President, Treasurer and Secretary of the Company.

 

In connection with the resignation of Mr. Zhang, all obligations owed to Mr. Zhang from the Company were cancelled and there are no further debts or liabilities owed by the Company to any affiliate or former affiliate of the Company.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Accounting Policies, by Policy (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Prior to the consummation of the Merger as of December 31, 2020, the Company’s functional currency is the Chinese Renminbi (“RMB”); however, the accompanying financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.

 

After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

Use of Estimates

Use of Estimates

 

The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

 

Reclassification

Reclassification

 

Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.

 

Basis of Consolidation

Basis of Consolidation

 

For the periods prior to the consummation of the Merger as of December 31, 2020, the Company consolidated financial statements including Dynamic Elite, its former wholly owned subsidiaries, and controlled VIEs. The financial statements of Dynamic Elite and controlled VIEs were included as part of the Company’s discontinued component. All significant inter-company accounts and transactions have been eliminated in the consolidation.

 

Foreign Currency Translation

Foreign Currency Translation

 

The accompanying financial statements are presented in USD. The functional currency of the Company is RMB for the periods prior to the consummation of the Merger as of December 31, 2020. The financial statements are translated into USD from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.

 

   December 31, 
   2020 
Year ended RMB: USD Exchange rate   6.5249 
Average yearly RMB: USD Exchange rate   6.8976 

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.

 

For the years ended December 31, 2021 and 2020 foreign currency translation adjustments of $0 and $165,413, have been reported as other comprehensive loss in the financial statements. After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

 

Other Comprehensive Income

Other Comprehensive Income

 

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners. Other comprehensive income is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Concentrations of Credit Risk

Concentrations of Credit Risk

 

Prior to the consummation of the Merger as of December 31, 2020, the Company’s operations were carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations were influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC were subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable.

 

As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 (formerly Statement of Financial Accounting Standard (“SFAS”) No. 157 Fair Value Measurements) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as the following:

 

  Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

  Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

  Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.

 

Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

 

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

 

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

Basic and Diluted Earnings per Share

Basic and Diluted Earnings per Share

 

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the years ended December 31, 2021 and 2020.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.

 

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

 

Deconsolidation

Deconsolidation

 

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

 

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

 

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

 

The following is a reconciliation of the deconsolidation:

 

   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of gains and losses from foreign currency transactions
   December 31, 
   2020 
Year ended RMB: USD Exchange rate   6.5249 
Average yearly RMB: USD Exchange rate   6.8976 

 

Schedule reconciliation of the deconsolidation
   Amount 
Selling price  $902,430 
Disposed assets and liabilities:     
Cash   79,446 
Current assets   1,133,812 
Fixed assets   3,194,533 
Intangible assets   465,007 
Liabilities   (1,977,822)
Accumulated other comprehensive income   (651,751)
    2,243,225 
Loss from disposal of discontinued component, net of income tax  $(1,340,795)
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Receivable from Related Party (Tables)
12 Months Ended
Dec. 31, 2021
Receivable From Related Party Disclosure [Abstract]  
Schedule of receivable from related party
   December 31, 
   2021   2020 
Crystal Globe  $
-
   $119,070 

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Schedule of payables due to related parties
   December 31, 
   2021   2020 
Jinghe Zhang  $3,999   $233,693 
Joway Shengshi   
-
    459,853 
Total  $3,999   $693,546 

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Organization (Details) - USD ($)
1 Months Ended 12 Months Ended
Jan. 31, 2021
Nov. 20, 2020
Dec. 31, 2020
Sep. 21, 2010
Jul. 28, 2010
Jul. 25, 2010
Jul. 09, 2010
May 17, 2007
Organization (Details) [Line Items]                
Ordinary shares of common stock (in Shares)     10,000          
Cash cancelled (in Dollars)     $ 119,070          
Cash cancelled merger consideration per share (in Dollars per share)     $ 0.45          
Description of common stock the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.              
Dynamic Elite [Member]                
Organization (Details) [Line Items]                
Ownership percentage       76.08%        
Tianjin Joway Shengshi Group Co., Ltd. [Member]                
Organization (Details) [Line Items]                
Ownership percentage               99.00%
Business acquisition percentage of remaining voting interests acquired               1.00%
Joway Shengshi owned of Joway Technology [Member]                
Organization (Details) [Line Items]                
Ownership percentage           90.91%    
Business acquisition percentage of remaining voting interests acquired           9.09%    
Joway Shengshi owned of Joway Decoration [Member]                
Organization (Details) [Line Items]                
Ownership percentage             90.00%  
Business acquisition percentage of remaining voting interests acquired             10.00%  
Joway Shengshi To Shengtang Trading [Member]                
Organization (Details) [Line Items]                
Ownership percentage         95.00%      
Business acquisition percentage of remaining voting interests acquired         5.00%      
Crystal Globe [Member]                
Organization (Details) [Line Items]                
Call option, description   On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”).            
Right to purchase call option extinguished in consideration (in Dollars)   $ 119,070            
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Going Concern (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Going Concern [Abstract]    
Incurred net losses $ 121,788 $ 2,300,000
Cash outflow 70,000.00 $ 600,000
Accumulated deficit $ 7,400,000  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details) - USD ($)
1 Months Ended 12 Months Ended
Jan. 31, 2021
Nov. 20, 2020
Dec. 31, 2021
Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]        
Foreign currency translation adjustments     $ 0 $ 165,413
Income taxes, description     A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement.  
Shareholder holding percentage   86.81%    
Cash consideration per share   $ 0.045 $ 0.045  
Common stock, shares outstanding   20,054,000 20,054,000 20,054,000
Transaction loss   $ 1,340,795    
Cash received $ 119,070      
Payment per share $ 0.045      
Offset shares 17,408,000      
Joway Health [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Common stock shares 2,646,000      
Crystal Globe [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Common stock shares 17,408,000      
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions
Dec. 31, 2021
Year ended RMB: USD Exchange rate [Member]  
2020  
Gains and losses from foreign currency transactions 6.5249
Average yearly RMB: USD Exchange rate [Member]  
2020  
Gains and losses from foreign currency transactions 6.8976
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation
Dec. 31, 2021
USD ($)
Schedule reconciliation of the deconsolidation [Abstract]  
Selling price $ 902,430
Disposed assets and liabilities:  
Cash 79,446
Current assets 1,133,812
Fixed assets 3,194,533
Intangible assets 465,007
Liabilities (1,977,822)
Accumulated other comprehensive income (651,751)
Loss from disposal of discontinued component, gross 2,243,225
Loss from disposal of discontinued component, net of income tax $ (1,340,795)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Receivable from Related Party (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Jan. 31, 2021
Joway Health's [Member]    
Receivable from Related Party (Details) [Line Items]    
Shares on hold 2,646,000  
Crystal Globe [Member]    
Receivable from Related Party (Details) [Line Items]    
Due from related party   $ 119,070
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Receivable from Related Party (Details) - Schedule of receivable from related party - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Crystal Globe [Member]    
Receivable from Related Party (Details) - Schedule of receivable from related party [Line Items]    
Crystal Globe $ 119,070
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Special Dividend Payable (Details) - USD ($)
1 Months Ended
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Nov. 20, 2020
Special Dividend Payable (Details) [Line Items]        
Dividend payables   $ 0 $ 119,070  
Percentage of shares held by shareholder   86.81%    
Cash consideration per share   $ 0.045   $ 0.045
Merger agreement, description Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.      
Joway Health's [Member]        
Special Dividend Payable (Details) [Line Items]        
Shares available to shareholders   2,646,000    
Common stock, shares outstanding       20,054,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Other Payables (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]    
Other payables $ 103,053 $ 51,344
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Apr. 28, 2021
Jinghe Zhang [Member]      
Related Party Transactions (Details) [Line Items]      
Due from related parties for continuing operating component $ 66,235 $ 182,515  
Amount of indebtedness     $ 295,928
Total unpaid principal balance 3,999 233,693  
Joway Shengshi [Member]      
Related Party Transactions (Details) [Line Items]      
Due from related parties for continuing operating component $ 3,844 0  
Amount of indebtedness     $ 463,698
Equity interest 99.00%    
Unpaid principal balance in advance $ 0 $ 0  
Sale of stock, description Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $902,430 in cash (the “Merger Consideration”). The Company was obligated to distribute the Merger Consideration to its shareholders in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. The Merger Consideration due from Crystal Globe was partly offset by the distribution due to Crystal Globe at the amount of $783,360. The remaining portion of $119,070 of Merger Consideration was paid by Crystal Globe in cash and distributed to the Company’s minority shareholders as a special dividend in January 2022.    
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details) - Schedule of payables due to related parties - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]    
Total $ 3,999 $ 693,546
Jinghe Zhang [Member]    
Related Party Transaction [Line Items]    
Total 3,999 233,693
Joway Shengshi [Member]    
Related Party Transaction [Line Items]    
Total $ 459,853
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details)
Feb. 03, 2022
shares
Subsequent Event [Member]  
Subsequent Events (Details) [Line Items]  
Common stock shares 16,644,820
XML 43 f10k2021_jowayhealth_htm.xml IDEA: XBRL DOCUMENT 0001263364 2021-01-01 2021-12-31 0001263364 2022-03-29 0001263364 2021-06-30 0001263364 2021-12-31 0001263364 2020-12-31 0001263364 2020-01-01 2020-12-31 0001263364 us-gaap:CommonStockMember 2019-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2019-12-31 0001263364 us-gaap:RetainedEarningsMember 2019-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001263364 2019-12-31 0001263364 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2020-01-01 2020-12-31 0001263364 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001263364 us-gaap:CommonStockMember 2020-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2020-12-31 0001263364 us-gaap:RetainedEarningsMember 2020-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001263364 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001263364 us-gaap:RetainedEarningsAppropriatedMember 2021-01-01 2021-12-31 0001263364 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001263364 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001263364 us-gaap:CommonStockMember 2021-12-31 0001263364 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001263364 us-gaap:RetainedEarningsMember 2021-12-31 0001263364 gtvi:DynamicEliteMember 2010-09-21 0001263364 gtvi:TianjinJowayShengshiGroupCoLtdMember 2007-05-17 0001263364 gtvi:JowayShengshiToJowayTechnologyMember 2010-07-25 0001263364 gtvi:JowayShengshiToJowayDecorationMember 2010-07-09 0001263364 gtvi:JowayShengshiToShengtangTradingMember 2010-07-28 0001263364 gtvi:CrystalGlobeMember 2020-11-01 2020-11-20 0001263364 2021-01-01 2021-01-31 0001263364 2020-11-01 2020-11-20 0001263364 2020-11-20 0001263364 gtvi:JowayHealthMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 2021-01-31 0001263364 gtvi:YearEndedRMBUSDExchangeRateMember 2021-12-31 0001263364 gtvi:AverageYearlyRMBUSDExchangeRateMember 2021-12-31 0001263364 gtvi:JowayHealthsMember 2021-01-01 2021-12-31 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-12-31 0001263364 gtvi:CrystalGlobeMember 2020-12-31 0001263364 gtvi:JowayHealthsMember 2021-12-31 0001263364 gtvi:JowayHealthsMember 2020-11-20 0001263364 gtvi:JingheZhangMember 2021-01-01 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-01-01 2020-12-31 0001263364 gtvi:JingheZhangMember 2021-04-28 0001263364 gtvi:JingheZhangMember 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-12-31 0001263364 gtvi:JowayShengshiMember 2021-01-01 2021-12-31 0001263364 gtvi:JowayShengshiMember 2020-01-01 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-04-28 0001263364 gtvi:JowayShengshiMember 2020-12-31 0001263364 gtvi:JingheZhangMember 2021-12-31 0001263364 gtvi:JingheZhangMember 2020-12-31 0001263364 gtvi:JowayShengshiMember 2021-12-31 0001263364 gtvi:JowayShengshiMember 2020-12-31 0001263364 us-gaap:SubsequentEventMember 2022-02-03 shares iso4217:USD iso4217:USD shares pure 10-K true 2021-12-31 --12-31 2021 false 333-108715 Joway Health Industries Group Inc NV 98-0221494 600 South 3rd Street Las Vegas NV 89101 Common Stock, par value $0.001 No No Yes Yes Non-accelerated Filer true false false true 92610 20054000 HHC Forest Hills, New York 5867 119070 119070 119070 119070 103053 51344 3999 693546 107052 863960 0.001 0.001 1000000 1000000 0.001 0.001 200000000 200000000 20054000 20054000 20054000 20054000 20054 20054 7228862 6469236 -7355968 -7234180 -107052 -744890 119070 -121788 -222607 121788 222607 -121788 -222607 252 -252 -121788 -222859 -121788 -222859 -760538 -1340795 -121788 -2324192 165413 -121788 -2158779 -0.01 -0.01 -0.1 20054000 20054000 20054000 20054 7361665 354052 -5264040 486338 2958069 -2324192 -2324192 -892429 -354052 354052 -651751 -1544180 165413 165413 20054000 20054 6469236 -7234180 -744890 -121788 -121788 759626 759626 20054000 20054 7228862 -7355968 -107052 -121788 -222859 -15000 51709 25344 -70079 -182515 -382246 -70079 -564761 119070 119070 -79446 119070 -79446 119070 70079 182515 -48991 182515 424562 -48991 607077 37130 783360 119070 119070 759626 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – ORGANIZATION </b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements include the financial statements of Joway Health Industries Group Inc. (referred to herein as “Joway Health”). Joway Health is hereinafter referred to as the “Company,” “we” and “us”.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Texas on March 21, 2003. On September 21, 2010, Joway Health entered into a Share Exchange Agreement (the “Share Exchange”) with the sole stockholder of Dynamic Elite International Limited. As a result of the Share Exchange, Dynamic Elite became a wholly-owned subsidiary of Joway Health and the stockholders of Dynamic Elite acquired approximately 76.08% of the issued and outstanding stock of Joway Health. The share exchange transaction resulted in the shareholders of Dynamic Elite acquiring a majority voting interest in Joway Health. Generally accepted accounting principles in the United States of America require that the company whose shareholders retain the majority interest in the combined business be treated as the acquirer for accounting purposes. The reverse acquisition process utilized the capital structure of Joway Health and the assets and liabilities of Dynamic Elite recorded at historical cost. On December 22, 2010, Joway Health changed its jurisdiction of incorporation from the State of Texas to the State of Nevada.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dynamic Elite International Limited (referred to herein as “Dynamic Elite”) was incorporated under the laws of the British Virgin Islands on June 2, 2010 as a limited liability company (a BVI company). Dynamic Elite engaged in manufacturing and distributing tourmaline products in China. Its wholly owned subsidiary, Tianjin Junhe Management Consulting Co., Ltd. was incorporated on September 15, 2010 in Tianjin, People’s Republic of China (“PRC”). Other than the equity interest in Junhe Consulting, Dynamic Elite does not own any assets or conduct any operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianjin Junhe Management Consulting Co., Ltd. (referred to herein as “Junhe Consulting”) conducted its business through Tianjin Joway Shengshi Group Co., Ltd.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianjin Joway Shengshi Group Co., Ltd. (referred to herein as “Joway Shengshi”) was incorporated in PRC on May 17, 2007. Joway Shengshi was owned 99% by Jinghe Zhang, the Company’s current CEO and President and 1% by Song Baogang. Joway Shengshi engages in manufacturing and distributing tourmaline products in China. Shenyang Joway Electronic Technology Co., Ltd., Tianjin Joway Decoration Engineering Co., Ltd. and Tianjin Oriental Shengtang Trading Import &amp; Export Trading Co., Ltd. are subsidiaries of Joway Shengshi.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenyang Joway Electronic Technology Co., Ltd. (referred to herein as “Joway Technology”) was originally named Liaoning Joway Technology Engineering Co., Ltd. which was incorporated on March 28, 2007 in PRC. The name was changed on June 22, 2011. It engages in the distribution of Tourmaline Activated Water Machines and the construction of Tourmaline Wellness Houses. Prior to July 25, 2010, Joway Shengshi owned 90.91% of Joway Technology. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Technology on July 25, 2010 to acquire the remaining 9.09% of the share of Joway Technology. As a result of the share acquisition, Joway Technology became a wholly-owned subsidiary of Joway Shengshi.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianjin Joway Decoration Engineering Co., Ltd. (referred to herein as “Joway Decoration”) was incorporated on April 22, 2009 in PRC. It engages in the distribution of Tourmaline Activated Water Machines, Tourmaline Wellness Room for family use and Tourmaline Wellness House materials. Prior to July 9, 2010, Joway Shengshi owned 90% of Joway Decoration. Joway Shengshi entered into a share acquisition agreement with Jingyun Chen, another stockholder of Joway Decoration on July 9, 2010 to acquire the remaining 10% of the shares of Joway Decoration. As a result of the share acquisition, Joway Decoration became a wholly-owned subsidiary of Joway Shengshi. Jingyun Chen is currently the General Manager of Joway Decoration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tianjin Oriental Shengtang Import &amp; Export Trading Co., Ltd. (referred to herein as “Shengtang Trading”) was incorporated on September 18, 2009 in the PRC. It engages in purchasing raw materials which it sells to other companies of the group. Prior to July 28, 2010, Joway Shengshi owned 95% of Shengtang Trading. Joway Shengshi entered into a share acquisition agreement with Wang Aiying, another stockholder of Shengtang Trading on July 28, 2010 to acquire the remaining 5% of the shares of Shengtang Trading. As a result of the share acquisition, Shengtang Trading became a wholly-owned subsidiary of Joway Shengshi.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health became a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.</span></p> 0.7608 0.99 0.01 0.9091 0.0909 0.90 0.10 0.95 0.05 On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). 119070 10000 119070 0.45 the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger. <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – GOING CONCERN</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">As reflected in the accompanying financial statements, for the years ended December 31, 2021 and 2020, we incurred net losses of $121,788 and $2.3 million, respectively. In addition, we reported cash outflow of $0.07 million and $0.6 million from our operating activities for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of approximately $7.4 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continuation of our company as a going concern through the next twelve months is dependent upon (1) the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due, and (2) that it will be able to implement its business plan to expand our company’s operations and generate sufficient revenues to meet its obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.</span></p> 121788 2300000 70000.00 600000 7400000 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Prior to the consummation of the Merger as of December 31, 2020, the Company’s functional currency is the Chinese Renminbi (“RMB”); however, the accompanying financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassification</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the periods prior to the consummation of the Merger as of December 31, 2020, the Company consolidated financial statements including Dynamic Elite, its former wholly owned subsidiaries, and controlled VIEs. The financial statements of Dynamic Elite and controlled VIEs were included as part of the Company’s discontinued component. All significant inter-company accounts and transactions have been eliminated in the consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign Currency Translation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying financial statements are presented in USD. The functional currency of the Company is RMB for the periods prior to the consummation of the Merger as of December 31, 2020. The financial statements are translated into USD from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Year ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Average yearly RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the years ended December 31, 2021 and 2020 foreign currency translation adjustments of $0 and $165,413, have been reported as other comprehensive loss in the financial statements. After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Comprehensive Income</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners. Other comprehensive income is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the consummation of the Merger as of December 31, 2020, the Company’s operations were carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations were influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC were subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 (formerly Statement of Financial Accounting Standard (“SFAS”) No. 157 Fair Value Measurements) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 <i>Accounting for Income Taxes)</i>, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and Diluted Earnings per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the years ended December 31, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deconsolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the deconsolidation:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1.5pt">Selling price</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Prior to the consummation of the Merger as of December 31, 2020, the Company’s functional currency is the Chinese Renminbi (“RMB”); however, the accompanying financial statements have been translated and presented in United States Dollars (“USD”). All significant inter-company transactions and balances have been eliminated. The financial statements include all adjustments that, in the opinion of management, are necessary to make the financial statements not misleading.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassification</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances were reclassified to conform to the current year’s presentation with consideration of reflecting all of the Company’s subsidiaries and VIEs as discontinued operations. None of these reclassifications had an impact on reported financial position or cash flows for any of the periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the periods prior to the consummation of the Merger as of December 31, 2020, the Company consolidated financial statements including Dynamic Elite, its former wholly owned subsidiaries, and controlled VIEs. The financial statements of Dynamic Elite and controlled VIEs were included as part of the Company’s discontinued component. All significant inter-company accounts and transactions have been eliminated in the consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign Currency Translation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The accompanying financial statements are presented in USD. The functional currency of the Company is RMB for the periods prior to the consummation of the Merger as of December 31, 2020. The financial statements are translated into USD from RMB at period-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Equity accounts are translated at their historical exchange rates when the equity transactions occurred. The resulting transaction adjustments are recorded as a component of stockholders’ equity. Gains and losses from foreign currency transactions are included in net income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Year ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Average yearly RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into USD at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the years ended December 31, 2021 and 2020 foreign currency translation adjustments of $0 and $165,413, have been reported as other comprehensive loss in the financial statements. After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left">Year ended RMB: USD Exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.5249</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Average yearly RMB: USD Exchange rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.8976</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> 6.5249 6.8976 0 165413 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Comprehensive Income</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners. Other comprehensive income is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the consummation of the Merger as of December 31, 2020, the Company’s operations were carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations were influenced by the political, economic, and legal environment in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC were subject to specific considerations and significant risks not typically associated with companies in North America. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and trade accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 (formerly Statement of Financial Accounting Standard (“SFAS”) No. 157 Fair Value Measurements) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Merger Agreement, with respect to sales of product to both franchisee and non-franchisee customers, the Company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. Sales prices are based on fixed price lists that are different depending on whether the price list is for franchisee customers or for non-franchisee customers. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 <i>Accounting for Income Taxes)</i>, which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and Diluted Earnings per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the years ended December 31, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deconsolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the deconsolidation:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1.5pt">Selling price</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 0.8681 0.045 20054000 1340795 119070 2646000 17408000 0.045 17408000 <table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Amount</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 88%; text-align: left; padding-bottom: 1.5pt">Selling price</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 902430 79446 1133812 3194533 465007 1977822 -651751 2243225 -1340795 <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – RECEIVABLE FROM RELATED PARTY</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable from related party consist of the following:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 4pt">Crystal Globe</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">119,070</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The receivable from Crystal Globe is related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders.</span></p> <table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 4pt">Crystal Globe</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">119,070</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> 119070 2646000 119070 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – SPECIAL DIVIDEND PAYABLE</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2021 and December 31, 2020, the Company reported $0 and $119,070 as special dividend payables, respectively. The payables are related to the Merger Agreement which is part of the Merger Consideration for Joway Health’s minority shareholders who hold 2,646,000 shares of Joway Health’s common stock. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, Chief Executive Officer, Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Merger Agreement, Joway Health needs to distribute proportionately the Merger Consideration to the Company’s shareholders. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.</span></p> 0 119070 2646000 0.8681 0.045 20054000 Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 – OTHER PAYABLES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">As of December 31, 2021 and 2020, the Company reported $103,053 and $51,344 as its other payables, respectively. The other payables mainly consist of payables for professional services, including audit, legal, and financial statement filing services. </p> 103053 51344 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – RELATED PARTY TRANSACTIONS</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payables due to related parties consist of the following:</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">233,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Joway Shengshi</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">459,853</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,999</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">693,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts owed to related parties are non-interest bearing and have no specified repayment terms.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions with Jinghe Zhang</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, we received financial supports of $66,235 and $182,515 from our former CEO and chairman, Mr. Jinghe Zhang. The loans due to him are for our daily operating activities without interest charge and due on demand.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2021, the Company entered into an agreement with Mr. Jinghe Zhang to release the Company from $295,928 of indebtedness owed to him. As of December 31, 2021 and 2020, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $3,999 and $233,693, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions with Joway Shengshi</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joway Shengshi was one of the Company’s subsidiaries but has been sold via the Merger Agreement on December 31, 2020. Mr. Jinghe Zhang owns 99% of the equity interest in Joway Shengshi. For the years ended December 31, 2021 and 2020, we received $3,844 and $0 of advances from Joway Shengshi, respectively, for our daily operating activities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2021, Joway Shengshi released the Company from $463,698 of indebtedness owed to it. As of December 31, 2021 and 2020, the total unpaid principal balance due to Joway Shengshi was $0.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disposal of all of Joway Health’s subsidiaries and VIEs</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $902,430 in cash (the “Merger Consideration”). The Company was obligated to distribute the Merger Consideration to its shareholders in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. The Merger Consideration due from Crystal Globe was partly offset by the distribution due to Crystal Globe at the amount of $783,360. The remaining portion of $119,070 of Merger Consideration was paid by Crystal Globe in cash and distributed to the Company’s minority shareholders as a special dividend in January 2022. The transaction was completed on December 31, 2020.</span></p> <table cellpadding="0" cellspacing="0" style=" width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,999</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">233,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Joway Shengshi</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">459,853</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,999</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">693,546</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> 3999 233693 459853 3999 693546 66235 182515 295928 3999 233693 0.99 3844 0 463698 0 0 Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $902,430 in cash (the “Merger Consideration”). The Company was obligated to distribute the Merger Consideration to its shareholders in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. The Merger Consideration due from Crystal Globe was partly offset by the distribution due to Crystal Globe at the amount of $783,360. The remaining portion of $119,070 of Merger Consideration was paid by Crystal Globe in cash and distributed to the Company’s minority shareholders as a special dividend in January 2022. <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – INCOME TAXES</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – SUBSEQUENT EVENTS</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change in Control</i></b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe Limited, a company incorporated under the laws of British Virgin Islands (the “Seller”), and JHP Holdings, Inc., a Nevada corporation (the “Buyer”), pursuant to which the Buyer purchased 16,644,820 shares of common stock of the Company from the Seller.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2, 2022, Mr. Ramon Lata was appointed to the board of the directors upon the resignation of Jinghe Zhang, the sole officer and director of the Company. Mr. Lata was also appointed as the President, Treasurer and Secretary of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the resignation of Mr. Zhang, all obligations owed to Mr. Zhang from the Company were cancelled and there are no further debts or liabilities owed by the Company to any affiliate or former affiliate of the Company.</span></p> 16644820 384-1990 702 GTVI NONE false FY 0001263364 EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 65 177 1 false 21 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://jowayhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheets Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet Balance Sheets Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Operations and Comprehensive Loss Sheet http://jowayhealth.com/role/ConsolidatedIncomeStatement Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Statement of Stockholders??? Equity Sheet http://jowayhealth.com/role/ShareholdersEquityType2or3 Statement of Stockholders??? Equity Statements 5 false false R6.htm 005 - Statement - Statement of Cash Flows Sheet http://jowayhealth.com/role/ConsolidatedCashFlow Statement of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Organization Sheet http://jowayhealth.com/role/Organization Organization Notes 7 false false R8.htm 007 - Disclosure - Going Concern Sheet http://jowayhealth.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Receivable from Related Party Sheet http://jowayhealth.com/role/ReceivablefromRelatedParty Receivable from Related Party Notes 10 false false R11.htm 010 - Disclosure - Special Dividend Payable Sheet http://jowayhealth.com/role/SpecialDividendPayable Special Dividend Payable Notes 11 false false R12.htm 011 - Disclosure - Other Payables Sheet http://jowayhealth.com/role/OtherPayables Other Payables Notes 12 false false R13.htm 012 - Disclosure - Related Party Transactions Sheet http://jowayhealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 013 - Disclosure - Income Taxes Sheet http://jowayhealth.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Subsequent Events Sheet http://jowayhealth.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 015 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://jowayhealth.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 16 false false R17.htm 016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 017 - Disclosure - Receivable from Related Party (Tables) Sheet http://jowayhealth.com/role/ReceivablefromRelatedPartyTables Receivable from Related Party (Tables) Tables http://jowayhealth.com/role/ReceivablefromRelatedParty 18 false false R19.htm 018 - Disclosure - Related Party Transactions (Tables) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://jowayhealth.com/role/RelatedPartyTransactions 19 false false R20.htm 019 - Disclosure - Organization (Details) Sheet http://jowayhealth.com/role/OrganizationDetails Organization (Details) Details http://jowayhealth.com/role/Organization 20 false false R21.htm 020 - Disclosure - Going Concern (Details) Sheet http://jowayhealth.com/role/GoingConcernDetails Going Concern (Details) Details http://jowayhealth.com/role/GoingConcern 21 false false R22.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 22 false false R23.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions Sheet http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 23 false false R24.htm 023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation Sheet http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 24 false false R25.htm 024 - Disclosure - Receivable from Related Party (Details) Sheet http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails Receivable from Related Party (Details) Details http://jowayhealth.com/role/ReceivablefromRelatedPartyTables 25 false false R26.htm 025 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party Sheet http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable Receivable from Related Party (Details) - Schedule of receivable from related party Details http://jowayhealth.com/role/ReceivablefromRelatedPartyTables 26 false false R27.htm 026 - Disclosure - Special Dividend Payable (Details) Sheet http://jowayhealth.com/role/SpecialDividendPayableDetails Special Dividend Payable (Details) Details http://jowayhealth.com/role/SpecialDividendPayable 27 false false R28.htm 027 - Disclosure - Other Payables (Details) Sheet http://jowayhealth.com/role/OtherPayablesDetails Other Payables (Details) Details http://jowayhealth.com/role/OtherPayables 28 false false R29.htm 028 - Disclosure - Related Party Transactions (Details) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 29 false false R30.htm 029 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties Sheet http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable Related Party Transactions (Details) - Schedule of payables due to related parties Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 030 - Disclosure - Subsequent Events (Details) Sheet http://jowayhealth.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://jowayhealth.com/role/SubsequentEvents 31 false false All Reports Book All Reports f10k2021_jowayhealth.htm f10k2021ex21-1_jowayhealth.htm f10k2021ex31-1_jowayhealth.htm f10k2021ex32-1_jowayhealth.htm f10k2021ex4-2_jowayhealth.htm gtvi-20211231.xsd gtvi-20211231_cal.xml gtvi-20211231_def.xml gtvi-20211231_lab.xml gtvi-20211231_pre.xml image_001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2021_jowayhealth.htm": { "axisCustom": 0, "axisStandard": 6, "contextCount": 65, "dts": { "calculationLink": { "local": [ "gtvi-20211231_cal.xml" ] }, "definitionLink": { "local": [ "gtvi-20211231_def.xml" ] }, "inline": { "local": [ "f10k2021_jowayhealth.htm" ] }, "labelLink": { "local": [ "gtvi-20211231_lab.xml" ] }, "presentationLink": { "local": [ "gtvi-20211231_pre.xml" ] }, "schema": { "local": [ "gtvi-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd" ] } }, "elementCount": 260, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 63, "http://jowayhealth.com/20211231": 6, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 76 }, "keyCustom": 37, "keyStandard": 140, "memberCustom": 12, "memberStandard": 6, "nsprefix": "gtvi", "nsuri": "http://jowayhealth.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://jowayhealth.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ReceivableFromRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Receivable from Related Party", "role": "http://jowayhealth.com/role/ReceivablefromRelatedParty", "shortName": "Receivable from Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ReceivableFromRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Special Dividend Payable", "role": "http://jowayhealth.com/role/SpecialDividendPayable", "shortName": "Special Dividend Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Other Payables", "role": "http://jowayhealth.com/role/OtherPayables", "shortName": "Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Related Party Transactions", "role": "http://jowayhealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Income Taxes", "role": "http://jowayhealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Subsequent Events", "role": "http://jowayhealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://jowayhealth.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ForeignCurrencyDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ForeignCurrencyDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Receivable from Related Party (Tables)", "role": "http://jowayhealth.com/role/ReceivablefromRelatedPartyTables", "shortName": "Receivable from Related Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Related Party Transactions (Tables)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheets", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "gtvi:OrdinarySharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Organization (Details)", "role": "http://jowayhealth.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "gtvi:OrdinarySharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Going Concern (Details)", "role": "http://jowayhealth.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "gtvi:ForeignCurrencyDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c42", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions", "role": "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "gtvi:ForeignCurrencyDisclosureTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c42", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "gtvi:SellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation", "role": "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule reconciliation of the deconsolidation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "gtvi:SellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c44", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Receivable from Related Party (Details)", "role": "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "shortName": "Receivable from Related Party (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c44", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Receivable from Related Party (Details) - Schedule of receivable from related party", "role": "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable", "shortName": "Receivable from Related Party (Details) - Schedule of receivable from related party", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "gtvi:ScheduleOfReceivableFromRelatedPartyTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Special Dividend Payable (Details)", "role": "http://jowayhealth.com/role/SpecialDividendPayableDetails", "shortName": "Special Dividend Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:OtherPayables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Other Payables (Details)", "role": "http://jowayhealth.com/role/OtherPayablesDetails", "shortName": "Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:OtherPayables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c50", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForContinuingOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Related Party Transactions (Details)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c50", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForContinuingOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Parentheticals)", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties", "role": "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "shortName": "Related Party Transactions (Details) - Schedule of payables due to related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c60", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c64", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Subsequent Events (Details)", "role": "http://jowayhealth.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c64", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Operations and Comprehensive Loss", "role": "http://jowayhealth.com/role/ConsolidatedIncomeStatement", "shortName": "Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statement of Stockholders\u2019 Equity", "role": "http://jowayhealth.com/role/ShareholdersEquityType2or3", "shortName": "Statement of Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statement of Cash Flows", "role": "http://jowayhealth.com/role/ConsolidatedCashFlow", "shortName": "Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c5", "decimals": "0", "lang": null, "name": "gtvi:IncreaseDecreaseInSpecialDividendPayables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization", "role": "http://jowayhealth.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Going Concern", "role": "http://jowayhealth.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2021_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 21, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security", "terseLabel": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "gtvi_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated deficit.", "label": "AccumulatedDeficit", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_AggregateIndebtednessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate indebtedness.", "label": "AggregateIndebtednessAmount", "terseLabel": "Amount of indebtedness" } } }, "localname": "AggregateIndebtednessAmount", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_AverageYearlyRMBUSDExchangeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AverageYearlyRMBUSDExchangeRateMember", "terseLabel": "Average yearly RMB: USD Exchange rate [Member]" } } }, "localname": "AverageYearlyRMBUSDExchangeRateMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "gtvi_BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition percentage of remaining voting interests acquired.", "label": "BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired", "terseLabel": "Business acquisition percentage of remaining voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfRemainingVotingInterestsAcquired", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "percentItemType" }, "gtvi_CallOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of call option.", "label": "CallOptionDescription", "terseLabel": "Call option, description" } } }, "localname": "CallOptionDescription", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_CashCancelled": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash cancelled", "label": "CashCancelled", "terseLabel": "Cash cancelled (in Dollars)" } } }, "localname": "CashCancelled", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_CashCancelledMergerConsiderationPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash cancelled merger consideration per share", "label": "CashCancelledMergerConsiderationPerShare", "terseLabel": "Cash cancelled merger consideration per share (in Dollars per share)" } } }, "localname": "CashCancelledMergerConsiderationPerShare", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "perShareItemType" }, "gtvi_CashConsiderationPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash consideration per share.", "label": "CashConsiderationPerShare", "terseLabel": "Cash consideration per share" } } }, "localname": "CashConsiderationPerShare", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "gtvi_CashFlowsFromInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CashFlowsFromInvestingActivitiesAbstract", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "CashFlowsFromInvestingActivitiesAbstract", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "gtvi_CashReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received", "label": "CashReceived", "terseLabel": "Cash received" } } }, "localname": "CashReceived", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_CommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares", "label": "CommonStockShares", "terseLabel": "Common stock shares" } } }, "localname": "CommonStockShares", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "gtvi_CrystalGlobeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crystal globe.", "label": "CrystalGlobeMember", "terseLabel": "Crystal Globe [Member]" } } }, "localname": "CrystalGlobeMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "gtvi_DeconsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deconsolidation Policy Text Block", "label": "DeconsolidationPolicyTextBlock", "terseLabel": "Deconsolidation" } } }, "localname": "DeconsolidationPolicyTextBlock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "gtvi_DescriptionOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of common stock", "label": "DescriptionOfCommonStock", "terseLabel": "Description of common stock" } } }, "localname": "DescriptionOfCommonStock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_DisposedAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DisposedAssetsAndLiabilitiesAbstract", "terseLabel": "Disposed assets and liabilities:" } } }, "localname": "DisposedAssetsAndLiabilitiesAbstract", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "stringItemType" }, "gtvi_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_DueFromRelatedPartiesForContinuingOperatingComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Due from related parties for continuing operating component.", "label": "DueFromRelatedPartiesForContinuingOperatingComponent", "terseLabel": "Due from related parties for continuing operating component" } } }, "localname": "DueFromRelatedPartiesForContinuingOperatingComponent", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_DynamicEliteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DynamicEliteMember", "terseLabel": "Dynamic Elite [Member]" } } }, "localname": "DynamicEliteMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_ForeignCurrencyDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for foreign currency.", "label": "ForeignCurrencyDisclosureTableTextBlock", "terseLabel": "Schedule of gains and losses from foreign currency transactions" } } }, "localname": "ForeignCurrencyDisclosureTableTextBlock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "gtvi_GoingConcernUncertaintyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernUncertaintyDisclosureAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_IncomeTaxesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes Description", "label": "IncomeTaxesDescription", "terseLabel": "Income taxes, description" } } }, "localname": "IncomeTaxesDescription", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "gtvi_IncreaseDecreaseInOtherPayable": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInOtherPayable", "terseLabel": "Other payables" } } }, "localname": "IncreaseDecreaseInOtherPayable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncreaseDecreaseInSpecialDividendPayables": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Special dividend payable.", "label": "IncreaseDecreaseInSpecialDividendPayables", "negatedLabel": "Prepaid Expense" } } }, "localname": "IncreaseDecreaseInSpecialDividendPayables", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncurredNetLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incurred net losses.", "label": "IncurredNetLosses", "terseLabel": "Incurred net losses" } } }, "localname": "IncurredNetLosses", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_JingheZhangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jinghe zhang.", "label": "JingheZhangMember", "terseLabel": "Jinghe Zhang [Member]" } } }, "localname": "JingheZhangMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayHealthMember", "terseLabel": "Joway Health [Member]" } } }, "localname": "JowayHealthMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayHealthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayHealthsMember", "terseLabel": "Joway Health's [Member]" } } }, "localname": "JowayHealthsMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayShengshiMember", "terseLabel": "Joway Shengshi [Member]" } } }, "localname": "JowayShengshiMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToJowayDecorationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to joway decoration.", "label": "JowayShengshiToJowayDecorationMember", "terseLabel": "Joway Shengshi to Joway Decoration [Member]", "verboseLabel": "Joway Shengshi owned of Joway Decoration [Member]" } } }, "localname": "JowayShengshiToJowayDecorationMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToJowayTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to joway technology.", "label": "JowayShengshiToJowayTechnologyMember", "terseLabel": "Joway Shengshi to Joway Technology [Member]", "verboseLabel": "Joway Shengshi owned of Joway Technology [Member]" } } }, "localname": "JowayShengshiToJowayTechnologyMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_JowayShengshiToShengtangTradingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joway shengshi to shengtang trading.", "label": "JowayShengshiToShengtangTradingMember", "terseLabel": "Joway Shengshi To Shengtang Trading [Member]" } } }, "localname": "JowayShengshiToShengtangTradingMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss from disposal of discontinued component, gross", "label": "LossFromDisposalOfDiscontinuedComponentGross", "terseLabel": "Loss from disposal of discontinued component, gross" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentGross", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "terseLabel": "Loss from disposal of discontinued component, net of income tax" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentNetOfTaxes": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss from disposal of discontinued component, net of taxes", "label": "LossFromDisposalOfDiscontinuedComponentNetOfTaxes", "terseLabel": "Loss from disposal of discontinued component, net of taxes" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentNetOfTaxes", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "gtvi_MergerAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger agreement, description.", "label": "MergerAgreementDescription", "terseLabel": "Merger agreement, description" } } }, "localname": "MergerAgreementDescription", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_OffsetShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offset shares", "label": "OffsetShares", "terseLabel": "Offset shares" } } }, "localname": "OffsetShares", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "gtvi_OrdinarySharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares of common stock", "label": "OrdinarySharesOfCommonStock", "terseLabel": "Ordinary shares of common stock (in Shares)" } } }, "localname": "OrdinarySharesOfCommonStock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "sharesItemType" }, "gtvi_OrganizationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Line Items]" } } }, "localname": "OrganizationDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_OrganizationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Table]" } } }, "localname": "OrganizationDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_OtherPayables": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "OtherPayables", "terseLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_PaymentPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment per share", "label": "PaymentPerShare", "terseLabel": "Payment per share" } } }, "localname": "PaymentPerShare", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "gtvi_PercentageOfSharesHeldByShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares held by shareholders.", "label": "PercentageOfSharesHeldByShareholders", "terseLabel": "Percentage of shares held by shareholder" } } }, "localname": "PercentageOfSharesHeldByShareholders", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "percentItemType" }, "gtvi_ReceivableFromRelatedPartyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable From Related Party Disclosure [Abstract]" } } }, "localname": "ReceivableFromRelatedPartyDisclosureAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_ReceivableFromRelatedPartyDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of receivable from related party.", "label": "ReceivableFromRelatedPartyDisclosureTextBlock", "terseLabel": "RECEIVABLE FROM RELATED PARTY" } } }, "localname": "ReceivableFromRelatedPartyDisclosureTextBlock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedParty" ], "xbrltype": "textBlockItemType" }, "gtvi_ReceivableUsedToOffsetTheSellingPriceOfDiposalOfDynamicEliteAndSubsidiaries": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Receivable used to offset the selling price of diposal of Dynamic Elite and Subsidiaries.", "label": "ReceivableUsedToOffsetTheSellingPriceOfDiposalOfDynamicEliteAndSubsidiaries", "terseLabel": "Receivable used to offset the selling price of disposal of Dynamic Elite and Subsidiaries" } } }, "localname": "ReceivableUsedToOffsetTheSellingPriceOfDiposalOfDynamicEliteAndSubsidiaries", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) [Line Items]" } } }, "localname": "ReceivablefromRelatedPartyDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) - Schedule of receivable from related party [Line Items]" } } }, "localname": "ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) - Schedule of receivable from related party [Table]" } } }, "localname": "ReceivablefromRelatedPartyDetailsScheduleofreceivablefromrelatedpartyTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "stringItemType" }, "gtvi_ReceivablefromRelatedPartyDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivable from Related Party (Details) [Table]" } } }, "localname": "ReceivablefromRelatedPartyDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "stringItemType" }, "gtvi_ReclassificationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReclassificationPolicyTextBlock", "terseLabel": "Reclassification" } } }, "localname": "ReclassificationPolicyTextBlock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "gtvi_RelatedPartyLoanReleasedByJowayShengshi": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party loan released by joway shengsh.", "label": "RelatedPartyLoanReleasedByJowayShengshi", "terseLabel": "Forgiveness of related party debts" } } }, "localname": "RelatedPartyLoanReleasedByJowayShengshi", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_RightToPurchaseCallOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right to purchase call option", "label": "RightToPurchaseCallOption", "terseLabel": "Right to purchase call option extinguished in consideration (in Dollars)" } } }, "localname": "RightToPurchaseCallOption", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_ScheduleOfGainsAndLossesFromForeignCurrencyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of gains and losses from foreign currency transactions [Abstract]" } } }, "localname": "ScheduleOfGainsAndLossesFromForeignCurrencyTransactionsAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfPayablesDueToRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of payables due to related parties [Abstract]" } } }, "localname": "ScheduleOfPayablesDueToRelatedPartiesAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReceivableFromRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of receivable from related party [Abstract]" } } }, "localname": "ScheduleOfReceivableFromRelatedPartyAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReceivableFromRelatedPartyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfReceivableFromRelatedPartyTableTextBlock", "terseLabel": "Schedule of receivable from related party" } } }, "localname": "ScheduleOfReceivableFromRelatedPartyTableTextBlock", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "gtvi_ScheduleReconciliationOfTheDeconsolidationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule reconciliation of the deconsolidation [Abstract]" } } }, "localname": "ScheduleReconciliationOfTheDeconsolidationAbstract", "nsuri": "http://jowayhealth.com/20211231", "xbrltype": "stringItemType" }, "gtvi_SellingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling price", "label": "SellingPrice", "terseLabel": "Selling price" } } }, "localname": "SellingPrice", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_ShareholderHoldingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder holding percentage", "label": "ShareholderHoldingPercentage", "terseLabel": "Shareholder holding percentage" } } }, "localname": "ShareholderHoldingPercentage", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "gtvi_SpecialDividendPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Special Dividend Payable (Details) [Line Items]" } } }, "localname": "SpecialDividendPayableDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_SpecialDividendPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Special Dividend Payable (Details) [Table]" } } }, "localname": "SpecialDividendPayableDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "gtvi_StockIssuedDuringValueDisposalOfSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal of subsidiary", "label": "StockIssuedDuringValueDisposalOfSubsidiary", "terseLabel": "Disposal of subsidiary" } } }, "localname": "StockIssuedDuringValueDisposalOfSubsidiary", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "gtvi_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "gtvi_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsLineItems", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of gains and losses from foreign currency transactions [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgainsandlossesfromforeigncurrencytransactionsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "gtvi_TianjinJowayShengshiGroupCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tianjin joway shengshi group co., ltd.", "label": "TianjinJowayShengshiGroupCoLtdMember", "terseLabel": "Tianjin Joway Shengshi Group Co., Ltd. [Member]" } } }, "localname": "TianjinJowayShengshiGroupCoLtdMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "gtvi_UncollectedConsiderationFromDisposalOfDynamicEliteAndSubsidiaries": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Uncollected consideration from Disposal of Dynamic Elite and Subsidiaries.", "label": "UncollectedConsiderationFromDisposalOfDynamicEliteAndSubsidiaries", "terseLabel": "Uncollected consideration from Disposal of Dynamic Elite and Subsidiaries" } } }, "localname": "UncollectedConsiderationFromDisposalOfDynamicEliteAndSubsidiaries", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_UndistributedConsiderationToShareholders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Undistributed consideration to shareholders.", "label": "UndistributedConsiderationToShareholders", "terseLabel": "Undistributed consideration to shareholders" } } }, "localname": "UndistributedConsiderationToShareholders", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_YearEndedRMBUSDExchangeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "YearEndedRMBUSDExchangeRateMember", "terseLabel": "Year ended RMB: USD Exchange rate [Member]" } } }, "localname": "YearEndedRMBUSDExchangeRateMember", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "gtvi_a2020Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "a2020Abstract", "terseLabel": "2020" } } }, "localname": "a2020Abstract", "nsuri": "http://jowayhealth.com/20211231", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "OTHER PAYABLES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OtherPayables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Special dividend payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r33", "r36", "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r34", "r36", "r43", "r44", "r45", "r78", "r79", "r80", "r182", "r260", "r261", "r276" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r149", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r78", "r79", "r80", "r146", "r147", "r148", "r191" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r73", "r107", "r110", "r115", "r123", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r177", "r185", "r195", "r219", "r221", "r239", "r249" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r12", "r13", "r30", "r73", "r123", "r126", "r127", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r177", "r185", "r195", "r219", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r60", "r66", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, end of year", "periodStartLabel": "CASH, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r198" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON-CASH TRANSACTIONS OF INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_CashIncludingDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Including Discontinued Operations [Abstract]", "terseLabel": "Discontinued operations:" } } }, "localname": "CashIncludingDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash provided by financing activities from discontinued component" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r7", "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash used in investing activities from discontinued component" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r7", "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash used in operating activities from discontinued component" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r125", "r243", "r252" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r78", "r79", "r191" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r38", "r40", "r41", "r49", "r246", "r257" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "OTHER COMPREHENSIVE LOSS:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r98", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r70", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r52", "r225" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "COST OF REVENUES" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": { "auth_ref": [ "r158", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.", "label": "Deferred Tax Liabilities, Regulatory Assets", "terseLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesRegulatoryAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Restrictions on Dividends, Loans and Advances Disclosure [Abstract]" } } }, "localname": "DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1": { "auth_ref": [ "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory capital and surplus computed using prescribed or permitted statutory accounting practice.", "label": "Dividend Payments Restrictions Schedule, Statutory Capital and Surplus", "terseLabel": "Dividend payables" } } }, "localname": "DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r76", "r129", "r131", "r132", "r136", "r137", "r138", "r214", "r241", "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Due from related party" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToEmployeesCurrentAndNoncurrent": { "auth_ref": [ "r214", "r242", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to employees, not to include stockholders or officers.", "label": "Due to Employees", "terseLabel": "Unpaid principal balance in advance" } } }, "localname": "DueToEmployeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r24", "r76", "r129", "r131", "r132", "r136", "r137", "r138", "r214" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "netLabel": "Total", "terseLabel": "Due to related parties", "verboseLabel": "Crystal Globe" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Discontinued operations - Basic & diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "LOSS PER COMMON SHARE, BASIC AND DILUTED:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r198" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r78", "r79", "r80", "r82", "r87", "r89", "r95", "r124", "r141", "r142", "r146", "r147", "r148", "r161", "r162", "r191", "r200", "r201", "r202", "r203", "r204", "r205", "r260", "r261", "r262", "r276" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership percentage", "verboseLabel": "Equity interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares available to shareholders" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate, Translation", "terseLabel": "Gains and losses from foreign currency transactions" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r64" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedLabel": "General and administrative expenses" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r50", "r73", "r107", "r109", "r111", "r114", "r116", "r123", "r126", "r127", "r128", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r195" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "negatedTotalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairedFinancingReceivableUnpaidPrincipalBalance": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unpaid principal balance of impaired financing receivables with related allowance for credit losses and without related allowance for credit losses.", "label": "Impaired Financing Receivable, Unpaid Principal Balance", "terseLabel": "Total unpaid principal balance" } } }, "localname": "ImpairedFinancingReceivableUnpaidPrincipalBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r51", "r65", "r83", "r84", "r85", "r86", "r90", "r92", "r174" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations", "totalLabel": "NET LOSS FROM CONTINUING OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow", "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r47", "r107", "r109", "r111", "r114", "r116", "r238", "r244", "r247", "r258" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Continuing operations - Basic & diluted (in Dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r8", "r9", "r167", "r255" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Loss from operations of discontinued component, net of taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r74", "r153", "r154", "r157", "r163", "r165", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r75", "r88", "r89", "r106", "r152", "r164", "r166", "r259" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r42", "r150", "r151", "r154", "r155", "r156", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r62", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of the entity to which the long-term intercompany foreign balances of the entity relate.", "label": "Intercompany Foreign Currency Balance by Description [Axis]" } } }, "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofgainsandlossesfromforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r58", "r61", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r73", "r123", "r195", "r221", "r240", "r251" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r73", "r123", "r126", "r127", "r128", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r178", "r185", "r186", "r195", "r219", "r220", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash provided by (used in) financing activities from continuing component" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r60" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash provided by investing activities from continuing component" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r63", "r65" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r60", "r63", "r65" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash used in operating activities from continuing component" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r9", "r37", "r39", "r45", "r48", "r65", "r73", "r81", "r83", "r84", "r85", "r86", "r88", "r89", "r90", "r107", "r109", "r111", "r114", "r116", "r123", "r126", "r127", "r128", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r192", "r195", "r245", "r256" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer": { "auth_ref": [ "r209", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).", "label": "Nonmonetary Transaction, Gain (Loss) Recognized on Transfer", "terseLabel": "Transaction loss" } } }, "localname": "NonmonetaryTransactionGainLossRecognizedOnTransfer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "OTHER LOSS, NET" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r107", "r109", "r111", "r114", "r116" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "INCOME FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r11", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r29", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r32", "r35", "r196", "r197", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation gain" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r31" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "negatedLabel": "Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SchedulereconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r25", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other payables" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r54" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expenses" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Receivable from related party" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r57" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Distribution of special dividend" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireFurnitureAndFixtures": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of furniture and fixtures.", "label": "Payments to Acquire Furniture and Fixtures", "terseLabel": "Cash outflow" } } }, "localname": "PaymentsToAcquireFurnitureAndFixtures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r140" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r140" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r55" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Cash received from disposal of subsidiaries" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Due to related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r9", "r37", "r39", "r45", "r59", "r73", "r81", "r88", "r89", "r107", "r109", "r111", "r114", "r116", "r123", "r126", "r127", "r128", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r175", "r180", "r181", "r188", "r189", "r192", "r195", "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r145", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r145", "r213", "r214", "r216" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r145", "r213", "r216", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "http://jowayhealth.com/role/ScheduleofreceivablefromrelatedpartyTable", "http://jowayhealth.com/role/SpecialDividendPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r211", "r212", "r214", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r142", "r149", "r221", "r250", "r263", "r264" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriatedMember": { "auth_ref": [ "r19", "r139" ], "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated [Member]", "terseLabel": "Statutory reserves" } } }, "localname": "RetainedEarningsAppropriatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r78", "r79", "r80", "r82", "r87", "r89", "r124", "r146", "r147", "r148", "r161", "r162", "r191", "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r46", "r73", "r104", "r105", "r108", "r112", "r113", "r117", "r118", "r119", "r123", "r126", "r127", "r128", "r131", "r132", "r133", "r134", "r135", "r137", "r138", "r195", "r247" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "REVENUES" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r176", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of Stock, Description of Transaction", "terseLabel": "Sale of stock, description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDividendPaymentRestrictionsTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of statutory restrictions on the payment of dividends as prescribed by the National Association of Insurance Commissioners or state regulatory authorities.", "label": "Dividend Payment Restrictions [Text Block]", "terseLabel": "SPECIAL DIVIDEND PAYABLE" } } }, "localname": "ScheduleOfDividendPaymentRestrictionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SpecialDividendPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule reconciliation of the deconsolidation" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of payables due to related parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r28", "r43", "r44", "r45", "r78", "r79", "r80", "r82", "r87", "r89", "r95", "r124", "r141", "r142", "r146", "r147", "r148", "r161", "r162", "r191", "r200", "r201", "r202", "r203", "r204", "r205", "r260", "r261", "r262", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r78", "r79", "r80", "r95", "r225" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Shares on hold" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ReceivablefromRelatedPartyDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Forgiveness of related party debts" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r73", "r121", "r123", "r195", "r221" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r44", "r73", "r78", "r79", "r80", "r82", "r87", "r123", "r124", "r142", "r146", "r147", "r148", "r161", "r162", "r172", "r173", "r187", "r191", "r195", "r200", "r201", "r205", "r261", "r262", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r206", "r223" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r206", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.", "label": "Temporary Equity, Foreign Currency Translation Adjustments", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Common stock shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r96", "r97", "r99", "r100", "r101", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(i))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "505", "Topic": "944", "URI": "http://asc.fasb.org/subtopic&trid=4738323" }, "r267": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r268": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r269": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r271": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r272": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r273": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r274": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r275": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" } }, "version": "2.1" } ZIP 51 0001213900-22-016222-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-016222-xbrl.zip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end